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The RNA-guided adaptive immune system CRISPR (clustered regularly interspaced short 
palindromic repeats)-Cas (CRISPR-associated) immunizes prokaryotic cells against mobile 
genetic elements (MGEs). The CRISPR-Cas immunity operates in three stages, i.e. adaptation 
or spacer acquisition, crRNA biogenesis and interference. During spacer acquisition, a short 
nucleic acid sequence (prespacer) is acquired from the MGEs, processed and finally integrated 
into the CRISPR array as a spacer, which serves as genetic memory to defend against the 
invasion of the cognate MGEs.  
 
Cas1 and Cas2, the key players for spacer acquisition, form an integrase complex that integrates 
the new spacers into the CRISPR array. The molecular mechanism for the spacer acquisition of 
the type II-A systems, which encode cas9, cas1, cas2, csn2 and tracrRNA, is still not fully 
understood. Therefore, we investigated the architecture of the type II-A CRISPR-Cas protein 
complex together with the requirement of the different Cas proteins for spacer acquisition. 
 
We verified the acquisition activity of the type II-A systems of Streptococcus thermophilus 
LMD-9 (CRISPR1 and CRISPR3 loci) via spacer acquisition studies by phage challenge. We 
observed higher acquisition rates in the CRISPR3 locus compared to the CRISPR1 locus. Our 
plasmid-based spacer acquisition study and concurrent over-expression of Cas proteins, 
confirmed in addition to Cas1, Cas2 and Csn2 the requirement of Cas9 for spacer acquisition. 
Crosstalk for spacer acquisition between CRISPR1 and CRISPR3 loci was not observed.  
 
To examine the interactions among the Cas proteins and the potential involvement of 
non-CRISPR proteins in spacer acquisition, we performed protein-protein interaction studies 
using yeast two-hybrid and pull-down approaches. These two approaches revealed specific 
interactions among the Cas proteins, as well as interactions between Cas and DNA repair 
proteins. We further investigated the interaction between Cas1 and Cas9. The interaction 
regions of Cas1 with Cas9 were identified by SPOT peptide assay, which demonstrated that the 
C-terminus of Cas1 interacts with Cas9. Altogether, our study suggests that Cas proteins 
interact with proteins within and beyond the CRISPR-Cas systems, and it provides a basis for 
the investigation of the potential roles of DNA repair proteins in the CRISPR-Cas systems 
and/or vice versa.  
 x 
Zusammenfassung 
Das RNA-guided adaptive Immunsystem CRISPR (clustered regularly interspaced short 
palindromic repeats)-Cas (CRISPR-associated) immunisiert prokaryotische Zellen gegenüber 
mobilen genetischen Elementen (MGEs). Die CRISPR-Cas Immunität läuft in drei Phasen ab: 
Adaption oder spacer-Gewinnung, Produktion der CRISPR RNS (crRNS) und Interferenz. Bei 
der Adaption wird eine kurze Nukleinsäurensequenz (prespacer) von den MGEs gewonnen, 
verarbeitet und schließlich als spacer in das CRISPR-Array integriert. Dieses dient als 
genetisches Gedächtnis zur Verteidigung gegen das Eindringen stammverwandter MGEs. 
 
Cas1 und Cas2, die Hauptbestandteile der Adaption, bilden einen Integrase-Komplex, welcher 
neue spacer in das CRISPR-Array integriert. Der molekulare Mechanismus für die Adaptiondes 
Typ II-A Systems, welches cas9, cas1, cas2, csn2 und tracrRNA codiert, ist bis heute nicht 
vollständig verstanden. Daher untersuchten wir den Aufbau des Typ II-A CRISPR-Cas 
Proteinkomplexes in Kombination mit den Anforderungen der verschiedenen Cas-Proteine für 
den Adaptionsprozess. 
 
Wir verifizierten die Adaptions-Aktivität von Typ II-A Systemen des 
Streptococcus thermophilus LMD-9 (CRISPR1 und CRISPR3 Loki) anhand von 
Adaptionsstudien nach Phagen-Infektion. Dabei beobachteten wir höhere Akquisitionsraten im 
CRISPR3-Lokus im Vergleich zum CRISPR1-Lokus. Unsere Plasmid-basierte 
Adaptionsstudie bei gleichzeitiger Überexpression von Cas-Proteinen bestätigte die 
Notwendigkeit von Cas9, zusätzlich zu Cas1, Cas2 und Csn2 bei der Adaption. Ein crosstalk 
von CRISPR1- und CRISPR3-Loki wurde dabei nicht beobachtet. 
 
Um die Interaktionen zwischen den verschiedenen Cas-Proteinen sowie die potenzielle 
Beteiligung anderer, nicht-CRISPR Proteine bei der Adaption zu untersuchen, führten wir 
Studien zur Protein-zu-Protein Interaktion  durch. Dabei nutzten wir den two-hybrid, sowie den 
pull-down Ansatz. Beide Ansätze zeigten sowohl spezifische Interaktionen zwischen den Cas-
Proteinen, als auch Interaktionen zwischen Cas-Proteinen sowie DNA-Reparatur Proteinen. 
Des Weiteren untersuchten wir die Interaktion zwischen Cas1 und Cas9. Die Regionen der Cas1 
und Cas9 Interaktion wurden durch SPOT peptide assay identifiziert und zeigten eine 
Interaktion des Cas1 C-terminus mit Cas9. Zusammenfassend weist unsere Studie darauf hin, 
dass Cas-Proteine sowohl mit Proteinen innerhalb, als auch außerhalb des CRISPR-Cas 
 xi 
Systems interagieren, und bietet somit eine Basis für die Erforschung der möglichen Funktionen 












Acr   Anti-CRISPR 
ABC transporters ATP-binding cassette transporters  
Abi   Abortive infection 
AD   Activation domain 
BER   Base excision repair 
BiFC   Bimolecular fluorescence complementation  
bp   Base-pair 
BRET   Bioluminescence resonance energy transfer 
BREX   Bacteriophage exclusion 
BS3   Bis(sulfosuccinimidy) suberate 
Cas   CRISPR-associated 
Cascade   CRISPR-associated complex for antiviral defense 
CDM   Chemically defined medium 
Chi   Crossover hotspot instigator 
Cos site  Cohesive end site 
CPD   Cysteine Protease Domain 
CRISPR or Cr  Clustered regularly interspaced short palindromic repeats 
crRNA   CRISPR RNA 
DBD   DNA binding domain 
dCas9   Dead Cas9 
DSB   Double-strand break 
dsDNA  Double-stranded DNA 
EMSA   Electrophoretic mobility shift assay  
FRET   Fluorescence resonance energy transfer  
GAS   Group A Streptococcus 
His6-tag  Hexahistidine-tag 
HR   Homologous recombination 
IHF   Integration host factor 
IMAC   Immobilized metal affinity chromatography  
 xiii 
IPTG   Isopropylthio-β-d-galactoside  
LB   Lysogeny broth 
mAU   Mili-Absorbance Units 
MBP   Maltose binding protein 
MGE   Mobile genetic element 
MjAgo   Methanocaldococcus jannaschii Argonaute 
MMC   Mitomycin C 
MOI   Multiplicity of infection 
MMR   Mismatch repair 
NER   Nucleotide excision repair 
NHEJ   Non-homologous end joining  
NHS   N-hydroxysulfosuccinimide  
nt   Nucleotide 
NUC lobe  Nuclease lobe 
OD   Optical density 
PAM   Protospacer adjacent motif 
PBS   Predicted biological score 
pre-crRNA  Precursor CRISPR RNA 
prespacer  Precursor spacer 
PfAgo   Pyrococcus furiosus Argonaute 
Phage λvir  Virulent variant of phage Lambda 
PPI   Protein-protein interaction 
REC   Recognition lobe 
RM   Restriction modification 
rPAM   RNA-protospacer adjacent motif or RNA-PAM 
RsAgo   Rhodobacter sphaeroides Argonaute 
RT   Reverse transcription or reverse transcriptase 
RT-PCR  Reverse transcription polymerase chain reaction 
SEC   Size-exclusion chromatography 
sgRNA  Single-guide RNA 
siDNA   Small interfering DNA  
Sie   Superinfection exclusion 
siRNA   Small interfering RNA 
SPR   Surface plasmon resonance 
 xiv 
ssDNA  Single-stranded DNA 
ssRNA   Single-stranded RNA     
THY   Todd-Hewitt broth supplemented with yeast extract 
tracrRNA  trans-activating crRNA 
TtAgo   Thermus thermophilus Argonaute 
UV   Ultraviolet 
WT   Wild type      
Y2H   Yeast two-hybrid     
 
 




1.1 Prokaryotic immune systems 
 
1.1.1 Phage-host relationships 
In nature, phages and their hosts constantly adapt to each other and co-evolve in order to secure 
their survival. Phages can enhance the fitness of prokaryotes. For example, acquisition of 
virulence factors encoded in the prophages transforms numerous bacteria, such as Vibrio 
cholerae, Streptococcus pyogenes, Staphylococcus aureus, Escherichia coli, Clostridium 
botulinum, and Corynebacterium diphtheriae, to highly virulent strains (Brussow et al., 2004; 
Keen, 2012). On the other hand, phages can also be harmful to their hosts. For instance, lytic 
phages are life-threatening to prokaryotes, whereas prophages are an energy burden (e.g. energy 
for replication, transcription and translation) to their prokaryotic hosts, especially when they do 
not express any gene that is beneficial for the fitness of the hosts (Vogan and Higgs, 2011). 
Additionally, random integrations of prophages might disrupt functional genes on the 
prokaryotic genomes (Vogan and Higgs, 2011). Throughout the bacteria-phage arms race, 
prokaryotes have developed multi-layer defense systems, which protect them from phage 
infections. Some of the innate defense systems, i.e. defense systems that do not target specific 
phages based on the record of infections, will be briefly addressed below. 
  
1.1.2 Inhibition of phage adsorption  
Phage infection starts with adsorption of the phage on the host cell. Through cell receptor 
modifications such as mutation, downregulation or masking, bacteria preclude phage 
adsorption, which is an important step for phage infection (Hyman and Abedon, 2010). 
However, as a counter-defense to the host receptor modifications, some phages introduce 
mutations on their receptor binding proteins, which enables them to bind to the modified host 
receptor (Meyer et al., 2012).  
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1.1.3 Restriction modification systems 
Prokaryotic defense systems may directly neutralize the phage DNAs via restriction 
modification (RM) systems. A classical RM system employs DNA methyltransferase that 
modifies only the self-DNA (i.e. host DNA), and a restriction endonuclease that digests the 
non-modified invading DNAs (i.e. phage DNAs), thereby protecting the host from the phages. 
As restriction endonucleases are sequence-specific, phages can evade DNA cleavage by 
mutations (point mutations) of the restriction sites on the phage DNA, thus preventing 
recognition by the RM system. (Labrie et al., 2010) 
 
1.1.4 Bacteriophage exclusion system 
Bacteriophage exclusion system (BREX) is a six-gene cassette, which contains PglZ 
phosphatase, PglX methyltransferase, BrxA (a NusB-like RNA-binding anti-termination 
protein), BrxB (an uncharacterized protein), BrxC (an ATP-binding protein) and BrxL (a Lon-
like protease protein). The BREX of Bacillus cereus protects against both lytic and temperate 
phages via DNA methylation to differentiate self-DNA from phage DNA, and subsequent 
inhibition of the phage DNA replication. In contrast to the RM systems, BREX does not seem 
to cleave or degrade the phage DNA. (Goldfarb et al., 2015) 
 
1.1.5 Argonaute-based immunity 
Prokaryotic Argonautes are speculated for their roles in prokaryotic immunity against foreign 
genetic elements, however the mechanisms of the prokaryotic Argonautes are still not well 
understood. Prokaryotic Argonautes demonstrate a broad spectrum of interference mechanisms, 
including RNA-guided and DNA-guided DNA interference (Hegge et al., 2017). In vitro studies 
showed that the Argonautes from Thermus thermophilus (TtAgo), Pyrococcus furiosus (PfAgo) 
and Methanocaldococcus jannaschii (MjAgo) are directed by a small interfering DNA (siDNA) 
guide to cleave DNA targets (Swarts et al., 2014, 2015; Zander et al., 2014). Both TtAgo, and 
MjAgo are able to cleave double-stranded DNA (dsDNA) in the absence of guides and 
subsequently use the cleavage DNA fragments as guides for target DNA neutralization (Swarts 
et al., 2017; Zander et al., 2017). Moreover, in vitro studies demonstrated that PfAgo reduces 
plasmid transformation efficiency (Swarts et al., 2015). On the other hand, a heterologous 
system in E. coli showed that the Argonautes from Rhodobacter sphaeroides (RsAgo) binds 
small interference RNA (siRNA), and the ribonucleoprotein complex reduces the number of 
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plasmids and plasmid transcripts via a yet to be elucidated mechanism (Olovnikov et al., 2013). 
SiRNAs sequences predominantly match ribosomal RNA sequences and mRNAs of plasmids, 
however, the underlying mechanism is still unclear (Olovnikov et al., 2013). 
 
1.1.6 Abortive infection 
A distinct defense system, named abortive infection (Abi) aims at defending the whole bacterial 
population by sacrificing the infected cells. Abi systems generally target essential cellular 
mechanisms such as replication, transcription and translation. (Labrie et al., 2010)) 
 
In the recent decade, the adaptive prokaryotic defense systems known as CRISPR-Cas 
(clustered regularly interspaced short palindromic repeats-CRISPR-associated proteins) 
systems have been rapidly characterized and harnessed as valuable tools in the fields of 
biotechnology and genome-editing. CRISPR-Cas systems will be addressed in details in the 
following sections.  
 
 
1.2 The adaptive immunity: CRISPR-Cas systems 
CRISPR-Cas systems are RNA-guided adaptive immune systems that protect prokaryotes 
against mobile genetic elements (MGEs), such as bacteriophages and plasmids. CRISPR-Cas 
systems are detected in around 90% of sequenced archaeal and 50% of bacterial genomes 
(Grissa et al., 2007; Makarova et al., 2015). The hallmark of the CRISPR-Cas systems is the 
CRISPR array, which is composed of a succession of repeat sequences interspaced with 
sequences generally derived from MGEs - termed spacers - that serve as a genetic memory of 
past infections (Mojica et al., 2005; Pourcel et al., 2005). Upstream of the CRISPR array is an 
AT-rich leader sequence, which contains the promoter for the transcription of the CRISPR 
array. Proximal to the CRISPR array is a set of cas genes (Jansen et al., 2002) that encodes Cas 
proteins responsible for the functionality of the CRISPR-Cas systems. 
 
1.2.1 The classification of CRISPR-Cas systems 
Based on the presence of the hallmark cas genes and the nature of the interference effector 
complex, CRISPR-Cas systems have been classified into two classes, which are additionally 
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divided into six types and many subtypes (Makarova et al., 2011, 2013, 2015; Shmakov et al., 
2015). Class 1 CRISPR-Cas systems include type I, III and IV, and employ multi-subunit Cas 
effector complexes for targeting MGEs; whereas class 2 (type II, V and VI) systems rely on a 
large single Cas protein with multiple domains (Makarova et al., 2015; Shmakov et al., 2015). 
 
1.2.2 The three stages of CRISPR-Cas immunity 
The CRISPR immunity is executed predominantly by Cas proteins via three stages: (1) 
adaptation or spacer acquisition, (2) CRISPR RNA (crRNA) biogenesis and (3) interference 
(Figure 1). Adaptation begins with the detection of the MGEs, from which short nucleic acid 
sequences (termed as precursor spacers or prespacers (Westra and Brouns, 2012)) are acquired 
and integrated into the CRISPR array as spacers. The key proteins for spacer acquisition are 
Cas1 and Cas2 (Datsenko et al., 2012; Heler et al., 2015; Swarts et al., 2012; Wei et al., 2015a; 
Yosef et al., 2012), which are almost ubiquitous in all the CRISPR-Cas types (Makarova et al., 
2011, 2015). During crRNA biogenesis, the CRISPR array is transcribed into a precursor 
CRISPR RNA (pre-crRNA), which will be processed into mature crRNAs. Each of the crRNAs 
consists of portions of both repeat and spacer and is bound to either a multi-subunit Cas complex 
(class 1) or a single-subunit Cas protein (class 2) to form a crRNA-effector complex. Upon the 
re-invasion of a MGE, crRNA guides the Cas effector complex towards the MGEs to cleave 
the target sequence (known as protospacer) that is complementary to the spacer portion of the 
crRNA, i.e. a process known as CRISPR interference.  
 
1.2.2.1 Prespacers and protospacers 
Prespacers and protospacers are essentially the same nucleic acid sequences on the MGEs. 
While prespacers are short foreign sequences that will be selected, processed and incorporated 
into the CRISPR array as spacers, protospacers refer to the short sequences on the re-invaded 
MGEs that match the existing spacers in the CRISPR array (Westra and Brouns, 2012). While 
some publications in the literature refer to the precursor of the spacer with the terminology 
“prespacer”, “protospacer” is more commonly used. In this thesis, the terminology “prespacer” 
will be used to specify the precursor sequences that will be processed and integrated into the 
CRISPR array. 
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Figure 1. Three stages of CRISPR-Cas immunity.  
Upon phage invasion, CRISPR immunity operates in three stages. The first stage is known as adaptation or spacer 
acquisition, where the adaptation machinery selects a short foreign sequence (prespacer) adjacent to a PAM and 
integrates it into the leader-end CRISPR array as a spacer. The adaptation machinery involves the Cas1-Cas2 
complex; depending on the CRISPR-Cas types, the adaptation machinery may include additional Cas proteins. In 
the second stage, the CRISPR array is transcribed into a long precursor CRISPR RNA (pre-crRNA), which is 
further processed into mature crRNAs by either Cas proteins or host RNase(s) during crRNA biogenesis. In the 
interference stage, a crRNA-effector complex, formed by the binding of a crRNA to either a multi-subunit Cas 
complex (class 1) or a single Cas protein (class 2), recognizes the cognate phage via PAM identification and 
sequence complementarity between the crRNA and protospacer. Upon target binding, the Cas nuclease digests the 
invading DNA. Rectangles, repeats; diamonds, spacers. The colors of the spacers indicate variable MGEs-derived 
sequences. (Figure adapted from (Hille et al., 2018)) 
 
 
1.2.2.2 Protospacer adjacent motif 
CRISPR immunity relies on the insertion of short sequences from the MGEs into the genomic 
CRISPR loci, which raises the question about how CRISPR-Cas systems distinguish between 
self-DNA (spacers in the CRISPR array) and non-self DNA (protospacers on the MGEs). In 
almost all CRISPR-Cas systems (except type III systems), the recognition of a protospacer 
adjacent motif (PAM), which is a short sequence flanking the protospacer (Deveau et al., 2008; 
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Mojica et al., 2009), is critical for the MGEs recognition and neutralization. The PAM is present 
on the MGE but absent on the CRISPR array, and is therefore important for self- versus non-self 
discrimination during interference to prevent autoimmunity. In view of the importance of the 
PAM during interference, selecting a prespacer with a canonical PAM during spacer acquisition 
is also crucial for CRISPR-Cas immunity (Datsenko et al., 2012; Deveau et al., 2008; Mojica 
et al., 2009; Swarts et al., 2012). In the type III-B system of Pyrococcus furiosus, an RNA-
PAM (rPAM) located at the 3´-end of the target RNA that is complementary to the crRNA is 
recognized as a non-self genetic element, which will be cleaved by the interference machinery 
(Elmore et al., 2016). Unlike type III-B system, type III-A system of Staphylococcus 
epidermidis does not depend on PAM or rPAM for self- versus non-self discrimination (Elmore 
et al., 2016). Instead, DNA cleavage only occurs when the potential target sequence is 
complementary to the spacer portion of the crRNA, but not the 5´-repeat handle, the partial 
repeat sequence on the 5´-end of the crRNA (Marraffini and Sontheimer, 2010). 
 
 
1.3 The type II-A CRISPR-Cas systems  
 
1.3.1 The subtypes of type II systems  
The multi-domain effector Cas9 is a hallmark protein of the type II CRISPR-Cas systems, 
which are further divided into type II-A, II-B and II-C systems, where cas1, cas2, cas9 and 
trans-activating crRNA (tracrRNA) are present in all the subtypes (Chylinski et al., 2013, 2014; 
Fonfara et al., 2014; Makarova et al., 2011). tracrRNA is a small RNA that contains an 
anti-repeat sequence complementary to the repeat sequences of pre-crRNAs (Deltcheva et al., 
2011).  
 
Bioinformatic studies demonstrated that two csn2 variants, i.e. a shorter csn2 (csn2a) that is 
always accompanied by the longer cas9, and a longer csn2 (csn2b) that always coexists with 
the shorter cas9 (Chylinski et al., 2014). Csn2 is the signature protein for the type II-A 
CRISPR-Cas systems (Makarova et al., 2011), and it is essential for spacer acquisition 
(Barrangou et al., 2007; Garneau et al., 2010; Heler et al., 2015; Wei et al., 2015a). Biochemical 
studies revealed that Csn2 exhibits a tetrameric ring-like structure (Ellinger et al., 2012; Koo et 
al., 2012; Lee et al., 2012; Nam et al., 2011) that could bind to the linear ends of dsDNA (Arslan 
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et al., 2013) and slide along the DNA in an energy-independent manner  (Arslan et al., 2013). 
The structure and properties of Csn2 share similarity to the Ku protein from the non-
homologous end joining (NHEJ) DNA repair pathway (Feldmann et al., 2000).  
 
In addition to cas1, cas2 and cas9, the type II-B systems encode cas4 (Makarova et al., 2011, 
2015). Cas4 has been shown to be necessary for spacer acquisition in several type I systems, as 
well as in Sulfolobus solfataricus and P. furiosus that encode several type I and type III systems 
together with different repeat families and an adaptation cassette (Kieper et al., 2018; Lee et 
al., 2018; Li et al., 2014; Liu et al., 2017; Rollie et al., 2018; Shiimori et al., 2017, 2018). 
Among the subtypes of the type II systems, the type II-C systems are minimal, as they only 
encode cas1, cas2 and cas9 (Chylinski et al., 2013, 2014; Fonfara et al., 2014). 
 
1.3.2 Type II-A crRNA biogenesis  
In the type II-A system, tracrRNA base-pairs with each repeat sequence of the pre-crRNA to 
form a tracrRNA anti-repeat:pre-crRNA repeat duplex, which will be bound to and stabilized 
by Cas9 (Deltcheva et al., 2011). RNase III recognizes and cleaves the 
tracrRNA:pre-crRNA duplexes within the anti-repeat sequences, resulting in intermediate 
tracrRNA:crRNA duplexes, of which the intermediate crRNAs consists of the 
5´-repeat-spacer-repeat-3´ sequences (Deltcheva et al., 2011). The intermediate 
tracrRNA:crRNA duplexes are further processed  by unknown RNase(s) into mature crRNAs, 
which are composed of 5´-spacer-repeat-3´ sequences (Deltcheva et al., 2011). Following the 
processing, Cas9 remains bound to the tracrRNA:crRNA duplex and forms the effector 
complex for interference (Deltcheva et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012). 
 
1.3.3 Type II-A CRISPR interference  
Structural studies disclosed that Cas9 possesses two lobes, which are the a-helical recognition 
(REC) lobe and the nuclease (NUC) lobe. These two lobes are connected together by a flexible 
linker and a highly conserved arginine-rich bridge helix that interacts with the guide RNA. The 
NUC lobe is comprised of a HNH nuclease domain, a RuvC nuclease domain and a 
PAM-interacting domain at the C-terminus (Anders et al., 2014; Hirano et al., 2016; Jiang et 
al., 2015, 2016; Jinek et al., 2014; Nishimasu et al., 2014, 2015; Yamada et al., 2017). The 
PAM-interacting region of Cas9 is disordered in apo-Cas9, therefore apo-Cas9 is unable to 
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specifically bind DNA (Jinek et al., 2014). Structural studies revealed that the binding of the 
engineered dual-tracrRNA:crRNA, known as single-guide RNA (sgRNA) chimera, to Cas9 
leads to conformational changes in the REC lobe and PAM-recognition region of Cas9, which 
transforms Cas9 from the inactive state (apo-Cas9) to the active state (sgRNA-bound Cas9) that 
can recognize the target DNA (Jiang et al., 2015). The critical element for this conformation 
activation is the seed sequence of the crRNA, which is composed of 10- to 12-PAM-adjacent 
nucleotides (nts) (Jiang et al., 2015; Jinek et al., 2012). 
 
During interference, the activated guide RNA-bound Cas9 scans the target DNA for recognition 
of the PAM on the non-target strand (Sternberg et al., 2014). Upon PAM recognition, crRNA 
probes for sequence complementarity with the target DNA. The base-pairing of the crRNA with 
the target DNA strand will displace the non-target strand through local DNA unwinding and 
lead to the formation of an R-loop (Anders et al., 2014; Jinek et al., 2012; Mekler et al., 2017; 
Sternberg et al., 2014; Szczelkun et al., 2014). The stable R--loop formation and subsequently 
interference are more tolerated to the mismatches outside of the seed sequence (Cong et al., 
2013; Jiang et al., 2013; Jinek et al., 2012; Sternberg et al., 2014). Upon R-loop formation, the 
HNH and RuvC nuclease domains of Cas9 cleave the target and the non-target DNA strands, 
respectively, which ultimately leads to a blunt double-stranded break (DSB) (Garneau et al., 
2010; Jinek et al., 2012). 
 
 
1.4 CRISPR adaptation (spacer acquisition) 
CRISPR adaptation or spacer acquisition, the first stage of the CRISPR-Cas immunity, is 
critical for the generation of heritable immunological memory. Several steps are involved in 
spacer acquisition, which include MGE recognition, prespacer selection, prespacer processing 
and spacer integration. The core proteins of spacer acquisition are the almost ubiquitous Cas1 
and Cas2 proteins (Koonin et al., 2017; Makarova et al., 2011, 2013, 2015; Shmakov et al., 
2015), which were shown to form an integrase complex consisting of one Cas2 dimer spanning 
two Cas1 dimers in the type I-E and type II-A systems (Nunez et al., 2014; Xiao et al., 
2017)3/11/19 7:38:00 PM. In this complex, Cas1 plays a catalytic role, whereas Cas2 plays a 
structural role in maintaining the Cas1-Cas2 complex (Nunez et al., 2014; Xiao et al., 2017). In 
the type I-E system of E. coli, Cas1 and Cas2 are the sole players in naïve spacer acquisition 
(Yosef et al., 2012), which refers to spacer incorporation when a pre-existing spacer against the 
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target is absent (Datsenko et al., 2012; Yosef et al., 2012). On the other hand, naïve spacer 
acquisition additionally requires Csn2, Cas9 and tracrRNA in type II-A systems of S. pyogenes 
and S. thermophilus (Heler et al., 2015; Wei et al., 2015a). 
 
Thus far, our knowledge of spacer integration arises mainly from type I-E and type II-A 
systems. In view of this, the spacer acquisition mechanism of type I-E will be described 
alongside the one of type II-A, which is the focus of this thesis. The subtype-specific accessory 
proteins and variations of spacer acquisition mechanisms will also be addressed. 
 
1.4.1 The provenance of prespacers 
Spacer acquisition commences with the recognition of MGEs. While acquiring foreign DNA 
as a genetic memory for future defense might be life-saving, acquiring self-DNA could be 
life-threatening. Therefore, as described above, a preference of acquiring non-self DNA against 
self-DNA is crucial to prevent auto-immunity and ensure that the immunity is specifically 
targeting MGEs. The self- versus non-self discrimination by the homologous recombination 
machinery AddAB (for Gram-positive bacteria) and the RecBCD complex (for Gram-negative 
bacteria) has been described in the type II-A system of S. pyogenes (Modell et al., 2017) and 
the type I-E system of E. coli (Levy et al., 2015), respectively.  
 
During DNA replication, DSBs often arise at the stalled replication forks. The RecBCD/AddAB 
complex is recruited to the DSBs, where the complex unwinds and degrades the dsDNA until 
a crossover hotspot instigator (Chi) site, which are short DNA motifs marking the DNA loci 
hotspot for the initiation of homologous recombination. The homologous recombination is 
commenced upon the loading of the RecA to the 3´-end overhang of the damaged DNA near 
the Chi site by RecBCD/AddAB. (Dillingham and Kowalczykowski, 2008; Smith, 2012; 
Wigley, 2013) 
 
A plasmid-based spacer acquisition in the type I-E system of E. coli revealed that the sequences 
between the stalled replication forks and the Chi sites are the prespacer sampling hotspots (Levy 
et al., 2015). The authors showed that spacer acquisition was decreased in the individual 
deletion mutants of recB, recC and recD, and the prespacer sampling hotspots between the 
stalled replication fork and the Chi site were impaired in these mutants. Thus, it was proposed 
that the degradation fragments generated by the RecBCD could be employed by the Cas1-Cas2 
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complex for spacer integration (Levy et al., 2015). It was suggested that the degraded 
single-stranded DNA (ssDNA) products occasionally re-anneal and form dual-forked DNAs 
(dsDNA with 5´- and 3´-overhangs at both ends), which are the preferred prespacer structure 
for Cas1-Cas2 (Levy et al., 2015; Wang et al., 2015). Since there are fewer Chi sites on a 
plasmid compared to the E. coli chromosomes, a longer fraction of plasmid DNAs will be 
degraded by RecBCD until a Chi site is encountered (Levy et al., 2015). Therefore, this leads 
to a larger supply of the plasmid-derived prespacer substrates and favors spacer acquisition 
from the plasmid DNA over bacterial chromosomes (Levy et al., 2015). In addition, high-copy 
number plasmids undergo frequent replications, therefore there are more stalled replication 
forks on the plasmids, which results in a higher number of DSBs on these DNAs. A higher 
number of DSBs leads to a higher frequency of plasmid DNA degradation by RecBCD, 
therefore high-copy number plasmids are favored for spacer acquisition instead of bacterial 
chromosomes (Levy et al., 2015).  
 
A phage infection study of the CRISPR-Cas type II-A system of S. pyogenes in a heterologous 
host S. aureus, demonstrated that the prespacers sampling hotspots are the DNA sequences 
between the cohesive end sites (cos sites) and the Chi sites (Modell et al., 2017). The cos site 
is the cohesive DNA ends of the linear viral DNA generated during the viral DNA packaging, 
and it allows the recircularization of the linear DNA upon DNA injection into the cell (Catalano 
et al., 1995). In the phage study of the type II-A system, the cos site manifests the free DNA 
end of the phage that initially enters the cell (Modell et al., 2017). An injected phage DNA 
could be degraded by the helicase-nuclease AddAB/RecBCD until a Chi site is encountered 
(Bobay et al., 2013; Dillingham and Kowalczykowski, 2008). In agreement with the 
observation that AddAB is required for efficient spacer acquisition in the type II-A system, it 
was proposed that AddAB supplies the DNA degradation products to the Cas1-Cas2 complex 
as prespacer substrates (Figure 2A) (Modell et al., 2017), which is also suggested for RecBCD 
in E. coli (Levy et al., 2015). Nevertheless, a very recent publication demonstrated that the 
helicase activity of the RecBCD is essential for promoting spacer acquisition in the type I-E 
system of E. coli, whereas the nuclease activity is not needed for spacer acquisition (Radovčić 
et al., 2018). Based on these findings, the authors suggested that the helicase-translocase 
activities of RecBCD promote spacer acquisition by removing the nucleoprotein complexes 
from the DNA damage sites, thereby allowing the access of Cas1-Cas2 for extracting the 
prespacer substrates. More studies are needed to clarify the roles of the homologous 
recombination machineries in spacer acquisition. 
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Figure 2. Spacer acquisition of type II-A systems.  
(A) Upon phage challenge in Gram-positive bacteria, if the injected linear phage DNA is uncapped (or 
unprotected) by phage proteins, the phage DNA can be bound and degraded by the DNA repair complex AddAB 
until a Chi site is encountered. Some of the degraded ssDNA fragments may re-anneal and form dsDNA fragments 
with 3´-overhangs at both ends, which can serve as prespacer substrates for the acquisition machinery.  (B) In the 
type II-A system, tracrRNA-bound Cas9 (tracrRNA-Cas9) selects the prespacers with canonical PAMs for spacer 
integration by Cas1-Cas2 complex. It remains unclear how the prespacer is transferred to the Cas1-Cas2 complex 
after the PAM recognition by tracrRNA-Cas9. The role of Csn2 in spacer acquisition is also not understood at this 
point. (C) Cas1-Cas2-prespacer complex recognizes the leader anchoring site (LAS) and leader-proximal end of 
the first repeat (*), and this enables preferential spacer integration at the leader-proximal CRISPR array. The 3´-OH 
of one strand of the prespacer carries out a nucleophilic attack on the leader-end of the first repeat (dotted arrow 
and circle in orange) and ligates the leader-end of the first repeat – an event known as the first integration. 
Subsequently, the 3´-OH of the other strand carries out a second nucleophilic attack and ligates on the spacer-end 
of the first repeat (dotted arrow and circle in blue), thereby resulting in the second integration event, i.e. full-site 
integration. The gap of the CRISPR array is presumably repaired by the DNA polymerase and ligase, and 
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1.4.2 The selection and processing of prespacers 
Apart from the AddAB/RecBCD-mediated role in spacer acquisition, prespacer selection 
during spacer acquisition is often not a random process. In type I and type II systems, a 
prespacer with a PAM is preferentially selected by the adaptation machinery to ensure the 
acquisition of a functional spacer that could result in interference (Datsenko et al., 2012; 
Deveau et al., 2008; Mojica et al., 2009; Swarts et al., 2012).  
 
1.4.2.1 The selection and processing of prespacers in the type II-A system 
In the type II-A system, Cas9 is responsible for selecting a prespacer with a canonical PAM 
(Figure 2B) (Heler et al., 2015). This is supported by the observation that mutations on the 
PAM-recognition domain of S. pyogenes Cas9 led to random selection of prespacers that are 
not located next to a PAM. Furthermore, when the S. pyogenes Cas9 and S. thermophilus Cas9 
from CRISPR3 locus (an ortholog of S. pyogenes Cas9) (Fonfara et al., 2014) were exchanged, 
the newly acquired spacers matched the PAMs that corresponded to the respective Cas9 
ortholog, i.e. NGG PAM for S. pyogenes Cas9 (Jinek et al., 2012) and NGGNG PAM for 
S. thermophilus Cas9 from the CRISPR3 locus (Horvath et al., 2008).  
 
It was shown that tracrRNA-bound Cas9 (tracrRNA-Cas9) is needed for crRNA biogenesis and 
interference (Deltcheva et al., 2011; Jinek et al., 2012). Likewise, the requirement of tracrRNA 
for spacer acquisition suggests a role for tracrRNA-Cas9 in spacer acquisition (Heler et al., 
2015). However, tracrRNA-Cas9 does not appear to be involved in prespacer processing, as 
spacer acquisition could still be detected in catalytically inactive Cas9 (dead Cas9 or dCas9) 
(Heler et al., 2015; Wei et al., 2015a). The responsible player and the detailed mechanism for 
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Figure 3. Spacer acquisition of type I systems.  
(A) Naïve spacer acquisition occurs when there is no pre-existing spacer matching the invader. In type I-E systems, 
it was suggested that the degraded fragments of the foreign DNA generated by RecBCD complex (not illustrated 
here) can be used as prespacer substrates by the Cas1-Cas2 complex if the double-stranded substrates contain 
PAM. The prespacer is processed by Cas1-Cas2 prior to spacer integration into the leader-end of the CRISPR 
array. (B) Primed spacer acquisition occurs in the presence of a pre-existing spacer matching the target DNA. 
Mutation on the PAM or seed sequence of the protospacer abrogate interference, however, Cascade (green) can 
still bind to the target sequence with mutated PAM or seed sequence, but Cascade is unable to recruit the Cas3 
nuclease (brown). In this case, the recruitment of Cas3 can be restored in the presence of Cas1-Cas2 complex. This 
non-canonical recruitment allows bidirectional translocation (grey dotted line with double arrows) of Cas3 together 
with Cas1-Cas2 complex without DNA cleavage. Upon identification of another canonical PAM, the sequence 
proximal to PAM can be used by Cas1-Cas2 as a prespacer substrate. (C) During interference-driven spacer 
acquisition, the DNA cleavage products generated by Cas3 nuclease could be captured by Cas1-Cas2 for spacer 
integration, thereby enlarging the spacer repertoire against a specific MGE. Unlike Cas1-Cas2-dependent 
recruitment of Cas3, Cascade recruits Cas3 upon target DNA identification. Cas3 cleaves the non-target DNA 
strand while translocating in 3´to 5´direction (grey arrow). Rectangles, repeats; diamonds, spacers. The colors of 
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1.4.2.2 The selection and processing of prespacers in the type I-E system of 
E. coli 
Interestingly, in vivo studies of the type I-E system of E  coli demonstrated that, unlike to the 
type II-A system, the presence of Cas1 and Cas2 are sufficient for PAM recognition 
(Figure 3A) (Datsenko et al., 2012; Swarts et al., 2012). In line with this finding, a structural 
study also demonstrated that the Cas1 subunits of the type I-E Cas1-Cas2 complex preferably 
bind to the PAM-complementary sequence at the 3´-overhang (Wang et al., 2015). In addition 
to PAM, dual-forked DNA substrates with a minimum of 7-nt overhangs at both of the 3´-ends 
are also preferably bound by Cas1-Cas2 (Wang et al., 2015). When Cas1-Cas2 binds the dual-
forked DNA, Cas1 twists the 3´-overhangs from the duplex DNA and stabilizes the dual-forked 
DNA substrate via two of its tyrosine residues (Wang et al., 2015). This structural arrangement 
allows the 3´-overhangs of the substrate to be located proximal to the active sites of Cas1 for 
processing, which leads to a 33-nt cleavage product that contains a 23-nt duplex DNA and 5-nt 
3´-overhangs with 3´-OH at both ends. During the processing, parts of the 
PAM-complementary sequence are trimmed, thereby avoiding the integration of spacer with a 
PAM-sequence that could result in self-cleavage. In the Cas1-Cas2 complex, the distance of 
the two tyrosine residues of each of the Cas1 dimers allows the accommodation of a duplex 
DNA with the length of 22-23-bp. Hence, the assembly of the Cas1-Cas2 complex serves as a 
molecular ruler that pre-determines the length of the prespacers (Nunez et al., 2015a; Wang et 
al., 2015). 
 
1.4.2.3 The selection and processing of prespacers in the type I-E system of 
S. thermophilus DGCC7710 
 
Unlike the type I-E system of E. coli, in the type I-E system of S. thermophilus DGCC7710, 
Cas2 is fused to a DnaQ exonuclease domain, which allows to trim the 3´-overhangs of the 
prespacer with its 3´–5´ exonuclease activity to promote optimal spacer integration by the 
Cas1––Cas2-DnaQ complex (Drabavicius et al., 2018). In this in vitro study, efficient 
integration was observed when the 3´-ends possesses a pyrimidine deoxynucleotide.  
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1.4.2.4 The selection and processing of prespacers in the type I systems that 
encode Cas4  
In several type I systems that encode Cas4, Cas4 has been reported to have a role in PAM 
recognitions and prespacer processing (Kieper et al., 2018; Lee et al., 2018; Rollie et al., 2018; 
Shiimori et al., 2018). Cas4 is a widespread protein that could be identified in the type I (I-A, 
I-B, I-C, I-D and I-U), II (II-B) and V (V-A, V-B and V-E) systems (Hudaiberdiev et al., 2017; 
Koonin et al., 2017; Makarova et al., 2015; Shmakov et al., 2015).  
 
Cas4 possesses four conserved cysteine residues that allow its binding to the iron-sulfur 
clusters, and RecB-like nuclease motifs that are important for nuclease activity (Lemak et al., 
2013, 2014; Zhang et al., 2012). DNA helicase, metal-dependent endonuclease and exonuclease 
activities have been reported for Cas4 (Lemak et al., 2013, 2014; Zhang et al., 2012).  
 
In an in vitro experiment, Cas4 the type I-A system of S. solfataricus, was shown to be involved 
in the processing of the 3´-overhang of prespacer substrates in a PAM-dependent manner 
(Rollie et al., 2018). In the presence of Cas1-Cas2, Cas4 of the type I-C system of 
Bacillus halodurans promotes the processing of the 3´-overhang of prespacer in a 
PAM-dependent manner to ensure that only interference-favored prespacers will be integrated 
into the CRISPR array (Lee et al., 2018). In this regard, the nuclease activity of Cas1 also 
contributes to prespacer processing, although the nuclease activity of Cas4 would be sufficient 
(Lee et al., 2018). In agreement with that, an in vivo study in type I-D system (Synechocystis 
sp. 6803) also demonstrated that the nuclease activity of Cas4 is important for the processing 
of prespacers and promoting selection of spacers with a canonical PAM before spacer 
integration (Kieper et al., 2018).  
 
A recent study showed that Pyrococcus furiosus encodes Cas4-1 and Cas4-2, which recognize 
a PAM and a NW motif, respectively, upstream and downstream of the prespacer; thereby it 
allows the nuclease activities of Cas4 to define the spacer length while processing the prespacer 
(Shiimori et al., 2018). P. furiosus encodes a type I-A Csa, a type I-G Cst and a type III-B Cmr 
effector complexes and seven CRISPR arrays with highly conserved leaders and repeats 
(Shiimori et al., 2017). In P. furiosus, cas1, cas2 and cas4-1 share the same locus with cst, cmr 
and cas6 genes, whereas cas4-2 is distant from other cas genes (Shiimori et al., 2017). It is still 
remains to be investigated whether Cas4 from the type II-B, V-A, V-B and V-E systems, are 
also involved in the prespacer processing. 
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1.4.3 Spacer integration into the CRISPR array 
 
1.4.3.1 Recognition of the CRISPR array 
The leader sequence (located at the upstream of the CRISPR array) polarizes the spacer 
integration predominantly at the leader-proximal CRISPR array, thereby maintaining the 
chronological order of the MGE invasions (Barrangou et al., 2007; Pourcel et al., 2005). In 
type II-A systems, the preference of spacer integration at the leader-proximal CRISPR array is 
determined by a short DNA motif named leader-anchoring site (LAS), which comprises 5 bp 
of the leader sequence immediately upstream of the CRISPR array (Figure 2C) (McGinn and 
Marraffini, 2016). In the type II-A system of E. faecalis, a LAS with a size of 4 bp is sufficient 
for determining the spacer integration at the leader-proximal CRISPR array (Xiao et al., 2017). 
Cas1-Cas2 uses the LAS as a landmark and inserts new spacers into the CRISPR array 
immediately downstream of the LAS (McGinn and Marraffini, 2016). However, when the LAS 
was mutated, inefficient ectopic spacer integration occured in the middle of the CRISPR array. 
Hence, the tolerance of Cas1-Cas2 to the mutations of the LAS allows flexible spacer 
integration at the non-leader-proximal sites of the CRISPR array, although the phage resistance 
is reduced possibly due to the lower expression of the crRNAs further from the leader (McGinn 
and Marraffini, 2016). In addition to the LAS recognition in the type II-A system, the 
S. pyogenes type II-A Cas1-Cas2 complex also recognizes the palindromic ends of the repeats 
via the Cas1 active sites (Wright and Doudna, 2016). Although the first integration could occur 
at either ends of the first repeat (leader-proximal repeat), the preference of spacer integration at 
the leader-end of the first repeat is directed by the concurrent recognition of both, the LAS and 
the palindromic end of the leader-end of the first repeat by Cas1-Cas2 (Figure 2C) (McGinn 
and Marraffini, 2016; Wright and Doudna, 2016; Xiao et al., 2017). A recent study 
demonstrated that the middle part of the repeat in E. faecalis is also important for spacer 
acquisition, as spacer acquisition was abrogated when the middle part of the repeat sequence of 
E. faecalis was replaced with the middle part of the repeat sequence of S. pyogenes (Xiao et al., 
2017). 
 
Unlike the type II-A system, the recognition of the leader-proximal CRISPR array in the 
type I-E system of E. coli relies on the non-CRISPR protein named integration host factor (IHF) 
(Nunez et al., 2015a, 2016; Yoganand et al., 2017). Upon binding of IHF on the leader 
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sequence, the leader sequence bends into a U-shaped DNA structure that facilitates the 
recognition of the leader-repeat boundary by Cas1-Cas2, which positions the prespacer 
pre-loaded on the Cas1-Cas2 close to the leader-repeat boundary for integration (Wright et al., 
2017). 
 
1.4.3.2 Spacer integration 
In the type II-A systems, upon binding of Cas1-Cas2 to the LAS-repeat sequence, the 
palindromic-repeat recognition loop of Cas1 undergoes a conformational change, which allows 
the 3´-OH ends of the prespacer to be positioned close to the catalytic sites of Cas1 before the 
first half-site integration (the integration of one strand of the prespacer at one end of the repeat) 
(Xiao et al., 2017). During the first half-site integration in both type II-A (Figure 2C) and 
type I-E systems, Cas1 catalyzes the nucleophilic attack of the 3´-OH end of the prespacer on 
the leader-end of the repeat, thereby attaching the 3´-overhang of the prespacer to the leader-end 
of the repeat (Nunez et al., 2015a; Wright and Doudna, 2016; Xiao et al., 2017).  
 
In both type II-A and type I-E systems, the second integration relies on the recognition and 
binding of Cas1-Cas2 at the palindromic repeat motif at the spacer-end of the repeat, which 
subsequently leads to the bending of the repeat sequence, thereby allowing the accessibility of 
Cas1 to the second integration site at the spacer-end of the repeat (Goren et al., 2016; Wright 
et al., 2017; Xiao et al., 2017). In addition, a prespacer with the proper length is also important 
for the second integration (Wright and Doudna, 2016). During the second nucleophilic attack, 
the 3´-OH of another strand of the prespacer is ligated to the spacer-end of the repeat, hence, 
full spacer is completely inserted into the CRISPR array (Figure 2C) (Nunez et al., 2015a, 
2016; Wright and Doudna, 2016). If the mentioned criteria are not met, the full-site integration 
could be restrained, probably through the reversal of the first half-side integration reaction by 
the acquisition machinery, or the elimination of the half-side integration intermediate product 
by DNA repair proteins (Wright and Doudna, 2016). Subsequently, the gaps of the CRISPR 
array are presumed to be repaired by DNA polymerase and ligase, which leads to spacer 
integration and repeat duplication. 
 
The proper orientation of the integrated spacer in the CRISPR array ensures the production of 
crRNA that can bind to the protospacer with a PAM and thus to enable interference. In the 
type I-E system of E. coli, the proper orientation of the newly integrated spacer is determined 
by the presence of the partial PAM on the prespacer, which is trimmed possibly after the binding 
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of Cas1-Cas2 to the leader-repeat boundary and prior to spacer integration (Shipman et al., 
2016; Shmakov et al., 2014; Wang et al., 2015). In P. furiosus, Cas4-1 and Cas4-2 maintain the 
orientation of the integrated spacer: (1) via processing the 5´-NGG PAM (by Cas4-1) and the 
3´-NW motif (by Cas4-2) of the prespacer prior to the integration, and (2) by staying associated 
with the spacer during the integration process (Shiimori et al., 2018). 
 
The in vitro spacer integration in the type II-A system of S. pyogenes system does not require 
Csn2 (Wright and Doudna, 2016), which was shown to be essential for spacer acquisition in 
vivo (Barrangou et al., 2007; Garneau et al., 2010; Heler et al., 2015; Wei et al., 2015a). Csn2 
was shown to co-purify with Cas1, Cas2 and Cas9, which are also critical for spacer acquisition 
(Heler et al., 2015) (Heler 2015). Moreover, size-exclusion chromatography (SEC) showed the 
direct interaction of Csn2 with Cas1 and Cas9, respectively (Ka et al., 2016, 2018). Based on 
the observation that the N-terminal interacting site of Cas1 with Csn2 is located close to the 
DNA end of the prespacer, Csn2 was suggested for its role associated with prespacer generation 
or a role as a scaffold protein for connecting other Cas proteins (Ka et al., 2018; Wright and 
Doudna, 2016) or host factors. However, the roles of Csn2 in spacer acquisition still remains to 
be clarified experimentally. 
 
1.4.4 Primed spacer acquisition 
Mutating the protospacers or PAMs is one of the strategies applied by MGEs to escape 
CRISPR-Cas immunity (Deveau et al., 2008; Fineran et al., 2014; Semenova et al., 2011). From 
the perspective of CRISPR-Cas immunity, harboring multiple-spacers targeting a single-MGE 
could counter-combat mutated MGEs (Paez-Espino et al., 2013; Xue et al., 2015) and hamper 
the proliferation of MGE escape mutants effectively (Andersson and Banfield, 2008; van Houte 
et al., 2016). With this regard, a pre-existing spacer (in the CRISPR array) that corresponds 
either to a mutated protospacer or a mutated PAM, can accelerated the spacer uptake through a 
process named primed spacer acquisition (also known as priming) (Figure 3B) (Datsenko et 
al., 2012; Fineran et al., 2014; Li et al., 2014; Richter et al., 2014; Swarts et al., 2012). In 
contrast to the primed spacer acquisition, naïve spacer acquisition refers to the spacer uptake 
from newly confronted MGEs (Figure 3A), therefore there is no pre-existing spacer against the 
newly confronted MGEs, and it shows relatively lower rate of spacer uptake in comparison to 
primed spacer acquisition (Yosef et al., 2012). To date, primed spacer acquisition has only been 
described in the type I CRISPR-Cas systems, and it remains to be studied whether other types 
Introduction   
 19 
of CRISPR-Cas systems also adopt this counter-strategy against MGE mutants. Among the 
type I systems, primed spacer acquisition in the type I-E system of E. coli is the most 
extensively studied. Thereby, type I-E primed acquisition will be the focus here. 
 
In the type I-E system, Cas1, Cas2 and the interference machinery, i.e. Cas3 and Cascade, are 
required for primed spacer acquisition (Datsenko et al., 2012; Li et al., 2014; Richter et al., 
2014; Savitskaya et al., 2013; Swarts et al., 2012). When the target DNA matches the crRNA 
of the Cascade, Cascade binds to the protospacer and recruits Cas3 to cleave the MGE 
(Hochstrasser et al., 2014; Mulepati and Bailey, 2011; Sinkunas et al., 2011, 2013; Westra et 
al., 2012). When CRISPR interference is abrogated by the mutations in the PAM or seed 
sequence of the protospacer, Cascade binds to the target DNA but fails to recruit Cas3 
(Figure 3B)  (Blosser et al., 2015; Redding et al., 2015; Xue et al., 2016). If Cas1 and Cas2 are 
present, however, Cas3 can still bind to the target DNA and translocate bi-directionally along 
the DNA, presumably together with Cas1 and Cas2, searching for a prespacer with a canonical 
PAM for integration (Redding et al., 2015). In line with this, an adaptation complex constituted 
by Cas1 and Cas2-Cas3 fusion protein was reported in the type I-F system of 
Pectobacterium atrosepticum (Fagerlund et al., 2017; Richter et al., 2012) and 
Pseudomonas aeruginosa (Rollins et al., 2017), suggesting similarity between the primed 
acquisition mechanisms of the type I-F and the type I-E systems. 
 
1.4.5 Interference-driven spacer acquisition 
A variety of primed spacer acquisition known as interference-driven spacer acquisition also 
promotes rapid spacer acquisition in the presence of pre-existing spacers (Künne et al., 2016; 
Staals et al., 2016). However, as suggested by the name, interference-driven spacer acquisition 
is promoted by CRISPR interference (Künne et al., 2016; Staals et al., 2016), which is contrary 
to the mutation-stimulated primed spacer acquisition (Datsenko et al., 2012; Fineran et al., 
2014; Li et al., 2014; Richter et al., 2014; Swarts et al., 2012). Studies in the type I-E system of 
E. coli and type I-F of P. atrosepticum demonstrated that the DNA cleavage products generated 
by Cas3 during interference, could be used by the Cas1-Cas2 for spacer acquisition, resulting 
in multiple spacers targeting the same MGEs (Figure 3C) (Künne et al., 2016; Staals et al., 
2016). It is suggested that the ssDNA fragments generated by Cas3 re-annealed into various 
partial duplexes, including 3´- and/or 5´-overhangs, with an intermediate spacer length and 
3´-PAM enrichments (Künne et al., 2016). Among the pool of prespacers with various 
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structures, Cas1-Cas2 shows binding preference to the partial duplexes with 3´-overhangs and 
3´-PAMs and further trims the substrates before integration (Nunez et al., 2015b; Wang et al., 
2015). Thus, cooperation between the adaptation and interference machineries allows 
Cas1-Cas2 to reuse the DNA degradation products for spacer integration, thereby, expanding 
the spacer repertoire. Interference-driven spacer acquisition promotes diverse spacer 
repertoires, which allows efficient interference against the same phage (Paez-Espino et al., 
2013; Xue et al., 2015) and reduces the possibility of the propagation of escaped phages (van 
Houte et al., 2016; Künne et al., 2016; Staals et al., 2016). Both primed and interference-driven 
spacer acquisitions have only been reported in type I systems thus far, implying that different 
types of CRISPR-Cas systems adopt different modes of acquisition strategies that serve the best 
for their survival and fitness. 
 
1.4.6 Reverse transcription spacer acquisition 
While spacers are commonly acquired from foreign DNA across numerous types of 
CRISPR-Cas systems, both DNA and RNA could be acquired as spacers in the type III-B 
system of Marinomonas mediterranea. The type III-B system of M. mediterranea possesses a 
fusion protein of Cas1 with reverse transcriptase (RT-Cas1), which together with Cas2 inserts 
an RNA prespacer into the leader-proximal repeat, and subsequently reverse transcribes the 
inserted RNA into a cDNA spacer via the RT domain of Cas1. In addition, RT-Cas1-Cas2 can 




1.5 Co-evolution of phages and prokaryotes 
The arm race between prokaryotes and phages is an endless process and the driving force for 
both parties to constantly evolve the defense and counter-defense strategies against each other.  
Similar to other prokaryotic defense systems, phages have also evolved a couple of 
CRISPR-Cas evasion strategies which were characterized. However, there are probably many 
more of these anti-CRISPR strategies awaiting to be discovered. 
 
As a counter CRISPR-Cas strategy, some phages have evolved anti-CRISPR (acr) genes to 
directly hinder the CRISPR interference mechanism (Pawluk et al., 2017). The anti-CRISPR 
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proteins encoded in the temperate phages of P. aeruginosa demonstrated inhibitory activities 
against the type I-F system (Pawluk et al., 2017). For example, AcrF1 and AcrF2 interact with 
the Csy complex (crRNA-effector of type I-F system) subunits, thereby interfering with the 
binding of Cascade to the target DNA (Bondy-Denomy et al., 2015; Chowdhury et al., 2017; 
Peng et al., 2017), whereas AcrF3 prohibits the recruitment of the Cas3 effector for target DNA 
cleavage (Bondy-Denomy et al., 2015). In the type II-C system of Neisseria meningitides, 
AcrIIC prevents CRISPR interference by binding to Cas9 and blocking DNA cleavage in vitro 
(Pawluk et al, 2016, Cell). The type II-A anti-CRISPR protein, AcrIIA4, inhibits the PAM-
interacting residues of Cas9 of Listeria monocytogenes (Dong et al., 2017; Rauch et al., 2017; 
Shin et al., 2017; Yang and Patel, 2017). A very recent study revealed that the AcrIIA5 and 
AcrIIA6 proteins inhibit Cas9 of the type II-A systems of S. thermophilus (CRISPR1 and 
CRISPR3) and S. pyogenes, however, the detailed mechanism remains to be investigated 
(Hynes et al., 2017, 2018). 
 
While anti-CRISPR systems are protein-based strategies that have evolved in some phages over 
a longer timescale, some phages also use a random mutation strategy that depends on sequence 
specificity to evade CRISPR-Cas systems. With this regard, escaped mutants hamper CRISPR 
interference via the introduction of mutations in the PAM or seed sequence of the protoscaper 
(Deveau et al., 2008; Fineran et al., 2014; Semenova et al., 2011). However, the type III-A 
system of S. epidermidis is more tolerant towards the mutations in the protospacer and proximal 
regions due to its wide mismatches-tolerant, and PAM- and seed sequence-independent features 
(Pyenson et al., 2017). As a counter-strategy to escaped mutants, primed spacer acquisition has 
evolved in some type I systems, which boosts spacer acquisition when interference is 
interrupted by PAM or seed sequence mutations (Datsenko et al., 2012; Fineran et al., 2014; Li 
et al., 2014; Richter et al., 2014; Swarts et al., 2012). Primed spacer acquisition promotes spacer 
diversity in bacterial populations and subsequently relieves the evasion rate of the phage 
mutants (van Houte et al., 2016). On the other hand, S. thermophilus co-evolution studies 
revealed that multi-phage infection enhances the persistence duration of the phages (Paez-
Espino et al., 2015). Furthermore, recombination of two phages were reported to diversify the 
phage genetic contents, consequently enhancing the chance to evade CRISPR-Cas systems 
(Paez-Espino et al., 2015). 
 
Interestingly, instead of being sabotaged by the CRISPR-Cas systems, some phages exploit the 
CRISPR-Cas systems for their own benefits. For example, some of the Campylobacter jejuni 
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phages encode Cas4 (Siringan et al., 2014) that is absent in the type II-C system of C. jejuni, 
which encodes only cas9, cas1, cas2 and tracrRNA (Chylinski et al., 2013, 2014). The 
phage-encoded Cas4 allows the uptake of spacers that are targeting solely C. jejuni genome 
(Siringan et al., 2014). Furthermore, the type I-F CRISPR-Cas system encoded by 
Vibrio cholerae phages is exploited to target other host phage defense systems on the genomic 
islands (Seed et al., 2013). 
 
 
1.6 CRISPR-Cas systems and DNA repair pathways 
Despite the fact that the CRISPR-Cas system is well known for its role in the adaptive defense 
system, CRISPR-Cas was initially proposed for functioning in DNA repair or chromosomal 
segregation pathways (Makarova et al., 2002). In line with the initial hypothesis, studies of the 
type I-E system of E. coli revealed the physical and genetic interaction between Cas1 and 
proteins from the DNA repair and homologous recombination pathways, including RecB, RecC 
and RuvB (Babu et al., 2011). Some of the DNA substrates of the Cas1 nuclease activity share 
similar structures with the intermediate products derived from the DNA repair and homologous 
recombination pathways, for example, Holiday junctions, replication forks and 5’-flaps (Babu 
et al., 2011; Nunez et al., 2015b; Wiedenheft et al., 2009). Furthermore, studies of the type I-E 
system of E. coli and type II-A system of S. pyogenes suggested that the Cas1-Cas2 complex 
possibly employs the degradation products generated by the RecBCD or AddAB complex for 
spacer acquisition (Levy et al., 2015; Modell et al., 2017). However, a very recent study 
reported that the nuclease activity of RecBCD is not required for spacer acquisition, instead, 
the helicase activity of RecBCD is essential for spacer acquisition (Radovčić et al., 2018). 
 
In vivo, a cas1 deletion mutant of E. coli is more sensitive to DNA damage caused by genotoxic 
agent mitomycin C (MMC) and ultraviolet irradiation. Correspondingly, Cas1 is also detected 
at the DNA damage sites in MMC-treated E. coli. Furthermore, a cas1 deletion mutant 
demonstrates abnormal cells elongation after MMC treatment, implying a role of Cas1 in cell 
division and chromosomal segregation (Babu et al., 2011). In agreement with the studies in 
E. coli, MMC-induced DNA damage in Acinetobacter baylyi ADP1 that encodes a type I-F 
CRISPR-Cas system, increased the expression of cas1, as well as other cas genes, such as cas6, 
csy2 and csy3 (Hare et al., 2014). In type I-A of Pyrococcus furiosus, cas genes were 
upregulated upon exposure to gamma irradiation (Williams et al., 2007). Additionally, nalidixic 
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acid-induced SOS response causes accumulation of crRNA (Klaiman et al., 2014). Another 
study in E. coli revealed that the DNA repair proteins RecG, PriA and DNA polymerase I are 
required for primed adaptation, whereas RecB and DNA polymerase I are needed for naïve 
adaptation (Ivancic-Bace et al., 2015). A recent study showed that the non-homologous 
end-joining (NHEJ) system does not impact CRISPR immunity, and csn2 of type II-A systems 
restrains the co-occurrence of the NHEJ system in bacteria (Bernheim et al., 2017). Despite 
these initial experimental evidences showing the connection between CRISPR-Cas systems and 
DNA repair pathways, the complex interactions between these systems and the detailed 
mechanisms involved are still yet to be elucidated. 
 
 
1.7 The type II-A CRISPR-Cas systems of 
Streptococcus pyogenes SF370 and 
Streptococcus thermophilus LMD-9 
 
1.7.1 Streptococcus pyogenes  
 
1.7.1.1 General characteristics and pathogenesis of S. pyogenes 
S. pyogenes, also known as group A Streptococcus (GAS), is a Gram-positive bacterium and a 
human pathogen that causes a wide spectrum of infections such as streptococcal toxic-shock 
syndrome, necrotizing fasciitis, pharyngitis and impetigo (Carapetis et al., 2016; Walker et al., 
2014). While S. pyogenes is still susceptible to penicillin and cephalosporin treatments, there is 
a growing global concern of resistance to other antibiotics such as macrolides and clindamycin. 
Hitherto, an effective and safe vaccine to prevent S. pyogenes infections is still needed (Walker 
et al., 2014). 
 
1.7.1.2 CRISPR-Cas loci in S. pyogenes SF370 
S. pyogenes SF370 (also known as M1 GAS) possesses two CRISPR-Cas loci, i.e. the 
CRISPR01 locus, which belongs to the type II-A system; and the CRISPR02 locus, which 
belongs to the type I-C system (Deltcheva et al., 2011; Nozawa et al., 2011). The CRISPR locus 
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of the type II-A system of S. pyogenes SF370 showed expression, whereas the CRISPR locus 
of the type I-C system appears to be not expressed (Deltcheva et al., 2011). The type II-A 
system of S. pyogenes SF370 encodes tracrRNA, cas9, cas1, cas2 and csn2 and harbors a 
CRISPR array containing 7 repeats interspaced with 6 spacers (Figure 4). Spacer 6 does not 
match to any sequence, whereas spacers 1 to 5 share high sequence similarity to prophage 
sequences, i.e. endopeptidase, superantigen (speM), adenine-specific methyltransferase, 
hyaluronidase and phage protein (Deltcheva et al., 2011). The first spacer in the type II-A 
CRISPR array matches the prophage-encoded Spy_0700 gene existing in the genome of SF370 
strain. However, the PAM corresponding to the first spacer is mutated (Deltcheva et al., 2011), 




Figure 4. Type II-A CRISPR-Cas locus in S. pyogenes SF370. 
Type II-A CRISPR-Cas systems encode four cas genes, i.e. cas9, cas1, cas2, csn2, and a tracrRNA. Brown line, 
leader; rectangles, repeats; diamonds, spacers. 
 
 
1.7.2 Streptococcus thermophilus 
 
1.7.2.1 General characteristics and the industrial values of S. thermophilus 
Streptococcus thermophilus is classified as lactic acid bacteria, which ferment carbohydrate to 
lactate for metabolic energy generation. Unlike the other pathogenic Streptococci including 
S. pyogenes, S. thermophilus has followed a different evolutionary path, and has lost many of 
the virulence-associated properties. Thus, it is regarded as a ‘generally recognized as safe’ 
species. On the other hand, S. thermophilus has gained industrially valuable features such as 
polysaccharide biosynthesis, bacteriocin biosynthesis, RM systems or oxidative stress 
endurance (Bolotin et al., 2004; Hols et al., 2005). S. thermophilus is regarded as the second 
most valuable bacteria in the dairy industry after Lactococcus lactis due to its extensive use as 
a starter culture in the production of yogurt and cheeses (Hols et al., 2005). Furthermore, 
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S. thermophilus, Lactobacillus sp., Bifidobacterium sp., and Saccharomyces boulardii are 








Figure 5. S. thermophilus LMD-9 and phage DT1. 
(A) Scanning electron microscopy of S. thermophilus LMD-9 infected by phage DT1 at the multiplicity of 
infection (MOI) of 100 with the adsorption time of 1 minute at room temperature (Photograph courtesy of Manfred 
Rohde, Helmholtz Centre for Infection Research, Braunschweig). (B) CRISPR-Cas loci in S. thermophilus 
LMD-9. Brown line, leader; rectangles, repeats; diamonds, spacers. 
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1.7.2.2 Bacteriophage infection in S. thermophilus 
During fermentation process in the dairy industry, phage infection in the starter cultures 
(Figure 5A) can cause huge problems in the dairy production and financial loss, as it could be 
an obstruction for the milk acidification by the starter cultures in the fermentation tanks 
(Brüssow, 2001; Quiberoni et al., 2010). Additionally, the endurance of phages to 
pasteurization and their airborne propagation leads to persistence of phages in the dairy 
production facilities. Hence, several bacterial defense systems have been exploited in dairy 
manufacturing industry to combat phage infection in the starter culture and minimize the 
negative impacts of phage infection during the manufacturing process (Barrangou et al., 2013). 
CRISPR-Cas systems can be harnessed to improve phage resistance of S. thermophilus along 
with other defense systems or in combination with numerous strain rotations to protect the dairy 
manufacturing process (Barrangou et al., 2013). 
 
1.7.2.3 CRISPR-Cas loci in S. thermophilus LMD-9 
S. thermophilus LMD-9 contains three CRISPR loci in its genome, namely the CRISPR1 and 
CRISPR3 loci that belong to type II-A systems, and the CRISPR2 locus that belongs to type 
III-A system (Figure 5B). Both type II-A CRISPR loci were shown to be active in spacer 
acquisition, whereas CRISPR2 of the type III-A system seems to be inactive (Horvath et al., 
2008). The type III-A system of S. thermophilus LMD-9 contains the almost universal cas1 and 
cas2 genes, cas6 that is important for crRNA biogenesis, and other cas genes encoding the 
subunits that form the Csm complex, namely cas10, csm2, csm3, csm4, csm5 and csm6 (Horvath 
et al., 2008). On the other hand, cas9, cas1, cas2, csn2 and tracrRNA are encoded in the type 
II-A systems of the CRISPR1 and CRISPR3 loci (Horvath et al., 2008), of which the marked 
differences are CRISPR1 that contains short cas9 and long csn2 (csn2b), while CRISPR3 
contains long cas9 and short csn2 (csn2a) (Chylinski et al., 2013). The CRISPR array of the 
CRISPR1 locus contains 15 spacers, whereas the CRISPR array of CRISPR3 locus contains 8 
spacers (Horvath et al., 2008).  
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2 Aims of the Thesis 
 
During CRISPR adaptation, a short piece of genetic material is acquired from the invading 
MGE and integrated into the CRISPR array as a heritable genetic memory to defend the 
prokaryotes against the re-invasion of the cognate MGEs. Spacer acquisition was first reported 
in the type II-A system of S. thermophilus in 2007 (Barrangou et al., 2007), however, the 
detailed molecular mechanism of spacer acquisition and the elements needed for the type II-A 
system were not understood at the time. In type I-E systems of E. coli, the almost universal 
Cas1 and Cas2 proteins are sufficient to activate naïve spacer acquisition in vivo (Yosef et al., 
2012), and the mechanism was presumed to be similar in the type II-A system. When a 
S. thermophilus strain with deactivated csn2 was challenged with lytic phage, spacer acquisition 
was abrogated, suggesting a role of Csn2 in this stage (Barrangou et al., 2007). The aim of my 
thesis was to characterize the molecular mechanism and the requirements for type II-A spacer 
acquisition. In addition to the implicated Cas1, Cas2 and Csn2, we were interested in 
investigating whether Cas9, tracrRNA and other non-Cas proteins were also involved in 
type II-A spacer acquisition. Furthermore, we planned to elucidate the role of every single 
element essential for spacer acquisition. This included examination of the direct protein-protein 
interactions among these proteins and with external co-factors, identification of the interacting 
regions and investigation of the significance of these interactions in spacer acquisition or other 
cellular processes. This thesis also aimed to examine whether there is any crosstalk in spacer 
acquisition between the Cas proteins from different CRISPR-Cas loci. 
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3 Results  
 
3.1 Spacer acquisition in the type II-A CRISPR-Cas 
system of S. pyogenes SF370 
At beginning of my PhD project, the understanding of the spacer acquisition mechanism in 
CRISPR-Cas immunity was limited. Cas1 and Cas2 was shown to be sufficient for spacer 
acquisition in the type I-E system of E. coli (Datsenko et al., 2012; Yosef et al., 2012). The 
essentiality of Cas1 and Cas2 in spacer acquisition were presumed to be same in other 
CRISPR-Cas types, including the type II-A systems, due to the high conservation of Cas1 and 
Cas2 in the CRISPR-Cas systems (Makarova et al., 2011), and their dispensability in crRNA 
biogenesis and interference (Barrangou et al., 2007; Bhaya et al., 2011; Brouns et al., 2008). 
Csn2 was shown to be additionally needed for spacer acquisition in the type II-A systems of 
S. thermophilus (Barrangou et al., 2007).  We started our study by examining the significance 
of all CRISPR-associated elements, i.e. Cas1, Cas2, Csn2, Cas9 and tracrRNA, of the type II-A 
system in spacer acquisition. We then investigated whether any additional element was also 
required for the adaptation process.  
 
3.1.1 The heterologous type II-A CRISPR-Cas system of 
S. pyogenes is established in E. coli BL21-AI 
In order to genetically and biochemically characterize the spacer acquisition mechanism of 
S. pyogenes type II-A system, the type II-A system was cloned into plasmids and investigated 
in E. coli BL21-AI. This E. coli strain does not encode endogenous cas genes which makes it a 
suitable host for heterologous studies (Yosef et al., 2012). E. coli BL21-AI encodes T7 RNA 
polymerase that is regulated by L-arabinose-induced promoter, thereby allowing inducible 
expression of the genes under a T7-lac promoter of a plasmid. 
 
The type II-A system was separated into two parts and cloned into two different plasmids. This 
aimed to separate the CRISPR array from cas1, cas2 and csn2 genes, to allow antibiotics 
selection of the clones that have lost the plasmids harboring the three cas genes, as result of 
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spacer acquisition. The combination of cas1-cas2-csn2 genes was cloned into the pCDF-DUET 
vector, whereas tracrRNA-Leader-CRISPR was cloned into the pEC85. The expression of cas1, 
cas2, csn2 was controlled by the inducible T7-lac promoter, whereas the expression of 
tracrRNA and CRISPR was regulated by their native promoters.  
 
We confirmed the transcription of csn2 in E. coli BL21-AI via semi-quantitative reverse 
transcription polymerase chain reaction (RT-PCR) (Figure 6). Since, cas1, cas2 and csn2 genes 
are located in the same operon and controlled by the same inducible promoter, the transcription 
of csn2 is sufficient to show the transcription of the whole operon. The expression of the 
heterologous genes was also observed in the samples without induction, which might be due to 
leaky expression. The Cas proteins translation was not verified by Western Blot analysis due to 
the lack of antibodies against the Cas proteins at that time. After confirming the transcription 
of the cas operon with cas1, cas2 and csn2, two different spacer acquisition setups were tested 




   
Figure 6. Validation of csn2 gene expression in the heterologous type II-A CRISPR-Cas system of 
S. pyogenes SF370 in E. coli BL21-AI.  
The agarose gel picture of semi-quantitative RT-PCR shows the expression level of csn2 gene of 
pCDF-DUETΩcas1-cas2-csn2. The expression of cas genes was induced with 1 mM IPTG and 0.2% arabinose 
for 2 hours. A PCR reaction was additionally performed to confirm that the RNA templates were free from DNA 
contamination. pCDF-DUET is abbreviated as “p” in the picture.  SF370 gDNA, genomic DNA of 
S. pyogenes SF370; “-”, without induction; “+”, with induction; M, GeneRuler™ 100-bp DNA Ladder 
(Thermo Scientific).  
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3.1.1.1 Plasmid-based spacer acquisition in the heterologous system of 
S. pyogenes 
We asked the question whether cas1, cas2, csn2 and tracrRNA are sufficient for spacer 
acquisition in the type II-A system. To address this question, we induced the expression of cas1, 
cas2 and csn2 with isopropylthio-β-d-galactoside (IPTG) and arabinose in E. coli BL21-AI that 
harbored pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩtracrRNA-Leader-CRISPR. The 
bacterial culture was sub-grown daily for two weeks and the spacer acquisition activity was 
monitored. If these three cas genes are sufficient for spacer acquisition, prespacers would be 
sampled from the plasmids or from the genome (Wei et al., 2015a) and incorporated into the 
type II-A CRISPR array on the plasmid. To analyze the spacer acquisition activity, an aliquot 
of the bacterial culture was sampled daily for total DNA extraction, and the extracted DNA was 
used as PCR template for amplifying the CRISPR arrays of S. pyogenes and E. coli, 
respectively. The parental DNA band (PCR-amplified CRISPR array without spacer uptake) is 
expected to expand 65-66-nt in size with every single spacer being acquired (Figure 7A).  
 
There are two CRISPR arrays present in the genome of E. coli BL21-AI, one of which (array I, 
type I-E systems) contains a conserved leader sequence (Yosef et al., 2012). A type I-E 
plasmid-based acquisition study in E. coli BL21-AI detected spacer acquisition only in the 
CRISPR array I with a conserved leader (Yosef et al., 2012). We wondered whether type II-A 
system is active in E. coli. Therefore, the CRISPR array I of E. coli BL21-AI was also 
monitored for spacer acquisition. Our result showed that expression of cas1, cas2, csn2 and 
tracrRNA from the type II-A system in E. coli BL21-AI did not confer new spacers in the 
CRISPR array I of E. coli (data not shown) (Supplementary Table S1). Pairwise sequence 
alignment of the leader and the repeat sequences of the type II-A system of S. pyogenes and the 
type I-E system of E. coli BL21-AI showed low sequence identities (Supplementary 
Figure S1). This explains that it is unlikely for type II-A adaptation machinery to integrate 
spacer into the type I-E CRISPR array of E. coli BL21-AI. In line with this, type II-A system 
relies on LAS sequence to direct Cas1-Cas2 towards the spacer integration site (McGinn and 
Marraffini, 2016), whereas type I-E system is dependent on IHF (Nunez et al., 2016). PCR 
monitoring showed that spacer acquisition was also not detected in the S. pyogenes CRISPR 
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Figure 7. The spacer acquisition screening of S. pyogenes heterologous system in E. coli BL21-AI. 
 (A) Schematics of PCR screening for acquisition. A single spacer acquisition gives a 65-66-nt increment of size 
to the parental band. Arrows indicate forward and reversed primers. ‘0’, parental band without acquisition; ‘+1’, 
DNA band with one newly acquired spacer; ‘+2’, DNA band with two newly acquired spacers; black rectangles, 
repeats; green rectangles, existing spacers; red rectangles, newly acquired spacers. (B) Spacer acquisition 
screening for S. pyogenes heterologous system challenged with plasmids. E. coli BL21-AI harboring two plasmids, 
i.e. pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩtracrRNA-Leader-CRISPR was used in this assay. No expanded 
band (no spacer acquisition) was detected in this assay. (C) Spacer acquisition screening for S. pyogenes 
heterologous system challenged with plasmids. E. coli BL21-AI harboring three plasmids, i.e. 
pCDF-DUETΩcas1-cas2-csn2, pEC85ΩtracrRNA-Leader-CRISPR-cas9 and pUC19ΩSpy_0700-NTG(PAM) 
was studied in this assay. Expanded band was not observed in this assay. (D) Spacer acquisition screening for 
S. pyogenes heterologous system challenged with lytic phage Lambda. E. coli BL21-AI harboring two plasmids, 
i.e. pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩtracrRNA-Leader-CRISPR-cas9 was challenged with phage 
Lambda in this assay. The agarose gel picture shows the acquisition result of the phage challenge with MOI of 1. 
This assay did not detect any expanded band. Representative 2% agarose gel pictures for the spacer acquisition 
screenings are shown here. ‘0’, the expected size of the parental band without acquisition; ‘+1’, the expected size 
of the DNA band with one newly acquired spacer. M, GeneRuler™ 100-bp DNA Ladder (Thermo Scientific).  
 
 
We did not detect spacer acquisition in the heterologous system expressing cas1, cas2 and csn2 
and tracrRNA, and we questioned whether it was due to the lack of Cas9. To investigate whether 
Cas9 is required for spacer acquisition in the type II-A systems, we included Cas9 in the 
plasmid-based spacer acquisition assay, by introducing pEC85ΩtracrRNA-Leader-CRISPR-
cas9, of which the expression of cas9 was controlled under the native promoter of the cas 
operon. Since it is unclear whether primed spacer acquisition exists in the type II-A systems, 
we wondered if Cas9 plays a similar role like the interference machinery in the primed spacer 
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acquisition of the type I-E systems (Datsenko et al., 2012; Swarts et al., 2012). Therefore, we 
designed a three-plasmid system that mimics the primed acquisition by including 
pCDF-DUETΩcas1-cas2-csn2, pEC85ΩtracrRNA-Leader-CRISPR-cas9 and 
pUC19ΩSpy_0700-NTG(PAM). Spy_0700-NTG(PAM) is a protospacer with a mutated PAM, 
(the NGG PAM was mutated to NTG), which is supposed to accelerate the spacer acquisition 
activity via priming if primed spacer acquisition exists in the type II-A system. The 
three-plasmid acquisition assay was similar to the two-plasmid acquisition assay described 
earlier, with a small modification for the sampling of the template DNA for PCR screening (see 
Materials and Methods). In this assay, the colonies that had lost 
pUC19ΩSpy_0700-NTG(PAM) were selected via replica plating on the non-selective and 
selective plates, followed by colony PCR screening. Spacer acquisition was not detected in 
S. pyogenes CRISPR array, as well as the E. coli CRISPR array (Figure 7C; Supplementary 
Table S1). In summary, spacer acquisition was not detected in the two- and three-plasmid 
acquisition assay. 
 
3.1.1.2 Spacer acquisition in the S. pyogenes heterologous system with 
phage challenge 
The plasmid-based acquisition was possibly not able to confer strong selective pressure to the 
bacteria to activate spacer acquisition. To trigger spacer acquisition with high selective pressure 
and positively select the bacteria that acquire and survive, we challenged the bacteria with a 
virulent variant of phage Lambda (phage λvir) (Brouns et al., 2008), which lacks its lysogenic 
regulatory regions. In this study, a two-plasmid system comprised of pCDF-DUETΩcas1-cas2-
csn2 and pEC85ΩtracrRNA-Leader-CRISPR-cas9 was used. Since spacer acquisition would 
eventually lead to interference while the cells are challenged by a cognate invader, wild type 
(WT) cas9 is crucial for the phage challenge assay to ensure the survival of the cells, unless 
they were protected by other anti-viral defense systems. The bacteria that survived the phage 
challenge would appear as colonies on the plates, and these colonies were screened for spacer 
acquisition with colony PCR. Various multiplicities of infections (MOIs), i.e. MOIs of 1, 10 
and 100 have been used for the phage infection, yet, no spacer acquisition was detected 
(Figure 7D; Supplementary Table S1).  
 
Altogether, we did not detect spacer acquisition in the S. pyogenes heterologous system. Since 
spacer acquisition of the type II-A system has not been studied heterologously in the E. coli, 
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we did not know whether the S. pyogenes heterologous system is active in E. coli. Hence, we 
also studied spacer acquisition of the type II-A systems in S. pyogenes. 
 
3.1.2 Plasmid challenge spacer acquisition study in 
S. pyogenes SF370  
Although the heterologous system is more convenient for genetic manipulation, it is unsuitable 
for studying the potential strain-specific host factor(s) necessary for spacer acquisition, which 
is better to study in the native host. To investigate endogenous spacer acquisition, the shuttle 
vector pEC85, which serves as a prespacer source, was transformed into the S. pyogenes SF370 
WT strain. The WT strain was grown in THY medium without antibiotic to allow the 
occurrence of spacer acquisition from the plasmid without killing the cells that have lost the 
plasmid. The colonies from every cycle of culture were checked for spacer acquisition by PCR. 
Every cycle of sub-growing represents every time the culture was transferred to a fresh culture 
for growing. Spacer acquisition was monitored until the 30th cycle, yet no acquisition was 
detected under the tested condition (data not shown) (Supplementary Table S1).  
 
In the WT strain, spacer acquisition will lead to the cleavage of the plasmid by Cas9, and the 
use of antibiotic for the maintenance of the plasmid could result in cell death. To maintain the 
survival of the acquisition-positive cells and improve the plasmid maintenance with the use of 
antibiotic, a cas9 deletion mutant was complemented with pEC85 harboring either tracrRNA-
cas9-D10A-speM (a Cas9 RuvC mutant) or tracrRNA-cas9-H840A-speM (a Cas9 HNH 
mutant). The mutation of the catalytic residue in the RuvC or HNH domain of Cas9 allows 
Cas9 mutants to nick the plasmid DNA instead of cleaving the dsDNA (Jinek et al., 2012), and 
it would not disturb spacer acquisition (Heler et al., 2015; Wei et al., 2015a). Here, we included 
speM, a protospacer that matches a spacer in the type II-A CRISPR array of S. pyogenes, to 
check whether this could accelerate the spacer acquisition activity in a manner similar to the 
primed spacer acquisition in the type I-E systems (Datsenko et al., 2012; Swarts et al., 2012). 
In this study, no spacer acquisition was detected until the 56th day of sub-culturing period for 
all the S. pyogenes cas9 deletion mutant harboring pEC85 vector or pEC85ΩspeM plasmid, as 
well as Cas9 RuvC mutant with tracrRNA and speM, and Cas9 HNH mutant with tracrRNA 
and speM (Figure 8; Supplementary Table S1). Altogether, we did not detect spacer 
acquisition in the heterologous type II-A system of S. pyogenes, as well as the native type II-A 
system S. pyogenes. 
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Figure 8. The screening for the plasmid-based spacer acquisition of endogenous type II-A system of 
S. pyogenes.  
S. pyogenes Dcas9 was transformed with pEC85 vector, pEC85WspeM, pEC85WtracrRNA-cas9-D10A-speM (a 
Cas9 RuvC mutant) (abbreviated as DR) or pEC85WtracrRNA-cas9-H840A-speM (a Cas9 HNH mutant) 
(abbreviated as DH) and monitored for spacer acquisition via PCR screening. Selected agarose gel (1.5%) pictures 
from the 33rd, 47th and 56th day of sub-culturing are indicated here. ‘0’, the expected size of the parental band 
without acquisition; ‘+1’, the expected size of the DNA band with one newly acquired spacer. M, GeneRuler™ 
100-bp DNA Ladder (Thermo Scientific).  
 
 
3.2 Spacer acquisition in the type II-A CRISPR-Cas 
system of S. thermophilus LMD-9 
Due to unsuccessful detection of S. pyogenes spacer acquisition activity in vivo, we decided to 
use S. thermophilus as a model organism for the investigation of type II-A spacer acquisition. 
S. thermophilus has been shown to be naturally active in spacer acquisition (Barrangou et al., 
2007; Horvath et al., 2008), and the type II-A CRISPR-Cas systems of S. thermophilus LMD-9 
and S. pyogenes SF370 are similar (Supplementary Table S2) (Chylinski et al., 2014; Fonfara 
et al., 2014; Makarova et al., 2011). 
 
3.2.1 The heterologous type II-A CRISPR-Cas system of 
S. thermophilus is established in E. coli BL21-AI 
Similar to S.  pyogenes, the type II-A system of S. thermophilus LMD-9 was studied in 
E. coli BL21-AI to obtain insights in the acquisition mechanism. Our study focused on 
CRISPR1 (Cr1) locus of the strain LMD-9, as the CRISPR1 locus of 
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S. thermophilus DGCC7710 was previously described for being more active in spacer 
acquisition than CRISPR3 (Horvath et al., 2008). Pairwise sequence alignment showed that the 
Cas1 from the CRISPR1 loci of LMD-9 and DGCC7710 strains are 100% identical, whereas 
their Cas2, Csn2 and Cas9 are also almost identical (Supplementary Table S3; 
Supplementary Figure S2), which is in agreement with the literature (Chylinski et al., 2014; 
Fonfara et al., 2014). Unless otherwise specified, all the cas genes or Cas proteins mentioned 
here refer to those from CRISPR1 locus. The heterologous system of S. thermophilus was 
established in a similar way as the heterologous system of S.  pyogenes. The transcription of 
csn2 gene of the pCDF-DUETΩcas1-cas2-csn2 was confirmed by semi-quantitative RT-PCR, 
which could represent the transcription of the whole cas operon as described before (Figure 9). 
The proteins expression was not verified by Western Blot analysis due to the absence of the 




Figure 9. Verification of the transcription of csn2 in the heterologous type II-A CRISPR-Cas system of 
S. thermophilus in E. coli BL21-AI.  
RNA expression of heterologous S. thermophilus type II-A CRISPR-Cas system in E. coli BL21-AI was verified 
with semi-quantitative RT-PCR. 2% agarose gel picture of RT-PCR showing the expression level of csn2 gene of 
pCDF-DUETΩcas1-cas2-csn2. The cas genes expression was induced in E. coli BL21-AI with 1 mM IPTG and 
0.2% arabinose for 2 hours. A PCR reaction was additionally performed to confirm that the RNA templates were 
free from DNA contamination. pCDF-DUET is abbreviated as “p” in the picture. LMD-9 gDNA, genomic DNA 
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3.2.1.1 The plasmid-based spacer acquisition in the heterologous system of 
S. thermophilus 
We started the plasmid-based acquisition study with E. coli harboring 
pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩLeader-CRISPR1. These two heterologous 
plasmids served as prespacer sources due to the distribution of a number of PAMs, NNAGAAW 
(Horvath et al., 2008), throughout the plasmids. This study was similar to the S. pyogenes 
heterologous system with some modifications (refer to Materials and Methods for details). The 
induced culture was monitored from the 1st cycle until the 24th cycle of sub-growing, however, 
no acquisition was detected (data not shown). In addition to that, we also monitored the spacer 
acquisition from the culture that had lost pCDF-DUETΩcas1-cas2-csn2 with the presumption 
that plasmid loss might be caused by acquisition. For this assay, an aliquot of the culture from 
the 16th cycle was plated on a LB (lysogeny broth) plate with non-selective antibiotic for 
pCDF-DUETΩcas1-cas2-csn2, followed by replica plating on the non-selective and selective 
plates for pCDF-DUETΩcas1-cas2-csn2. Only 4 colonies out of 200 colonies grew on the 
selective plate for pCDF-DUETΩcas1-cas2-csn2, which indicated that most of the colonies had 
lost pCDF-DUETΩcas1-cas2-csn2. For those colonies that have lost pCDF-
DUETΩcas1-cas2-csn2, 38 colonies were screened for spacer acquisition, however, spacer 
acquisition was not detected (Figure 10A).  
 
3.2.1.2 Phage challenge spacer acquisition in the heterologous system of 
S. thermophilus 
To trigger spacer acquisition by introducing higher selective pressure, we used phage λvir to 
challenge the S. thermophilus heterologous system containing pCDF-DUETΩcas1-cas2-csn2 
and pEC85ΩLeader-CRISPR1. To investigate the optimal infection conditions for triggering 
the acquisition activity, various MOIs and adsorption times (bacteria-phage incubation time at 
37°C without agitation) were tested. This included MOIs of 0.1, 1 and 10 with adsorption times 
of 5, 10, 15 and 20 minutes, respectively. Despite trying numerous phage challenge conditions, 
none of the screened colonies were positive for spacer acquisition (Figure 10B). 
 
In conclusion, we did not detect spacer acquisition in the heterologous system that harbored 
cas1, cas2 and csn2. While the acquisition study with cas1, cas2 and csn2 was performed, the 
pEC85ΩCRISPR1-tracrRNA-Cas9 was still in process of cloning. Later, two studies showed 
that Cas9 and tracrRNA are needed for spacer acquisition (Heler et al., 2015; Wei et al., 2015a). 
Results   
 37 
The absence of Cas9 and tracrRNA in our heterologous system is a reason that spacer 








Figure 10. The spacer acquisition screening of S. thermophilus heterologous system in E. coli BL21-AI. 
(A) Spacer acquisition screening for S. thermophilus heterologous system challenged with plasmid. E. coli 
BL21-AI harboring two plasmids, i.e. pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩLeader-CRISPR1, was studied 
in this assay. This agarose gel picture shows the acquisition screening of the colonies from the cycle 16, which 
had lost pCDF-DUETΩcas1-cas2-csn2. No expanded band (no spacer acquisition) was detected in this assay. A 
representative 2% agarose gel picture for the spacer acquisition screenings is shown here. (B) Spacer acquisition 
screening for S. thermophilus heterologous system challenged with lytic phage Lambda. E. coli BL21-AI 
harboring two plasmids, i.e. pCDF-DUETΩcas1-cas2-csn2 and pEC85ΩLeader-CRISPR1, was studied in this 
assay. Expanded band was not detected in this assay. A representative 2% agarose gel for the screenings is shown 
here. Controls for the acquisition study are shown in lane 1 to 3, where ‘P’ indicates pEC85ΩCRISPR1, and ‘C’ 
indicates colony harboring this plasmid. ‘0’, the expected size of the parental band without acquisition; ‘+1’, the 
expected size of the DNA band with one newly acquired spacer. M, GeneRuler™ 100-bp DNA Ladder 
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3.2.2 The endogenous type II-A system of S. thermophilus LMD-9 
is active in spacer acquisition 
 
3.2.2.1 Phage challenge in S. thermophilus shows active spacer acquisition  
We started the spacer acquisition study with the heterologous system, as we did not have the 
lytic phages for S. pyogenes and S. thermophilus at the beginning of our studies. As soon as the 
lytic phage (phage DT1) for S. thermophilus LMD-9 was available, we challenged 
S. thermophilus with phage DT1 to study spacer acquisition. The bacteria that survived from 
phage challenge were screened for spacer acquisition via colony PCR. The WT strain showed 
acquisition in both CRISPR1 and CRISPR3 loci, with higher spacer acquisition rate in the 
CRISPR3 locus compared to the CRISPR1 locus (Figure 11; Table 1). Spacer acquisition of a 
double knock-out mutant of S. thermophilus LMD-9, with the deletions of the entire CRISPR2 
and CRISPR3 loci (known as ∆Cr2∆Cr3 strain), was compared to the WT in order to test for a 
potential increase of the spacer acquisition rate in this mutant. Our results, however, showed no 
significant difference in the rate of spacer acquisition in the CRISPR1 loci between the WT and 
the ∆Cr2∆Cr3 strains (Table 1). In summary, spacer acquisition was detected in both CRISPR1 
and CRISPR3 loci when S. thermophilus LMD-9 WT was challenged with phage DT1. 
 
 
Table 1. The number of colonies with newly acquired spacers upon phage challenge in 
S. thermophilus LMD-9 WT and ∆Cr2∆Cr3 mutant.  























Figure 11. Both CRISPR1 and CRISPR3 loci of S. thermophilus LMD-9 WT showed spacer acquisition 
upon phage challenge.  
A representative result of endogenous S. thermophilus spacer acquisition study with phage challenge for (A) 
CRISPR1 and (B) CRISPR3 loci. S. thermophilus WT strain was infected with phage DT1 at MOIs of 1 or 10. 
The survivors of the phage challenge were screened for spacer acquisition with colony PCR and analyzed on 2% 
agarose gel. ‘0’, the expected size of the parental band without acquisition; ‘+1’, the expected size of the DNA 
band with one newly acquired spacer; ✔, new spacer being acquired; M, GeneRuler™ 100-bp DNA Ladder 
(Thermo Scientific).  
 
 
3.2.2.2 Cas proteins over-expression in S. thermophilus increases spacer 
acquisition 
To allows easy genetic manipulation of cas genes, we investigated spacer acquisition in 
S. thermophilus LMD-9 by over-expressing the Cas proteins. We did not have a suitable vector 
for S. thermophilus, therefore we examined whether the spacer acquisition in LMD-9 could be 
facilitated by over-expressing the CRISPR1 Cas proteins of DGCC7710 in LMD-9 WT, as the 
CRISPR1 loci of S. thermophilus LMD-9 and DGCC7710 strains are close orthologs 
(Supplementary Table S3; Supplementary Figure S2) (Chylinski et al., 2014; Fonfara et al., 
2014). Elevating the expression of Cas9, Cas1, Cas2 and Csn2 increases the spacer acquisition 
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rate in the CRISPR1 array of LMD-9 WT and ∆Cr2∆Cr3 strains (Figure 12A), which is in 
agreement with the literature (Wei et al., 2015a). Nevertheless, increasing the expression of all 
the four Cas proteins from the CRISPR1 locus, did not increase the spacer acquisition in the 
CRISPR3 locus of the WT strain, suggesting a lack of crosstalk between the Cas proteins from 
CRISPR1 and CRISPR3 loci (Figure 12B). We further confirmed that Cas9 is essential for 
spacer acquisition as spacer acquisition was not detected in ∆Cr2∆Cr3∆cas9_Cr1 (a triple 
knock-out mutant, i.e. deletion of cas9 from the CRISPR1 locus of the ∆Cr2∆Cr3 strain) when 
only Cas1, Cas2 and Csn2 of the CRISPR1 were over-expressed (Figure 12A), which is line 
with other studies (Heler et al., 2015; Wei et al., 2015a). Altogether, we showed that spacer 
acquisition in the type II-A systems is locus-specific, and we also confirmed the requirement 
of all the Cas proteins in spacer acquisition (Heler et al., 2015; Wei et al., 2015a), which led us 
to further investigate the interactions among the Cas proteins. 
 
 
A             B 
  
Figure 12. Over-expression of cas genes in S. thermophilus LMD-9 increases spacer acquisition. 
cas1cas2csn2cas9 or cas1cas2csn2 of the CRISPR1 locus of S. thermophilus DGCC7710 strain were 
over-expressed in the close ortholog, S. thermophilus LMD-9. Spacer acquisition on (A) CRISPR1 (Cr1) and (B) 
CRISPR3 (Cr3) arrays was examined via PCR. PCR reactions were visualized on 2% agarose gel. ∆Cr2∆Cr3, a 
CRISPR2 and CRISPR3 double knock-out mutant of LMD-9; ∆Cr2∆Cr3∆cas9_Cr1, a CRISPR2, CRISPR3 and 
cas9 (CRISPR1) triple knock-out mutant of LMD-9. ∆Cr2∆Cr3∆cas9_Cr1 is abbreviated as ∆cas9_Cr1 in this 
figure. ‘-’, without plasmid; ‘A’, with plasmid pcas1-cas2-csn2-cas9; ‘B’, with plasmid pcas1-cas2-csn2; ‘0’, 
parental band without acquisition; ‘+1’, DNA band with one newly acquired spacer; ✔, new spacer being acquired, 
M, GeneRuler™ 100-bp DNA Ladder (Thermo Scientific). 
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3.3 Characterization of protein-protein interactions 
of type II-A CRISPR-Cas systems  
 
3.3.1 Cas proteins interact with proteins within and beyond 
CRISPR-Cas systems  
Protein-protein interactions (PPIs) within the Cas family during various stages of CRISPR 
immunity have been reported. For instance, complex formations were reported for Cas1 and 
Cas2 in type I-E and II-A systems (Nunez et al., 2014; Xiao et al., 2017), Cas1 and Cas2-Cas3 
fusion protein in type I-F system of P. atrosepticum (Fagerlund et al., 2017), Cas1 and Cas4 in 
type I-C of B. halodurans (Lee et al., 2018). Besides, Cas1 interacts with Cas6 and Cas7 
subunits of the Cascade in the type I-E system, as well as DNA repair proteins such as RecB, 
RecC and RuvB (Babu et al., 2011). In the type II-A systems of S. pyogenes, Cas9, Cas1, Cas2 
and Csn2 were co-purified when N-terminal His6-tagged Cas9 was used as a bait in Ni-NTA 
affinity chromatography, and when C-terminal His6-tagged Csn2 was used as a bait in ion 
exchange chromatography (Heler et al., 2015). Altogether, these studies showed CRISPR-Cas 
type-specific interactions between various Cas proteins for different functions, as well as their 
interactions with proteins beyond CRISPR-Cas systems. 
 
Although all Cas proteins of the type II-A systems, i.e. Cas1, Cas2, Csn2 and Cas9, are essential 
for spacer acquisition (Heler et al., 2015; Wei et al., 2015a), the details of their interactions with 
one another are still obscure. We hypothesized that the Cas1-Cas2 complex acts as the core 
proteins that only interact with Cas9 and Csn2 during a specific mechanistic step of spacer 
acquisition. Studies have revealed the involvement of the non-CRISPR proteins in the type I-E 
primed spacer acquisition (Ivancic-Bace et al., 2015), as well as the connections of the DNA 
repair pathways with several CRISPR-Cas systems (Babu et al., 2011; Klaiman et al., 2014; 
Levy et al., 2015; Modell et al., 2017; Williams et al., 2007). Hence, we speculated that 
type II-A Cas proteins also interact with other host factors, especially during the spacer 
acquisition stage. We examined these hypotheses by identifying the interacting partners for the 
type II-A Cas proteins and investigated the interactions regions. 
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3.3.1.1 Yeast two-hybrid screening for the interacting partners of 
S. pyogenes Cas proteins  
We hypothesised that type II-A Cas proteins interact among themselves and also with other 
host proteins for different purposes. Therefore, we used the yeast two-hybrid (Y2H) screen 
service provided by Hybrigenics Services to study the PPIs of S. pyogenes Cas proteins, as we 
were studying S. pyogenes spacer acquisition at that time. The Y2H screen is a high throughput 
technique for detecting PPIs via examining the physical interactions of two proteins in yeast 
cells. This technique allows the positive selection of yeast in a histidine-free medium, when a 
protein of interest (bait) that is fused to a DNA binding domain (DBD) interacts with a potential 
interacting partner (prey) that is fused to an activation domain of a transcription factor, resulting 
in the transcription of HIS3 reporter gene and histidine synthesis (Figure 13A) (Brückner et al., 
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Figure 13. Cas proteins interact with proteins from different pathways.  
(A) Schematics of yeast two-hybrid systems. A bait and a potential prey are respectively fused to a DNA binding 
domain (DBD) and an activation domain (AD) of a transcription factor of the HIS3 reporter gene. The bait-DBD 
binds to the upstream activator sequence (UAS) of the promoter. (Left panel) In the absence of the interaction 
between bait and prey, there is no transcription of HIS3. Therefore, yeast cannot grow on the histidine-free 
medium. (Right panel) The interaction of the prey with the bait brings the activation domain of the transcription 
factor to the proximity of the DNA binding domain of the promoter. This allows the transcription of HIS3 and 
synthesis of histidine. Consequently, yeast can grow on the histidine-free medium. (B) Illustration summarizes the 
Cas proteins’ interacting partners from the CRISPR-Cas systems (CRISPR1) and the DNA repair pathways, 
detected by the yeast two-hybrid screening (S. pyogenes SF370) and the in vitro pull-down 
(S. thermophilus LMD-9). MMR, mismatch repair; NER, nucleotide excision repair; BER, base excision repair; 
HR, homologous recombination. 
 
 
The interaction reliability in Y2H is evaluated by Predicted Biological Score (PBS), with values 
ranging from A to F, which are the thresholds that are defined by the probability of an 
interaction to be non-specific via comparing the amount of independent prey fragments detected 
versus the background (their random detection). The scores of A, B and C indicate that the 
interaction is very highly confident, highly confident or confident, respectively. The PBS of D 
shows that the interaction is moderately confident, which comprises a mix of false positives or 
hardly detectable interaction that is caused by under-representation of the mRNA in the library, 
prey folding or prey toxicity in yeast. Therefore, careful verification is needed for the PBS of D.  
Risk of unspecific interaction and experimentally proven technical artifacts are labeled as 
PBS of E and F, respectively (Rain et al., 2001). 
 
In this study, either Cas1, Cas2, Csn2 or Cas9 were used as a bait for screening a cDNA library 
of potential preys that are cloned into plasmids to determine their interacting partners. Y2H 
analysis revealed that the interacting partners of the Cas proteins are mainly the proteins from 
the CRISPR-Cas systems and DNA repair/homologous recombination (HR) (Figure 13B; 
Supplementary Tables S4-S7), where some of interacting partners share the same pathways 
as the interacting partners of Cas1 identified via the in vitro pull-down assay (see section 
3.3.1.2) or correspond to other studies (Babu et al., 2011; Kim et al., 2013; Wiedenheft et al., 
2009; Xiao et al., 2017). Among the candidates, the Cas1-Cas1 (prey is underlined) (PBS of A) 
(Supplementary Table S4) and Cas2-Cas1 (PBS of B) (Supplementary Table S5) 
interactions are in agreement with Cas1 dimer and Cas1-Cas2 complex formation reported in 
the literature (Nunez et al., 2014; Xiao et al., 2017). The Cas1-Csn2 interaction (PBS of C) 
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(Supplementary Table S4) indicated in this study conforms to SEC experiments that provided 
the evidence of interaction of these two proteins (Ka et al., 2016). Our Y2H study additionally 
revealed the direct interaction of Csn2-Cas9 (PBS of D) (Supplementary Table S6), which 
was also confirmed by a very recent study (Ka et al., 2018). The PBS of D obtained by Csn2-
Cas9 interaction might be due to the toxicity of Cas9 in yeast, which was observed in the Y2H 
analysis that used Cas9 as a bait.  
 
Our Y2H screen also demonstrated for the first time the interactions between several Cas 
proteins and proteins from three DNA repair pathways, which are the mismatch repair (MMR), 
nucleotide excision repair (NER) and base excision repair (BER) pathways (Figure 13B; 
Supplementary Table S5-S7). For instance, Cas2 interacts with XseA from MMR and UvrA 
from NER pathway (PBS of A for both candidates) (Supplementary Table S5); Cas9 interacts 
with UvrA from NER (PBS of A) and PcrA from NER and MMR pathways (PBS of B) 
(Supplementary Table S7); and Csn2 interacts with LigA from NER, MMR and BER (PBS 
of A) (Supplementary Table S6). Among these candidates, the interactions of Cas2-UvrA and 
Cas9-UvrA were suggested by PBS of A as very highly reliable interactions. Notably, the 
interactions of Cas proteins and the proteins from NER pathway are also supported by in vitro 
pull-down experiment (see section 3.3.1.2). Previous study in type I-E system of E. coli 
revealed the interactions of Cas1 and the DNA repair proteins (Babu et al., 2011). Therefore, it 
is not unlikely that type II-A Cas proteins interact with DNA repair proteins, although more 
studies are needed to confirm that. 
 
Altogether, our Y2H unveils the direct interactions among the Cas proteins, such as Cas2-Cas1, 
Cas1-Csn2 and Csn2-Cas9; as well as the interactions with DNA repair proteins, such as 
Cas2-XseA, Cas2-UvrA, Cas9-UvrA, Cas9-PcrA and Csn2-LigA. The Y2H results for 
S. pyogenes SF370 were obtained after we started using S. thermophilus LMD-9 for studying 
type II-A spacer acquisition. Since the type II-A CRISPR-Cas systems of both S. pyogenes and 
S. thermophilus are similar (Supplementary Table S2) (Barrangou and van der Oost, 2013; 
Makarova et al., 2011), comparable results were expected by using the in vitro pull-down assay 
in S. thermophilus. 
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3.3.1.2 In vitro pull-down of S. thermophilus Cas1 revealed interacting 
partners from various pathways  
Unlike Y2H, pull-down allows the discovery of novel interacting proteins in their native 
cellular environment, thereby it enables the detection of the interacting proteins that might be 
regarded as false negatives in Y2H due to the lack of native cellular environment (e.g. cytosolic 
or membrane-bound protein) for the protein interactions. In vitro pull-down assay is based on 
the principle that a purified tagged protein (bait) is immobilized on a resin to capture and “pulls-
down” the interacting protein (prey) from the cell lysates after several washes to remove the 
unspecifically bound proteins. The eluted bait-prey proteins are analyzed on SDS-PAGE gel 
and subsequently analyzed by mass-spectrometry. Pull-down assay is a technique to investigate 
physical protein interactions between two or more proteins with strong and stable interactions, 
but it is challenging to study transient protein interactions, which may dissociate during the 
pull-down experiment (Brückner et al., 2009).  
 
The Y2H screen described above revealed the interacting partners for the type II-A Cas proteins 
of S. pyogenes. After changing the model organism to S. thermophilus LMD-9, an in vitro 
pull-down assay was used as an alternative approach to verify the interacting partners of the 
type II-A Cas1 (CRISPR1) and further investigate the PPIs of Cas1. We decided to focus on 
Cas1, because it is one of the core proteins of the adaptation machinery that executes numerous 
key mechanistic steps during spacer acquisition. In this pull-down assay, we used C-terminal 
Cysteine Protease Domain (CPD)-His12-tagged Cas1 as a bait to pull-down the interacting 
partners from the cell lysate of S. thermophilus LMD-9 WT strain, because a cleaner 
background could be obtained via cleaving the CPD-His12-tag while eluting the bait-prey 
proteins from the affinity column. Here, the negative controls were: (1) The cell lysate only 
control, which serves to identify and exclude the false positives, i.e. proteins that are 
unspecifically bound to the resin; and (2) the Cas1 bait only control, which helps to identify 
and exclude the false positives caused by proteins that are unspecifically bound to the tag of the 
bait. Cas1 bait only control also additionally serves as a positive control to confirm the binding 
of the tagged-bait to the resin. 
 
To obtain the fold change of the pull-downed interacting partners, a software named Scaffold 
was used to compare the mass-spectrometry results of the bait-prey sample with the controls. 
Here, the result of the bait-prey sample containing the interacting proteins was used to subtract 
the one of the cell lysate only control, and the obtained result was subsequently compared to 
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the bait only control to remove the background. While a fold change with a cutoff of ³2 is 
widely used, a more stringent cutoff of ³3 was used here to narrow down the numbers of the 
candidates that we were interested in. With a fold change cutoff of ³3, the interacting partners 
of Cas1 identified from the mass-spectrometry analysis included Cas proteins, DNA repair 
proteins, ATP-binding cassette transporters (ABC transporters) and DNA replication proteins 
(Supplementary Table S8). Apart from the ABC transporters and the DNA replication 
proteins, most of the identified interacting partners correspond to the literature either directly 
(i.e. direct physical interactions) or indirectly (i.e. the proteins are involved in the same 
mechanistic steps, such as Cas1 and AddAB (Modell et al., 2017)), as shown in the 
(Figure 13B; Table 2). Therefore, the candidates from the CRISPR-Cas systems and DNA 
repair pathways seem to be more promising and they are our main focus here.  
 
 
Table 2. Selected interacting partners of S. thermophilus Cas1 (CRISPR1) obtained from in vitro pull-down 












Cas9 8.8 (Heler et al, 2015b; Wei et al, 2015b)  
Adaptation Cas1 4.1 
(Babu et al, 2011; Kim et al, 2013; 
Wiedenheft et al, 2009; Ka et al, 





(Babu et al, 2011; Levy et al, 2015b; 
Modell et al, 2017b) 
AddA  3.1 
(Babu et al, 2011; Levy et al, 2015b; 
Modell et al, 2017b) 
Nucleotide excision 
repair (NER) 
UvrB  3.5 
Correlate with UvrA (candidate of 
Y2H-Cas2 and Y2H-Cas9) 
Mismatch repair 
(MMR) 
MutS 3.6 (Babu et al, 2011) 
a Only candidates with fold change ³3.0 are shown 
b The direct physical interaction between Cas1 and the candidate has not been experimentally shown. However, Cas1 and the 
candidate are correlated in the same mechanistic steps. For example, the direct interaction between Cas1 and AddAB has not 
been shown, but it was proposed that Cas1-Cas2 captures the degradation product from AddAB.for spacer integration (Modell 
et al., 2017). 
 
 
Among the pull-down candidates, Cas9 showed the highest fold change enrichment (8.8-fold), 
which is supported by a previous work demonstrating the role of Cas9 in the selection of 
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prespacers with canonical PAMs in type II-A spacer acquisition (Heler et al., 2015). Cas1 was 
also highly enriched (4.1-fold) in the pull-down assay, which is presumably due to the Cas1 
dimer formation. Surprisingly, Cas2 was not pulled-down by Cas1 bait, although Cas1 and Cas2 
are known for forming a complex that is needed for spacer acquisition (Ka et al., 2018; Nunez 
et al., 2014; Xiao et al., 2017). One possible explanation to this is that the CPD-His12-tag of 
Cas1 hinders the interaction of Cas1 with Cas2 during the pull-down assay.  
 
The NER protein, UvrB, showed interaction with Cas1 in the pull-down approach with a 
fold change of 3.5. This finding correlates with the Y2H results, as UvrA was shown to interact 
with Cas2 and Cas9. Nevertheless, the Cas1-UvrB interaction was not detected in the Y2H 
assay. This could be attributed to several reasons, such as UvrB possibly having been 
considered as false negatives due to the stringent condition used for suppressing the auto-
activating activity of Cas1 or a non-native testing environment (yeast cellular compartment) in 
Y2H. Furthermore, the DNA binding domain fused to Cas1 might sterically block the 
interaction with UvrB. This is the first time that the interactions between type II-A Cas proteins 
and UvrAB proteins are shown. More studies are needed to investigate the details and the 
significance of these interactions.  
 
Conforming to an earlier work in the type I-E system (Babu et al., 2011), our pull-down assay 
demonstrated the interaction of the type II-A Cas1 and AddAB (the Gram-positive paralogs of 
RecBCD) (3.4-fold and 3.1-fold respectively) from the HR pathway, and MutS (3.7-fold) from 
the MMR pathway. It was suggested that in both type II-A and type I-E systems, Cas1-Cas2 
complex captures the degradation products generated from AddAB (type II-A) or RecBCD 
(type I-E) for spacer incorporation (Levy et al., 2015; Modell et al., 2017). With regard to this, 
our result suggests that Cas1 possibly interacts with AddAB during the process of capturing the 
degradation products from AddAB. As for MutS, the biological significance of its interaction 
with Cas1 remains to be elucidated. 
 
Altogether, we showed for the first time the physical interactions of Cas1, Cas2 and Cas9 with 
UvrAB from the NER pathway. More studies are needed to investigate the details and 
significance of the interactions between the these Cas proteins with UvrAB. Additionally, we 
also demonstrated the direct interaction of Cas9 and Cas1 for the first time, which was only 
shown indirectly previously (Heler et al., 2015). Via the pull-down approach we demonstrated 
Results   
 48 
the direct interaction of Cas1 of the type II-A system with AddAB from the HR pathway, which 
has only been shown in the type I-E system of E. coli so far (Babu et al., 2011). 
 
3.3.1.3 The Cas1 SPOT peptide assay identifies the dimerization region of 
Cas1 and the interacting region of Cas1 with Cas9   
Our Y2H and pull-down assays revealed that the interacting partners of the type II-A Cas 
proteins are mainly from the CRISPR-Cas systems and the DNA repair pathways. Among the 
candidates, we were particularly interested in the interaction between Cas9 and Cas1. In the 
type II-A systems, Cas9 selects prespacers with PAMs that will be used for spacer incorporation 
by Cas1-Cas2 complex (Heler et al., 2015). We hypothesized that Cas9 interacts with Cas1 
possibly via Cas1-Cas2 complex during the prespacers selection process in order to transfer the 
selected prespacer with PAM to Cas1-Cas2. To address this hypothesis, we used SPOT peptide 
assay to identify the interacting regions of Cas1 with Cas9, and additionally identify the Cas1 
dimerization regions.  
 
SPOT peptide assay is an assay that allows rapid and direct screening of protein-peptide 
interactions and identification of protein interaction regions. This technique involves incubation 
of a tagged-interacting protein with a SPOT peptide membrane that contains the peptide arrays 
of the protein of interest, followed by antibodies incubation and identification of the interacting 
peptides via the chemiluminescent signals detection. Here, we used a Cas1 SPOT peptide 
membrane consisting of 72 overlapping peptides, which represent the entire amino acids 
sequence of Cas1 (Figure 14A). On this membrane, each peptide contains 20 amino acids with 
an overlap of 16 amino acids. 
 
To identify the Cas1-Cas1 dimerization region, a recombinant C-terminal His6-tagged Cas1 
protein was incubated with Cas1 SPOT membrane. Positive signals were detected in four 
regions that were labeled as I, II, III and IV (Figure 14B). However, both of the 
regions I (residues 9 to 32) and IV (residues 257 to 280) are likely to be false positives, as they 
contain only two overlapping peptides. Since every peptide (20 amino acids) overlaps with the 
preceding and succeeding peptides by 16 amino acids, the peptide sequences in the two 
overlapping regions are also partially present in the continuous overlapping peptides preceding 
and succeeding the two peptides (Figure 14A). Therefore, in principle, the continuous 
neighboring overlapping peptides should also show positive signals in order to be considered 
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as a true positive interaction. The same applies to the region III (residues 145 to 204), it was 
regarded as a false positive due to the fact that the overlapping peptides are non-continuous. 
The region II (residues 73 to 112; b-sheet-8 to a-helix-3) most likely represents the 
dimerization site, because this region shows positive signals of a row of 6 continuous 
overlapping peptides that complies with the mentioned requirement for a true positive 
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Figure 14. SPOT peptide assay with Cas1.  
(A) Scheme showing an array of overlapping peptides (black horizontal lines) of a protein with N- and C-termini 
indicated. These overlapping peptides are chemically synthesized and immobilized to a cellulose membrane 
(SPOT peptide membrane) via SPOT peptide synthesis technology. The Cas1 SPOT membrane (synthesized by 
JPT Peptide Technologies GmbH) consists of 72 overlapping peptides of 20 amino acids. Each peptide overlaps 
with its preceding peptide by 16 amino acids, i.e. each peptide is shifted by 4 amino acids. aa, amino acid. (B) The 
dimerization regions of Cas1, and (C) the regions of Cas1 that interact with Cas9. Cas9 was pre-incubated with 
tracrRNA. (B-C) The upper panel shows signals of the Cas1 SPOT membrane after incubating with either Cas1 
or Cas9 protein, where the dark spots represent positive signals resulting from the interaction between the Cas1 
peptides and the incubated protein. The interacting regions are mapped to Cas1 and indicated at the lower panel. 
The horizontal numbers 1 to 20 and the vertical letters A to D indicate the coordinate of the spots, where A1 is the 
first peptide at the N-terminal of Cas1, whereas D12 is the last peptide at the C-terminal. Regions I to VII represent 
clusters of positive signals. 
 
 
Next, a Cas1 SPOT peptide membrane was tested with a recombinant N-terminal 
His6-tagged Cas9 protein pre-incubated with tracrRNA (abbreviated as tracrRNA-Cas9), to 
pinpoint the interacting region of Cas1 with Cas9. tracrRNA-Cas9 rather than Cas9, was used 
in this assay, as tracrRNA is critical for spacer acquisition, crRNA biogenesis and interference 
(Deltcheva et al., 2011; Heler et al., 2015; Jinek et al., 2012). Results show that the regions V 
(residues 77 to 96) and VI (residues 177 to 196), with a single positive signal each, are likely 
false positives. The C-terminus of Cas1, region VII (residues 261 to 292; b-sheet-10 to 
a-helix-10), is most likely the region of Cas1 that interacts with Cas9, as this region 
demonstrates positive signals of 4 continuous overlapping peptides (Figure 14C; 
Supplementary Figure S4B).  
 
3.3.1.4 Superimposition of the dimerization region of Cas1 and the 
interacting region of Cas1 with Cas9   
While SPOT peptide assay allows rapid identification of the Cas1 dimerization site and Cas1 
interacting sites with Cas9, this technique is solely based on the analysis of sequence-dependent 
interaction, and it has a limitation for structure-dependent interaction. To analyze the interacting 
regions in the structural perspective, the interacting regions were superimposed on a model 
structure of S. thermophilus LMD-9 Cas1, which was modeled by using S. pyogenes Cas1 
crystal structure as a template (PDB: 4ZKJ) (Ka et al., 2016) (Figures 15A-B). Comparison of 
the Cas1 dimerization interface of the S. thermophilus, b-sheet-8 to a-helix-3 (region II), with 
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Cas1 dimer of S. pyogenes showed that the b-sheet-8 and the loop connecting b-sheet-8 and 
a-helix-2 matches the dimer interface of S. pyogenes Cas1 (Figure 15A). To have a closer look 
on the Cas1 dimerization region the Cas1-Cas2-prespacer complex, we superimposed the 
interacting region from our results, onto the Cas1-Cas2-prespacer structure of the type II-A 
system of E. faecalis (PDB: 5XVN) (Xiao et al., 2017) (Figure 15C). Similar to the Cas1 dimer 
of S. pyogenes, the b-sheet-8 and the connecting loop obtained from the SPOT peptide assay 
are matching the dimerization region of the Cas1 of E. faecalis. Thereby, we provided the 
evidence that b-sheet-8 and the connecting loop is the dimerization region of the 
S. thermophilus Cas1 by showing that this region matches to the dimerization region of the 
Cas1 of S. pyogenes and E. faecalis. As for the interacting region of Cas1 with Cas9 (Cas9 was 
pre-incubated with tracrRNA), superimposition showed that b-sheet-10 and a-helix-10 
(region VII) is located on the outer surface of Cas1 (Figures 15B-C), which, in principle, Cas9 
could access this region to interact with Cas1. Furthermore, region VII does not overlap with 
the putative Cas1 dimerization site (Figure 15A) and the N-terminal interacting sites of Cas1 
with Cas2 (Xiao et al., 2017) or Csn2 (Ka et al., 2016) reported in previous studies. Therefore, 
it is less possible that the binding of Cas9 to Cas1 would be blocked by the binding of Cas2 and 
Csn2, respectively, to Cas1. 
 
After confirming the interacting regions via structural comparison, we asked whether the 
interaction between Cas9 and Cas1 is important for spacer acquisition. Therefore, we 
investigated the critical residues involved in these interactions via multiple sequence alignment, 
as this information could be used to further study the impact of the interaction on spacer 
acquisition. Multiple sequence alignment of Cas1 proteins from several type II-A systems 
showed that the Cas1 dimerization region includes four strictly conserved residues (P73, Q93, 
W96 and K112 of Cas1) along with several other highly conserved residues (G82, L90, L94, 
K101, A104, W105, Q106 and V108) (Figure 16; green box). The interacting region of Cas1 
with Cas9 is located in the less conserved C-terminus of Cas1, and comprises numerous highly 
conserved residues (V268, T269, A271, M272, Y275, I280 and I283) (Figure 16; blue box). 
Mutants of these identified residues could be generated via site-directed mutagenesis, verified 
for their interactions (i.e. Cas1 dimerization and Cas9-Cas1 interactions) and subsequently 
tested for their spacer acquisition activities by using the plasmid-based spacer acquisition assay 
that was described in the previous section of this thesis. 
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Figure 15. Superimposition of the interacting regions of S. thermophilus Cas1 on the S. pyogenes Cas1 and 
E. faecalis Cas1-Cas2-prespacer complex. 
(A-B) The potential interacting regions are compared to a model structure of S. thermophilus LMD-9 Cas1 
protomer (CRISPR1) (grey), which was modeled based on the existing crystal structure of Cas1 of S. pyogenes 
(PDB: 4ZKJ) (Ka et al., 2016) (RMSD: 0.76; TM-score 0.896). The S. pyogenes Cas1 dimer is shown in 
white-blue and pink. (A) The region II (green; residues 73 to 112) of S. thermophilus Cas1 is compared with 
S. pyogenes Cas1 to verify the dimerization regions. The color scheme of the interacting regions is same as in 
Figure 14B and 14C. (B) The interacting region of S. thermophilus Cas1 with Cas9, i.e. region VII (blue; residues 
261 to 292), is superimposed on the S. pyogenes Cas1 dimer. (C) A structural study demonstrated that the 
Cas1-Cas2-prespacer complex of E. faecalis is formed by the interactions of one Cas2 dimer (light orange and 
pale yellow) bridging two Cas1 dimers, of which each of the Cas1 dimers is composed of one catalytic Cas1 
subunit (pale cyan) and one non-catalytic Cas1 subunit (brown) (PDB: 5XVN) (Xiao et al., 2017). The prespacer 
is a 22-bp duplex (dark orange) flanked by 4-nt 3´-overhangs and 2-nt 5´-overhangs. The interacting interfaces are 
only labelled on one of the Cas1 dimers. The interacting region of Cas1 with Cas9 obtained by SPOT peptide 
assay, is superimposed on Cas1-Cas2-prespacer structure and is labelled as blue and purple on the catalytic and 
the non-catalytic Cas1 subunit, respectively. The dimerization interface of Cas1 obtained by SPOT peptide assay 
is labeled as green on the catalytic Cas1 subunit only.  
 
 
In summary, we identified the dimerization region of Cas1 and interacting region of Cas1 with 
Cas9 via SPOT peptide assay, and further confirmed the results through structural comparison. 
By using multiple sequence alignment of type II-A Cas1 proteins, we pinpointed the conserved 
residues lying in these interacting regions, which provide the basis for studying the biological 
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Figure 16. Multiple sequence alignment of the Cas1 proteins of the type II-A CRISPR-Cas systems. 
Green box (residues 73 to 112 of Sth_Cr1; b-sheet-8 to a-helix-3; region II) highlights the dimerization region of Cas1 based on the results of SPOT assay, whereas blue box 
(residues 261 to 292 of Sth_Cr1; b-sheet-10 to a-helix-10; region VII) indicates the interacting region of Cas1 with Cas9 that was pre-incubated with tracrRNA. Cas1 sequences 
are labelled by their species names and GenInfo (GI) identifier. Mca, Mycoplasma canis PG 14; Mmo, Mycoplasma mobile 163K; Lrh, Lactobacillus rhamnosus GG; Oki, 
Oenococcus kitaharae DSM 17330; Cgi, Coriobacterium glomerans PW2; Ssa, Streptococcus sanguinis SK49; Sth_Cr3, Streptococcus thermophilus LMD-9, CRISPR3; Spy, 
Streptococcu  pyogenes SF370 (M1 GAS); Smu, Streptococcus mutans UA159; Sps, Staphylococcus pseudintermedius ED99; Pdu, Peptoniphilus duerdenii ATCC BAA-1640; 
Smo, Solobacterium moorei F0204; Vat, Veillonella atypica ACS-134-V-Col7a; Fal, Filifactor alocis ATCC 35896; Sth_Cr1, Streptococcus thermophilus LMD-9, CRISPR1; Efa, 
Enterococcus faecalis TX0027; Slu, Staphylococcus lugdunensis M23590; Edo, Eubacterium dolichum DSM 3991. The multiple sequence alignment was created using 
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3.3.2 Investigation of Cas9-Cas1 interaction 
 
3.3.2.1 Interaction studies of Cas9, Cas1 and Cas2 via size-exclusion 
chromatography 
Based on a previous study, the interactions between Cas9, Cas1, Cas2 and Csn2 were known 
(Heler et al., 2015), yet it was unclear whether Cas9 directly interacts with Cas1. Here, our 
study revealed the direct interaction of Cas9 and Cas1. However, it is still unclear how Cas9 
interacts with Cas1. Structural studies reported a stable Cas1-Cas2 complex formation in the 
type I-E and type II-A systems (Nunez et al., 2014; Xiao et al., 2017) and Cas1–Cas2-Cas3 
(Cas2 is naturally fused to Cas3) complex formation in the type I-F system (Fagerlund et al., 
2017). Interestingly, a structural study in the type I-C system of B. halodurans showed a direct 
interaction of Cas4 with Cas1, rather than Cas4 with Cas1-Cas2 complex (Lee et al., 2018). 
Nevertheless, how does the Cas4-Cas1 complex transform to the final adaptation complex is 
yet to be elucidated. Hence, we wondered whether the type II-A Cas9 interacts with Cas1 
directly or via the Cas1-Cas2 complex. To address this question, SEC was used as one of the 
approaches to analyze the protein complex formation. Additionally, this technique could be 
used to establish a read-out system to verify whether the site-directed mutations on the 
interacting residues obtained from our studies (Figures 14-16), could interfere the Cas9-Cas1 
interaction. Formation of a complex with higher molecular weight can be identified by 
comparing the elution profiles of the pre-incubated interacting proteins to the protein profiles 
of every single individual protein component.  
 
In these SEC studies, the complex formations involved different pre-incubation combinations 
of N-terminal His6-tagged Cas9, C-terminal His6-tagged Cas1 and untagged Cas2 (the 
N-terminal SUMO-His6-tag of Cas2 was cleaved during protein purification), which are 
abbreviated as Cas9, Cas1 and Cas2 here. In order to study whether Cas9 interacts with Cas1 
directly or via the Cas1-Cas2 complex, two protein combinations were analyzed via SEC, 
i.e. (1) Cas9, Cas1 and Cas2 and (2) Cas9 and Cas1. 
 
Cas9, Cas1 and Cas2 were individually expressed in E. coli because their expression conditions 
were different (see Materials and Methods). Afterward, the cell lysates of the three proteins 
were combined prior to the protein purification using immobilized metal affinity 
chromatography (IMAC) with TALON Co2+ resin and SEC. The amount of eluted proteins was 
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very low as indicated by the elution peaks of the chromatogram that were lower than 13 mAU 
(mili-Absorbance Units) at UV 280 nm (Supplementary Figure S5). SDS-PAGE gel of the 
eluted fractions demonstrated that Cas2 monomer (12.6 kDa) was eluted as peak 4, whereas 
Cas1 monomer (36.2 kDa) was eluted as peaks 1, 2 and 3. Based on the observation of our 
routine protein purifications with SEC, peak 5 was the elution of the imidazole used in the 
buffers for protein purification with IMAC. Three additional protein bands were detected at 
peak 3, i.e. bands 2, 3 and 4, which might be either co-purified unspecific proteins or Cas2 
aggregates. Band 3 could also be a Cas2 dimer that was not totally denatured in the SDS-PAGE 
gel, as the estimated molecular weight of band 3 is about the same as Cas2 dimer. Peak 1 
contained both Cas9 (130.4 kDa) and Cas1. There was neither evidence for co-purification of 
Cas9, Cas1 and Cas2, nor for co-purification of Cas2 and Cas1. The molecular weight of the 
additional band, band 1, indicates that band 1 could be the incompletely denatured Cas1 dimer 
in SDS-PAGE gel. It was unclear whether the co-elution of Cas9 and Cas1 as peak 1 was the 
outcome of Cas9-Cas1interaction or the overlapping of the elution fractions of Cas1 from the 
tail of peak 2 with Cas9 from peak 1.  
 
The resolution of the chromatogram for the study of Cas9-Cas1-Cas2 complex formation was 
not optimal, as the broad peak widths resulted the overlapping of one peak with another 
(Supplementary Figure S5). Therefore, the elution fractions at the borders of the peaks always 
consisted of more than one proteins. To improve the resolution of SEC, a lower sample load, 
i.e. 200 µl instead of 500 µl, was used in the following SEC (the SEC for Cas9 and Cas1 
complex formation). Moreover, a smaller elution volume per fraction, i.e. 250 µl instead of 
500 µl, was also applied in the following SEC in order to visualize well-defined changes of the 
protein components along the elution profile in the SDS-PAGE gel. 
 
As for the SEC of the Cas9 and Cas1 complex formation, both proteins were individually 
expressed and purified via IMAC with TALON Co2+ resin and SEC. This modified protocol 
allowed the flexible adjustment of the molar ratio of the pre-incubated Cas9 and Cas1 to obtain 
the optimal condition for the interaction. Purified Cas9 and Cas1 were pre-incubated in 
1:3 molar ratio before SEC. Here, higher amount of Cas1 was used as Cas1 usually forms a 
dimer. Analysis on a SDS-PAGE gel showed that Cas1 was eluted as peak 2 and 3, and both 
Cas9 and Cas1 co-eluted as peak 2 (Figure 17A). Mass-spectrometry (data not shown) 
identified that bands 1 and 2 were Cas9, which were probably Cas9 aggregates (Figure 17A). 
To verify whether the co-eluted Cas9 and Cas1 proteins was a complex, equal amount of Cas1 
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was analyzed under the same conditions, and the elution profile of Cas1 was compared to the 
elution profile of the pre-incubated Cas9 and Cas1. The Cas1 only SEC analysis showed that a 
low amount of Cas1 was also detected in the elution fractions of peak 2 (Figure 17B), which 
was probably due to different oligomerization states of Cas1. In fact, an extra peak that was 
eluted prior to Cas1 dimer was always observed in the routine SEC purifications of Cas1. The 
comparison of both elution profiles showed that peak 3 corresponded to the Cas1 elution, 
whereas peak 2 corresponded to the Cas9 elution together with a lower amount of Cas1 
(Figure 17C). Therefore, there is no strong evidence showing the interaction of Cas9 and Cas1 
in this study.  
 
Altogether, there was no solid observation of protein-protein interaction for the mentioned 
protein combinations under the tested conditions using SEC. The SEC resolution of the Cas9 
and Cas1 combination (Figures 17B-C) was improved compared to the SEC resolution of 
Cas9, Cas1 and Cas2 combination (Supplementary Figure S5).  Varying other parameters 
such as the salt concentration and pH of the mobile phase of SEC could optimize the conditions 
for protein complex formation. Since tracrRNA is essential in spacer acquisition (Heler et al., 
2015), pre-incubating Cas9 with tracrRNA prior to the incubation with Cas1 and Cas2 or Cas1 
only might facilitate the complex formation. Furthermore, introducing a prespacer with a PAM 
during the pre-incubation of the proteins mixture (i.e. tracrRNA, Cas9, Cas1, with Cas2 in one 
case and without Cas2 in the other) may also promote the complex formation. The rationale 
behind this is as follows: a prespacer with a PAM can be recognized by Cas9 in the presence 
of tracrRNA (Heler et al, 2015), and the PAM recognition could subsequently facilitate the 
interaction between Cas9 and Cas1 to allow the transfer of the prespacer to the Cas1-Cas2 
complex for spacer integration. In addition to SDS-PAGE gel, native polyacrylamide gel could 
be used in parallel for the direct detection of the protein complexes in their native forms at 
higher molecular weights. SEC is commonly used for protein purification and also protein 
complex formation. While this technique is more suitable for stronger protein interaction, other 
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Figure 17. Investigation of Cas9 and Cas1 interaction via size-exclusion chromatography.   
The recombinant N-terminal His6-tagged Cas9 and C-terminal His6-tagged Cas1 proteins were individually 
expressed and purified via IMAC with TALON Co2+ resin and size-exclusion chromatography (SEC) with the 
HiLoad® 16/600 Superdex® 200 pg (GE Healthcare). (A)  After first round of SEC purification, Cas9 (25 µM) 
and Cas1 (75 µM) were pre-incubated in 1:3 molar ratio before applying to the SEC column Superdex® 
200 Increase 10/300 GL (GE Healthcare). Protein eluates obtained by SEC were analyzed by 4-20% 
Coomassie stained-SDS-PAGE gels. Cas9 elutes as peak 2, whereas Cas1 eluates as peak 2 and 3. Peak 1 is 
possibly the elution of protein aggregates. (B) After first round of SEC purification, an individual Cas1 (75 µM) 
was analyzed with SEC column Superdex® 200 Increase 10/300 GL (GE Healthcare) using the same conditions 
as for (A). The eluted fractions were separated by 10% Coomassie stained-SDS-PAGE gels. Cas1 eluates as peak 2 
and 3. (C) The elution profiles of (A) and (B) were compared. Cas9, 130.4 kDa; Cas1, 36.2 kDa. M, PageRuler™ 
Plus Pre-stained Protein Ladder (Thermo Scientific).  
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3.3.2.2 Crosslinking studies of Cas9, Cas1 and Cas2 
In addition to SEC, we used crosslinking as a second approach to address the question regarding 
whether Cas1-Cas2 complex is needed for Cas9-Cas1 interaction, as well as to establish a 
read-out system for verifying the interacting residues. Furthermore, we applied crosslinking to 
confirm the oligomerization states of Cas1 and Cas2. Crosslinking reagents are used to preserve 
the protein-protein complexes by covalently linking the specific amino acid functional groups 
on the interacting proteins together upon their interaction. Crosslinking is commonly used to 
study proteins interactions, especially for weak or transient interactions, and it is also used to 
assess the distance of the interacting residues (Singh et al., 2010). 
Bis(sulfosusccinimidy) suberate (BS3), a commonly used crosslinker, was applied in this study. 
BS3 allows the amine-to-amine crosslinking between the interacting proteins via its 
homobifunctional N-hydroxysulfosuccinimide (NHS) ester with an 8-carbon spacer arm. 
Numerous primary amines usually present in the side chain of lysine residues of a protein and 
N-terminus of each polypeptide, therefore feasible for NHS-ester crosslinking. The 
recombinant His-tag Cas proteins used in this crosslinking study were same as those proteins 
used in SEC. 
 
In order to verify the oligomerization state of individual Cas1 and Cas2 proteins, Cas1 and Cas2 
were separately titrated with the BS3 crosslinker, and the reactions were visualized on 
Coomassie-stained gels (Figures 18A-B). When increasing amount of BS3 crosslinker was 
added, both Cas1 and Cas2 showed dimer formation, which confirmed that the Cas1 and Cas2 
of the type II-A system (CRISPR1) of S. thermophilus LMD-9 form dimers, respectively. These 
findings are agreement with the previous studies (Babu et al., 2011; Beloglazova et al., 2008; 
Kim et al., 2013; Nam et al., 2012; Samai et al., 2010; Wiedenheft et al., 2009; Xiao et al., 
2017). Due to the innate limited stability of Cas1, a small portion of Cas1 precipitated during 
the crosslinking reaction. The Cas1 precipitates appeared as bands above 70 kDa.  
 
To investigate the interactions between the different Cas proteins, various combinations 
(i.e. Cas1 and Cas2; tracrRNA-Cas9 and Cas1; tracrRNA-Cas9, Cas1 and Cas2) were 
pre-incubated before crosslinking. These reactions were divided into three portions and 
analyzed with Coomassie-stained gradient gel (Figure 18C) and Western Blots with Cas1 
(Figure 18D) and Cas2 antibodies in parallel (Figure 18E).  
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Figure 18. The study of protein-protein interaction via crosslinking assays. 
(A) Cas1-Cas1 crosslinking. 28 µM Cas1 was titrated with the BS3 crosslinker. The crosslinked reaction was 
analyzed on 10% Coomassie stained-SDS-PAGE gels. (B) Cas2-Cas2 crosslinking. 30 µM Cas2 was titrated with 
the BS3 crosslinker. The crosslinked reaction was analyzed on 15% Coomassie stained-SDS-PAGE gels. (C) Three 
different protein combinations were used for BS3 crosslinking study, i.e. (1) Cas1 and Cas2, (2) tracrRNA-Cas9 
and Cas1, and (3) tracrRNA-Cas9, Cas1 and Cas2. tracrRNA-Cas9 was prepared by pre-incubating these two 
components in 2:1 molar ratio at 37°C for 10 min before the incubation with other proteins. The individual protein 
components (20 µM each) were mixed pre-incubated for one hour at 4°C before the addition of BS3 crosslinker. 
The molar ratio of individual proteins is 1:1, whereas the molar ratio of individual proteins to BS3 is 1:4, i.e.  
20 µM individual proteins and 80 µM of BS3 crosslinker were used. The crosslinked proteins mixture was analyzed 
on the 4-20% Coomassie stained-SDS-PAGE gels. (D) The crosslinking reactions in (C) were analyzed on Western 
Blots with Cas1 antibody. (E) The crosslinking reactions in (C) were analyzed on Western Blots with Cas2 
antibody. Cas9 monomer, 130.4 kDa; Cas1 monomer, 36.2 kDa; Cas1 dimer, 72.4 kDa; Cas2 monomer, 12.6 kDa; 
Cas2 dimer, 25.2 kDa. Estimated sizes for speculated complexes are 170 kDa for Cas14-Cas22, 202.8 kDa for 
Cas9-Cas12, 300.4 kDa for Cas9-Cas14-Cas22. Asterisk, band A; black arrow, band B; M, PageRuler™ Plus 
Pre-stained Protein Ladder (Thermo Scientific).  
 
 
A likely intermediate interaction product of the Cas1-Cas2 complex (band B; marked with an 
arrow) with a molecular weight between 35-55 kDa was observed in the crosslinking reactions 
that involved both Cas1 and Cas2. (Figures 18D-E, lanes 1 and 5). The reported stoichiometry 
of the Cas1-Cas2 complex is Cas14-Cas22 in type II-A system of E. faecalis and type I-E system 
of E. coli (Nunez et al., 2014; Xiao et al., 2017), wherein one Cas2 dimer is sandwiched between 
two Cas1 dimers. Since Cas1 and Cas2 are very conserved in CRISPR-Cas systems (Makarova 
et al., 2011), the stoichiometry of the Cas1-Cas2 complex in type II-A systems of 
S. thermophilus is assumed to be same as the reported stoichiometry (Nunez et al., 2014; Xiao 
et al., 2017). This indicate that the molecular weight of the Cas14-Cas22 complex of 
S. thermophilus is possibly around 170 kDa. Nevertheless, the band of this molecular weight 
was not detected by Western Blot in the crosslinking reaction of Cas1 and Cas2 (Figures 18D-
E, lane 5).  
 
A faint band (band A; marked with an asterisk) with a molecular weight between 130-250 kDa 
was detected in the Western Blot for the crosslinking reaction of the tracrRNA-Cas9, Cas1 and 
Cas2 with the Cas2 antibody (Figure 18E, lane 1), but not with the Cas1 antibody 
(Figure 18D, lane 1). The molecular weight of the Cas1-Cas2 complex matches the molecular 
weight of band A. However, it is unclear whether band A is the Cas1-Cas2 complex, as band A 
was not detected in the crosslinking reaction of Cas1 and Cas2 (Figure 18D-E, lane 5). For the 
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Western Blot with Cas1 antibody, band A might have been masked by the high amount of smear 
(Figures 18D-E, lane 5). The molecular weight of Cas1 is about three times larger than Cas2, 
which means that Cas1 has more primary amines available for crosslinking reactions. Hence, 
crosslinking reactions occur more frequently in Cas1 compared to Cas2. The number of 
crosslinking events in Cas1 could affect the migration speed of the protein in the SDS-PAGE 
gel, therefore, a higher amount of smearing is visible on the Western Blot analysis with 
Cas1 antibody (Figure 18D). To reduce the smearing background, the amount of the proteins 
used in the crosslinking reactions could be further reduced and the crosslinking reactions could 
be directly analyzed with the Western Blot. 
 
Routine Cas2 purification and the subsequent SDS-PAGE gel analysis always showed two faint 
bands, which were slightly above and below the major Cas2 band. Mass-spectrometry analysis 
identified that the faint bands were Cas2 (data not shown). These two Cas2 moieties are 
probably improperly folded Cas2 or degraded Cas2 migrating at different speed. The band C 
could be the outcome of the crosslinking of these Cas2 moieties (Figure 18E, lanes 1-2 and 
5-8). 
 
It is not impossible that both bands A (Figure 18E, lane 1) and B (Figures 18D-E, lanes 1 and 
5) are the intermediate crosslinked products of tracrRNA-Cas9-Cas1-Cas2 and Cas1-Cas2, 
respectively. However, in order to detect the final crosslinked-complexes, if any, it requires the 
interactions and crosslinking that involves two crosslinked Cas1 dimers, one crosslinked Cas2 
dimers and/or one tracrRNA-Cas9. In addition, the amount of the final crosslinked complexes 
must be above the detection limit of the Western Blot. All these factors add complexity to the 
detection of the final crosslinked-complex with the crosslinking technique. The addition of 
protospacer with canonical PAM into the proteins mixture might also facilitate the interactions 
between tracrRNA-Cas9, Cas1 and Cas2, as per the explanation earlier.  
 
While the in vitro crosslinking assay has its limitation in crosslinking multiple proteins in 
different oligomerization states, other techniques could also be used for studying the 
interactions of these proteins. For instance, surface plasmon resonance (SPR) is a technology 
that based on surface plasmon resonance and it is used for studying PPIs. SPR detects the 
protein interactions via the change of refractive index when a prey is probed on a bait that is 
immobilized on a sensor chip. The proteins eluted from SPR are further analyzed by 
mass-spectrometry. However, SPR has its limitation in detecting transient protein interactions 
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(Brückner et al., 2009). In vivo methods such as fluorescence resonance energy transfer 
(FRET), bioluminescence resonance energy transfer (BRET) and bimolecular fluorescence 
complementation (BiFC) have the advantage of allowing the detection of proteins interactions 
in living cells via confocal microscopy or scanning force microscopy (Brückner et al., 2009). 
Many conditions could be investigated with in vivo detection of proteins interactions, for 
example, the protein interactions of Cas9 with Cas1 with and without phage infection. 
However, these in vivo methods are comparatively laborious.  
 
In summary, the dimer formations of Cas1 and Cas2, respectively, were confirmed via the 
crosslinking assays, and they are in line with other studies (Babu et al., 2011; Beloglazova et 
al., 2008; Kim et al., 2013; Nam et al., 2012; Samai et al., 2010; Wiedenheft et al., 2009; Xiao 
et al., 2017). There is a lack of solid conclusion regarding the complex formation of Cas1-Cas2, 
tracrRNA-Cas9-Cas1 and tracrRNA-Cas9-Cas1-Cas2. 
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4 Discussion  
 
4.1 Unravelling type II-A spacer acquisition 
In this work, we investigated the essential elements in type II-A spacer acquisition via two 
different approaches, i.e. a heterologous system expressed in the E. coli BL21-AI host and an 
endogenous system. In the absence of Cas9, spacer acquisition of the S. pyogenes and 
S. thermophilus heterologous type II-A systems were not detected. This could be explained by 
the requirement of Cas9 and tracrRNA in spacer acquisition in the type II-A systems which had 
been published in the course of this study (Heler et al., 2015; Wei et al., 2015a).  
 
Although all Cas proteins and tracrRNA are included in two experimental set-ups for the 
S. pyogenes heterologous type II-A system, we also did not observe spacer acquisition 
(Figures 7C and 7D; Supplementary Table S1). This could be due to the potential limitation 
of E. coli as a host for the heterologous systems for the type II-A spacer acquisition study. Thus 
far, E. coli has only been used as a host for the characterization of spacer acquisition 
mechanisms of the type I systems originating from different Gram-negative bacteria (Kieper et 
al., 2018; Vorontsova et al., 2015; Yosef et al., 2012). The type II-A systems are mainly 
encoded in Firmicutes (primarily Gram-positive bacteria) and they are absent in Proteobacteria 
(mainly Gram-negative bacteria) (Bernheim et al., 2017). Therefore, it is unclear whether the 
Gram-negative host, E. coli, could provide the native conditions required for spacer acquisition 
of the type II-A systems. 
 
While our studies were in process, spacer acquisition was shown in the heterologous type II-A 
systems of S. pyogenes SF370 in the Gram-positive host, S. aureus RN4420, which also does 
not encode any CRISPR-Cas system (Heler et al., 2015). This led to the question whether there 
are any non-CRISPR associated elements encoded in the Gram-positive host required for the 
type II-A spacer acquisition, which are absent in the Gram-negative host, E. coli BL21-AI. For 
example, AddAB, the homologous recombination proteins that are mainly encoded in the 
Gram-positive bacteria, was suggested to play a role in the prespacer generation in the type II-A 
system (Modell et al., 2017). Nonetheless, it is not known whether the interaction between 
AddAB and Cas1-Cas2 are required to facilitate the prespacer substrates generation and 
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capturing processes. Our work and a former study revealed the interactions between AddAB 
and Cas1 of the type II-A systems of S. thermophilus (Figure 13B; Table 2), and RecBC 
subunits (subunits of RecBCD complex) and Cas1 of the type I-E system of E. coli (Babu et 
al., 2011), respectively. These findings suggest that the interaction between the homologous 
recombination proteins and Cas1 (presumably via Cas1-Cas2 complex) is possibly necessary 
during the prespacer substrates generation and capturing steps. While AddAB complex 
possesses one helicase and two nuclease domains, RecBCD complex harbors two helicase and 
one nuclease domains (Wigley, 2013). Taking into the consideration of the structural 
differences between AddAB and RecBCD, it is possible that the type II-A Cas1-Cas2 complex 
could not interact with RecBCD. Assuming the above is correct, E. coli might not be a suitable 
host for spacer acquisition study of the type II-A systems that have been hitherto reported in 
Gram-positive bacteria only. To investigate this hypothesis, future experiment shall focus on 
determining whether the prespacer substrates generation and capturing processes require the 
interaction between the type II-A Cas1 and AddAB, and whether the type II-A Cas1 could 
interacts with RecBCD. 
 
To investigate spacer acquisition under native conditions, the acquisition of new spacers was 
investigated in S. pyogenes using a plasmid challenge approach. However, spacer acquisition 
was not observed in S. pyogenes WT, the Cas9 RuvC mutant (pEC85WtracrRNA-cas9-D10A-
speM) and the Cas9 HNH mutant (pEC85WtracrRNA-cas9-H840A-speM) (Figure 8; 
Supplementary Table S1). The undetectable spacer acquisition in S. pyogenes could be due to 
several reasons. For instance, it could be associated with the low endogenous expression of the 
type II-A cas genes demonstrated by our RNA sequencing data (data not shown). In this case, 
it is possible to boost the spacer acquisition activities in S. pyogenes by increasing the 
expression levels of all the Cas proteins. In agreement with that, spacer acquisition activity was 
increased and detectable in the endogenous type II-A system of S. thermophilus WT when the 
bacteria were challenged with an over-expression plasmid containing cas1, cas2, csn2 and cas9 
as shown in our study (Figure 12A) and a previous study (Wei et al., 2015a). On the other hand, 
lytic phage challenge might confer higher selective pressure to the bacteria for triggering spacer 
acquisition. However, spacer acquisition with phage challenge was not examined in 
S. pyogenes, due to the unavailability of the lytic phage in our laboratory.  
 
While spacer acquisition was not observed in the type II-A system of S. pyogenes via plasmid 
challenge approach, we detected active spacer acquisition in the endogenous type II-A system 
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of S. thermophilus LMD-9 via phage challenge and over-expression of Cas proteins. When 
S. thermophilus LMD-9 was challenged with lytic phage DT1, we observed an higher uptake 
of new spacers in CRISPR3 locus compared to CRISPR1 locus (Figure 11; Table 1), which 
could be explained by several possibilities, such as the PAM abundance in the phage genome. 
Based on phage challenge and in silico analyses, the PAM determined for CRISPR1 is 
5´-NNAGAAW-3´ and for CRISPR3 is 5´-NGGNG-3´ (Horvath et al., 2008). The number of 
CRISPR3-associated PAM sequences in the genome of phage DT1 is twice as high as for 
CRISPR1-associated PAMs. Since PAMs are important for ensuring the acquisition of 
functional spacers, the higher amount of CRISPR3-associated PAMs in the genome of 
phage DT1 might favor spacer acquisition by CRISPR3 over CRISPR1. Furthermore, the 
higher spacer acquisition rate in the CRISPR3 locus may imply that the expression level the 
cas genes of the CRISPR3 locus of S. thermophilus LMD-9 is higher than those of the 
CRISPR1, as higher the expression levels of Cas proteins could enhance the acquisition 
activities (Figure 12A) (Wei et al., 2015a). 
 
A very recent study revealed that AcrIIA6, an anti-type II-A CRISPR protein encoded by 
phage DT1, allows effective evasion of phage DT1 from CRISPR1 immunity but not from 
CRISPR3 immunity in a closely related strain, S. thermophilus SMQ-301 (Hynes et al., 2018). 
While the Cas9 inhibition mechanism of AcrIIA6 is still remained to be clarified (Hynes et al., 
2018); another members of the type II-A anti-CRISPR family, AcrIIA2 and AcrIIA4, inhibit 
the S. pyogenes Cas9 activity by blocking the PAM-interacting site and the RuvC catalytic site 
(the blocking of RuvC was only shown in AcrIIA4) of Cas9, thereby precluding the target DNA 
recognition and endonuclease activity of Cas9 (Dong et al., 2017; Yang and Patel, 2017). Since 
the PAM-recognition and endonuclease activities of Cas9 are essential for interference, 
AcrIIA6 possibly inhibits Cas9 in a manner similar to AcrIIA2 and AcrIIA4. Assuming that 
this speculation is correct, the blocking of the PAM-interacting domain of Cas9 of the CRISPR1 
locus by AcrIIA6 should not disturb spacer acquisition, however, it would lead to the 
acquisition of non-functional spacers (spacers without corresponding PAMs) in CRISPR1, as 
shown in a previous study (Heler et al., 2015). This would indicate that even though there is 
spacer acquisition in the CRISPR1 locus in the presence of AcrIIA6, the cells would still be 
killed by the lytic phage. With regard to this, the acquisition screening method to screen the 
survivors from the plaque assay could lead to bias results, which show low spacer acquisition 
rate in CRISPR1 locus. In this case, the acquisition-positive cells might have been killed by the 
lytic phages due to the acquisition of non-functional spacers and inhibition of the endonuclease 
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activity of Cas9 by AcrIIA6. Thereby, AcrIIA6 and survivor-based spacer acquisition screening 
method could be one of the reasons that we observed lower spacer acquisition in the CRISPR1 
locus of S. thermophilus when it was challenged with lytic phage DT1 that encodes AcrIIA6.  
 
Our spacer acquisition assay coupled with Cas proteins over-expression in S. thermophilus 
LMD-9 showed that Cas9 is essential for spacer acquisition, which is in line with the earlier 
studies (Heler et al., 2015; Wei et al., 2015a). When all type II-A Cas proteins from the 
CRISPR1 locus were over-expressed in the WT strain, spacer acquisition was detected in 
CRISPR1 locus (Figure 12A), but not CRISPR3 locus (Figure 12B). This suggests the absence 
evidence for the crosstalk between CRISPR1 and CRISPR3 for spacer acquisition. However, 
further experimental verification with the reciprocal over-expression of Cas proteins from the 
CRISPR3 locus and monitoring of the spacer acquisition in the CRISPR1 array is needed to 
confirm this. Additionally, it could be further verified by using a phage challenge approach to 
investigate spacer acquisition in the respective CRSIPR1 and CRISPR3 cas operon deletion 
mutants (the CRISPR arrays and leader sequences are not deleted). Since the leader-repeat 
boundary, especially LAS, is crucial for the recognition of Cas1-Cas2 for spacer integration 
(McGinn and Marraffini, 2016; Wei et al., 2015b; Wright and Doudna, 2016), crosstalk is 
unlikely due to the lack of sequence conservation on the leader-repeat boundaries and LAS 
between the CRISPR1 and the CRISPR3 as shown by our analyses (Supplementary 
Figure S3) and a literature (Van Orden et al., 2017). Furthermore, the lack of PPI between the 
Cas proteins from the CRISPR1 and the CRISPR3 in our pull-down assay also supports the 
unfeasibility of the crosstalk (Figure 13B; Table 2).  
 
Altogether, we demonstrated that the two CRISPR loci of the type II-A systems of 
S. thermophilus LMD-9 are active in spacer acquisition and Cas9 is essential for acquisition. 
To gain more insights about whether non-CRISPR associated elements are involved in the 
spacer acquisition of the type II-A systems and to understand the interactions among the Cas 
proteins, we investigated the PPIs of Cas proteins. 
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4.2 Protein-protein interactions within and beyond 
the CRISPR-Cas systems 
The association of Cas9, Cas1, Cas2 and Csn2 of S. pyogenes was demonstrated previously, 
however, the direct interactions between each of these components are still obscure (Heler et 
al., 2015). We addressed the direct interactions among the Cas proteins of the type II-A 
CRISPR-Cas systems via Y2H and pull-down assays in S. pyogenes and S. thermophilus, 
respectively. Pull-down assay revealed the direct interactions between Cas1 and Cas9 (prey is 
underlined) and Cas1-Cas1 dimer, whereas Y2H assay indicated the direct interactions between 
Cas1 and Csn2, Cas2 and Cas1, Csn2 and Cas9 and Cas1-Cas1 dimer. However, the identified 
interactions between two proteins are non-symmetric in Y2H assay, i.e. the interacting partner 
is not reversely detected when the fused domains of the bait and the prey are inverted, which 
could be explained by the fused domain-dependent steric hindrance – one of the limitations of 
Y2H assay (Brückner et al., 2009). The pull-down assay allows the detection of PPIs in their 
native conditions, which may be critical for some of the PPIs that might not be able to be 
detected in Y2H that lacks of the native cellular conditions (Brückner et al., 2009). This could 
explain the reason that some of the interacting partners detected in the pull-down assay were 
not observed in the Y2H assay. 
 
The Cas1-Cas1 interaction showed by pull-down, Y2H (Figure 13B) and crosslinking assays 
(Figure 18A) confirmed that Cas1 forms a dimer, which is agreement with literature (Babu et 
al., 2011; Ka et al., 2016; Kim et al., 2013; Wiedenheft et al., 2009; Xiao et al., 2017). 
Moreover, we provided the evidence that the b-sheet-8 and the loop linking the b-sheet-8 and 
a-helix-2 are the possible Cas1 dimerization regions, via SPOT peptide assay and structural 
comparison between the Cas1 model of S. thermophilus with the Cas1 crystal structures of 
S. pyogenes and the Cas1-Cas2-prespacer complex of E. faecalis (Figures 14B, 15A and 15C). 
Some of the dimerization regions reported in the Cas1 of S. pyogenes (b-sheet-6, a-helix-1, 
loop linking the a-helix-6 and a-helix-7 and a-helix-5 to a-helix-8) (PDB: 4ZKJ) (Ka et al., 
2016) and E. faecalis (b-sheet-6) (PDB: 5XVN) (Xiao et al., 2017), were not observed in our 
SPOT peptide assay, which indicates slight structural differences among the Cas1 orthologs. 
Although SPOT peptide assay could detect the sequence-dependent interaction, it has a 
limitation for the structure-dependent interaction, which could be one of the reasons that some 
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of the reported dimerization regions (Ka et al., 2016; Xiao et al., 2017) were not identified in 
our assay. 
 
Noteworthy, pull-down assay indicated the interaction between Cas1 of the type II-A system 
and AddAB (Figure 13B; Table 2), which is consistent with the Cas1-RecBC interaction 
reported earlier in the type I-E system of E. coli (Babu et al., 2011). The homologous 
recombination complexes, AddAB and RecBCD, were shown to promote spacer acquisition in 
the type II-A and type I-E systems, respectively (Levy et al., 2015; Modell et al., 2017). This 
led to a proposal that Cas1-Cas2 complex captures the DNA degradation fragments generated 
by AddAB/RecBCD for spacer integration (Levy et al., 2015; Modell et al., 2017). Nonetheless, 
this model was challenged by a very recent study, which demonstrated that the helicase activity 
of RecBCD is required to promote spacer acquisition, instead of the nuclease activity (Radovčić 
et al., 2018). The authors further proposed that the helicase activity of the RecBCD facilitates 
spacer acquisition by removing the nucleoprotein complexes from the DNA damage sites, 
thereby allowing Cas1-Cas2 to access the DNA substrates (Radovčić et al., 2018). Based on 
our findings and literature, it is tempting to speculate that AddAB/RecBCD complex possibly 
recruits Cas1 to the DNA damage site, where Cas1 subsequently extracts the prespacer 
substrates via its nuclease activity. This hypothesis is supported by an in vivo study in the 
type I-E system of E. coli that showed the recruitment of Cas1 to the MMC-induced DNA 
DSBs, and an in vitro study that demonstrated that Cas1 cleaves the DNA intermediates of 
DNA repair and recombination pathways, such as replication fork, 5´-flap, 3´-flap and Holiday 
junction (Babu et al., 2011). To investigate whether AddAB/RecBCD recruits Cas1 to the DSB 
sites, in vivo study such as FRET, BRET and BiFC, or in vitro study such as an electrophoretic 
mobility shift assay (EMSA), could be applied. 
 
The nuclease activity of Cas1 alone is not enough to ensure the acquisition of functional spacers 
that could provide immunity, and Cas9 is required for the PAM selection during the prespacer 
selection process to ensure the acquisition of functional spacers (Heler et al., 2015). In this 
work, our pull-down assay provided the evidence for a direct physical interaction between Cas1 
and Cas9 for the first time (Figure 13B; Table 2). Our SPOT peptide assay (Figure 14C) and 
structural comparison (Figures 15B-C) further indicated that the b-sheet-10 and a-helix-10 on 
the outer surface of the C-terminus of Cas1 of S. thermophilus are possibly the interacting sites 
of Cas1 with Cas9, as these regions could be accessible by Cas9. We propose that Cas1 interacts 
with Cas9 during the prespacer selection process, and upon PAM recognition by Cas9, Cas1 
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extracts the corresponding prespacer with its nuclease activity. Cas1 could still extract 
prespacers from the DNA substrates when the PAM recognition function of Cas9 is deactivated, 
however, the presence of Cas9 is essential. This model is supported by an experiment showing 
that a double point mutation on the PAM-binding motif of Cas9 did not abolish spacer 
acquisition, nevertheless, it led to acquisition of non-functional spacer, i.e. spacers match to the 
protospacers without PAMs (Heler et al., 2015). This model could be investigated by examining 
the spacer acquisition in vivo in the mutants with the Cas9-Cas1 interacting regions and/or 
PAM-binding motif of Cas9 disrupted. 
 
tracrRNA is essential for spacer acquisition, and the tracrRNA-bound Cas9 was suggested for 
exhibiting the proper conformation needed for spacer acquisition (Heler et al., 2015). It is worth 
mentioning that tracrRNA was present in our pull-down assay, therefore our pull-down 
approach provides the native conditions necessary for the direct interaction between Cas1 and 
tracrRNA-bound Cas9. The absence of tracrRNA in the Y2H assay could be a reason that 
Cas9-Cas1 interaction was not detected in the Y2H assay. While an earlier study showed the 
co-purification of all the four Cas proteins of the type II-A system of S. pyogenes by SEC (Heler 
et al., 2015), a more recent study could not show any evidence for the stable complex formation 
by the four Cas proteins of the type II-A system of S. pyogenes, neither the interactions between 
Cas9 and Cas1, Cas9 and His6-MBP(maltose binding protein)-Cas2 or Cas9 and 
Cas1-His6-MBP-Cas2 (Ka et al., 2018). Unlike our pull-down assay, tracrRNA was absent in 
the latter study (Ka et al., 2018) and our SEC studies (Figure 17; Supplementary Figure S5), 
which could be a possible reason that the Cas9-Cas1 interaction was not detected. Furthermore, 
the His6-MBP tag that was used to solubilize Cas2 might hinder the interaction of Cas9 and 
Cas1 when the combination of Cas9 and Cas1-His6-MBP-Cas2 was investigated via SEC (Ka 
et al., 2018). 
 
Although tracrRNA was absent in the Y2H assay, the interaction between Csn2 and Cas9 
protein was still detected (Figure 13B; Supplementary Table S6). This is consistent with a 
recent study demonstrating that both apo-Cas9 and sgRNA-bound Cas9 could interact with 
Csn2, however, the interaction that involves sgRNA-bound Cas9 is much stronger than 
apo-Cas9 (Ka et al., 2018). In addition to the Csn2-Cas9 interaction, the direct interaction 
between Cas1 and Csn2 was indicated in the Y2H assay (Figure 13B; Supplementary 
Table S4), which is in agreement with the previous studies (Ka et al., 2016, 2018). A model 
structure of Cas1-Cas2-Csn2 complex of the type II-A system of S. pyogenes generated by 
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in silico methods, indicates that a Csn2 tetramer and a Cas2 dimer, respectively, bind to of one 
of the N-terminal domains of a Cas1 dimer without overlapping (Ka et al., 2016). In line with 
the former studies (Ka et al., 2016, 2018), our findings showed the Cas1-Csn2 and Cas1-Cas2 
interactions (Figure 13B; Supplementary Tables S4 and S5), but not the Cas2-Csn2 
interaction. Although Cas2 does not interact directly with Csn2, the presence of Cas2 increases 
the binding affinity of Csn2 to Cas1 by approximately 10-fold (Ka et al., 2018). This indicates 
that Cas1-Cas2 complex possesses the appropriate conformation that facilitates the interaction 
between Csn2 and Cas1.  
 
Both Csn2 and Cas9 are not required for spacer integration in vitro, therefore they were 
proposed for their roles in other step of spacer acquisition, for instance the generation of 
prespacers (Wright and Doudna, 2016). Based on the interactions of Csn2 with both Cas9 and 
Cas1 (Figure 13B; Supplementary Tables S4 and S6) (Ka et al., 2016, 2018), respectively, 
and the DNA end binding activity of Csn2 (Arslan et al., 2013), we suggest that Cas9 and/or 
Cas1 might facilitate the recruitment of Csn2 to the free DNA ends of the prespacer that was 
loaded on Cas1-Cas2 complex. This recruitment possibly enables Csn2 to protect the free DNA 
ends of the prespacer from the degradation by the cellular nucleases, which was suggested 
earlier in a study (Arslan et al., 2013). The physical presence of Cas9 is critical for spacer 
acquisition, as spacer acquisition was still detected when the catalytic domain and 
PAM-binding motif were mutated, respectively, although it led to acquisition of non-functional 
spacers in the latter case (Heler et al., 2015). This implies that in addition to the PAM 
recognition role, the physical presence of Cas9 prior to spacer integration has another role, such 
as to facilitate the recruitment of Csn2 to the DNA ends of the prespacer either alone or together 
with Cas1. Previously, the binding activity of Csn2 on the DNA ends of the radiolabeled DNA 
fragment was demonstrated by EMSA (Arslan et al., 2013). However, this assay did not study 
whether Csn2 can bind to the ends of the DNA fragment (prespacer) that has been loaded on 
the Cas1-Cas2 complex. To investigate the binding activity of Csn2 on the DNA ends of the 
prespacer that has been loaded on the Cas1-Cas2 complex, similar EMSA (Arslan et al., 2013) 
could be performed by using a DNA fragment that was pre-bound to the Cas1-Cas2 complex 
with and without the presence of Cas9.  
 
In addition to the interactions among the Cas proteins, our work provides the indications of the 
interactions between the Cas proteins of the type II-A systems and DNA repair proteins 
(Figure 13B; Table 2; Supplementary Tables S5-S8), which included the interactions that 
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are supported by a previous study in E. coli, such as the interactions of Cas1 and AddAB 
(RecBC), and Cas1 and MutS (Babu et al., 2011). For the first time, we provide the evidence 
of the interactions between Cas proteins and the proteins from the NER, MMR and BER 
pathways, such as the interactions between Cas1 and UvrB, Cas2 and UvrA, Cas9 and UvrA, 
Cas2 and XseA, Cas9 and PcrA, and Csn2 and LigA. Among the interacting partners from the 
DNA repair pathways, UvrA and UvrB from the NER pathway are the most prominent 
candidates, because these two proteins are involved in the interactions with Cas1, Cas2 and 
Cas9 (Figure 13B; Table 2; Supplementary Tables S5, S7 and S8). UvrA and UvrB form a 
UvrAB complex surveillance scanning for a DNA lesion at the beginning of NER (Truglio et 
al., 2006; Van Houten et al., 2005). Therefore, Cas1, Cas2 and Cas9 are presumably interacting 
with the UvrAB complex, instead of the individual subunits. 
 
In addition to the physical and genetic interactions, several in vivo studies in the type I systems 
revealed the association of the CRISPR-Cas systems with DNA repair and chromosome 
segregation (Babu et al., 2011; Hare et al., 2014; Williams et al., 2007). DNA repair pathways 
are conserved in both eukaryotes and prokaryotes, whereas CRISPR-Cas systems are only 
found in the sequenced genome of 90% of archaea and 50% of bacteria (Grissa et al., 2007; 
Makarova et al., 2015), the potential roles of the CRISPR-Cas systems in DNA repair remains 
to be clarified. On the other hand, there are increasing amount of studies revealing the 
involvement of DNA repair proteins in the CRISPR-Cas systems, especially in the type I-E 
systems (Babu et al., 2011; Ivancic-Bace et al., 2015; Levy et al., 2015; Modell et al., 2017; 
Radovčić et al., 2018). Altogether, our study provides the initial clues about the potential 
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5 Conclusion 
This thesis shows active spacer acquisition in the type II-A systems of S. thermophilus LMD-9 
via phage challenge and over-expression of Cas proteins, respectively. While lytic phage 
challenge confers the selective pressure to the bacteria for triggering spacer acquisition, 
over-expression of Cas proteins increases the spacer acquisition activity in the plasmid-based 
acquisition, which is otherwise more difficult to investigate under native conditions. When all 
Cas proteins from the CRISPR1 locus were over-expressed in S. thermophilus WT, crosstalk in 
spacer acquisition between the CRISPR1 and the CRISPR3 loci was not observed. Our 
protein-protein interaction studies provide the evidence of the direct physical interactions 
among numerous Cas proteins of the type II-A systems, including Cas9-Cas1, Cas1-Csn2, 
Cas1-Cas2 and Csn2-Cas9. This work reveals that Cas1 is a central player in spacer acquisition, 
because it interacts with all the other three Cas proteins, i.e. Cas1, Csn2 and Cas9, presumably 
to mediate the spacer acquisition mechanism. These findings regarding the direct Cas protein 
interactions provide the basis for further investigation of the biological significance of these 
interactions in the spacer acquisition mechanism of the type II-A systems, which require all the 
four Cas proteins. Moreover, the protein-protein interaction studies indicate the interactions 
between the Cas proteins and the DNA repair proteins, such as Cas1-AddA, Cas1-AddB, 
Cas1-MutS, Cas1-UvrB, Cas2-UvrA, Cas9-UvrA, Cas2-XseA, Cas9-PcrA and Csn2-LigA, of 
which some have not been reported before. These findings show the connection between 
CRISPR-Cas systems and DNA repair pathways, which is less known for the type II-A systems. 
Based on the findings in this thesis, future work shall focus on addressing the biological 
significances of the interactions among the Cas proteins of the type II-A systems. Moreover, 
the biological significance of the involvement of the DNA repair proteins in the mechanism of 
CRISPR-Cas systems and vice versa, will be novel fields for further exploration.  
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6 Materials and Methods 
 
6.1 Bacterial strains and culture conditions 
Bacterial strains used in this study are listed in the Supplementary Table S10. S. pyogenes 
was either grown in THY broth (Todd Hewitt Broth; Becton Dickinson) containing 0.2% yeast 
extract (Oxoid)) or on TSA plate (TrypticaseTM Soy agar; Becton Dickinson) supplemented 
with 3% sheep blood, at 37°C supplemented with 5% carbon dioxide (CO2) without agitation. 
S. thermophilus was either grown in M17 broth or on M17 plate (DifcoTM M17 Broth) 
supplemented with 0.5% lactose (LM17), at 42°C supplemented with 5% CO2 without 
agitation. For transformation purpose, S. thermophilus was either grown in chemically defined 
medium (CDM) with 1% lactose or on LM17 plate with 1% lactose. E. coli was grown in LB 
broth (with agitation) or agar at 37°C. Whenever necessary, appropriate antibiotics were applied 
in the broth or agar, i.e. final concentration of 300 µg/ml of kanamycin for S. pyogenes; 
50 µg/ml of kanamycin, 5 µg/ml erythromycin, 2 µg/ml of chloramphenicol in LM17 broth (or 
5 µg/ml chloramphenicol on LM17 plate) for S. thermophilus; and 25 µg/ml of kanamycin, 
50 µg/ml of streptomycin, 5 µg/ml of tetracycline,100 µg/ml of ampicillin or 10 µg/ml of 
chloramphenicol for E. coli. The concentrations of the antibiotics differ from the ones 
mentioned here, will be indicated in the specific assays. 
 
6.2 Bacterial transformation 
Standard protocol was used for heat shock plasmid transformation into E. coli (Sambrook et 
al., 1989). Transformation of S. pyogenes was performed according to (Caparon and Scott, 
1991). Natural transformation of S. thermophilus was conducted according to previous 
publication (Gardan et al., 2009) with some modifications. Briefly, overnight culture of 
S. thermophilus in CDM was diluted 1:100 in fresh CDM and grown until an OD600 (optical 
density at a wavelength of 600 nm) of 0.2 was reached. Five hundred µl of the culture was 
transferred to an Eppendorf tube that contained 200 ng plasmid DNA or PCR fragment and 
grown for 2 hours. Finally, the culture was plated on LM17 plate with appropriate antibiotics 
and grown overnight. 
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6.3 DNA manipulations 
Standard protocols (Sambrook et al., 1989) were used for DNA manipulations, i.e. DNA 
preparation, PCR amplification, DNA digestion, ligation, purification, agarose gel 
electrophoresis. Genomic DNA preparation, plasmid DNA preparation and DNA purification 
were performed with kits (NucleoSpin Tissue Kit, Macherey-Nagel kit; Qiagen). Primers were 
provided by Sigma-Aldrich, and the primers were detailed in the Supplementary Table S12. 
PCR fragments and plasmid DNA were sequenced at either LGC Genomics or Seqlab GmbH 
to check for the insert sequences (for cloning) and acquired spacers (for spacer acquisition 
study). 
 
6.4 Plasmid constructions for the heterologous 
type II-A system of S. pyogenes 
Individual S. pyogenes cas genes or their combinations were PCR amplified and cloned into 
pCDF-DUET vector using BamHI and EcoRI restriction sites (Supplementary Table S11-12). 
TracrRNA-CRISPR and cas9 of S. pyogenes were cloned into pEC85 vector using BamHI and 
EcoRI, and SmaI and Sall restriction sites, respectively. Protospacer-mutated-PAM 
(spy0700-TG(PAM)) was cloned into pUC19 vector using ZraI restriction sites.  
 
6.5 RNA extraction 
Bacterial culture of E. coli BL21-AI harboring pCDF-DUETΩcas variants, was either not 
induced or induced with 0.5 mM IPTG and 0.2% arabinose for 2 hours, and then mixed with 
equal volume of ice-cold ethanol-acetone (1:1) solution. Total RNA was isolated using TRIzol 
(Invitrogen) reagent and chloroform, followed by isopropanol precipitation, and eventually 
purified with TurboDNase (Ambion), according to the manufacturer’s instructions. 
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6.6 Semi-quantitative reverse transcription PCR 
(RT-PCR) 
The DNase-free total RNAs were used as templates for RT-PCR, which was performed using 
Qiagen® OneStep RT-PCR Kit (Qiagen) according to the manufacturer’s protocol and the 
primers are indicated in Supplementary Table S12. The absence of DNA contamination was 
verified with PCR using HotStarTaq Polymerase (Qiagen) following manufacturer’s protocol. 
 
 
6.7 Plasmid-based spacer acquisition study in the 
heterologous type II-A system of S. pyogenes 
For two-plasmid system, the plasmids pCDF-DUETΩcas1cas2csn2 (pEC651) (streptomycin 
resistant) and pEC85ΩtracrRNA-Leader-CRISPR (pEC645) (kanamycin resistant) were 
stepwise transformed into the E. coli BL21-AI. A single colony harboring two plasmids was 
inoculated in 50 ml LB medium (streptomycin; kanamycin; 0.2% glucose) and grown over-day 
at 37˚C, which was subsequently diluted (1:250 dilution) in fresh LB medium (streptomycin; 
kanamycin; 0.2% glucose) and grown overnight at 37˚C. The next day, the overnight culture 
was diluted (1:250 dilution) and grown over-day again at 37˚C. The over-day culture was 
subsequently diluted (1:250 dilution) in two different sets of LB medium, i.e. (1) without 
antibiotics (0.2% arabinose and 0.1 mM IPTG) and another with antibiotics (streptomycin; 
kanamycin; 0.2% arabinose; 0.5 mM IPTG). At this point, 0.2% arabinose and 0.1 mM IPTG 
was added to both LB media to induce the expression of cas genes that were controlled under 
the T7-lac promoter. These media were incubated at 37˚C overnight. Afterwards, the 2 sets of 
culture were diluted with fresh LB medium with and without antibiotics, respectively, twice a 
day (over-day and overnight) and grown at 37˚C for a long period of time (~1 to 2 weeks). At 
the same time, an aliquot of the same overnight culture was also diluted in 50 ml LB medium 
(1:250 dilution) with 25 µg/ml kanamycin and 0.2% glucose to suppress the cas expression for 
sampling purpose. The bacterial culture was collected for every cycle of the dilution, followed 
by plasmid DNA purification, genomic DNA purification and PCR analysis. Each inoculation 
and sub-growing was named as one cycle. For spacer acquisition screening, the CRISPR arrays 
of S. pyogenes and E. coli BL21-AI were monitored by PCR by using primers listed in 
Supplementary Table S12.    
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For three-plasmid system, the plasmids pCDF-DUETΩcas1cas2csn2 (pEC651), 
pEC85ΩtracrRNA-Leader-CRISPR-cas9 (pEC663) and pUC19Ωspy0700-TG(PAM) 
(pEC687) (ampicillin resistant) were stepwise transformed into the E. coli BL21-AI. A single 
colony was inoculated in 10 ml LB medium (streptomycin; kanamycin and ampicillin) and 
incubated at 37˚C overnight. The overnight culture was diluted (1:50 dilution) in 25 ml LB 
medium (streptomycin; kanamycin and ampicillin) and incubated at 37˚C until an OD600 of 
approximately 0.5 was achieved. At this point, 1 ml of the culture was centrifuged and the pellet 
was resuspended with 1 ml of fresh LB medium, wherein 100 µl of the resuspension was 
inoculated in 25 ml of LB medium (1:250 dilution) (streptomycin; kanamycin and ampicillin), 
and the cas expression was induced with 0.2% arabinose and 0.5 mM IPTG. The culture was 
incubated at 37˚C overnight, and the overnight culture was diluted (1:250 dilution) in fresh LB 
medium (streptomycin; kanamycin; 0.2% arabinose; 0.5 mM IPTG) and grown at 37˚C 
over-day. These over-day and overnight dilution and growing steps were repeated for a long 
period of time (~1 to 2 weeks). The culture was plated on LB agar plate (streptomycin; 
kanamycin; 0.2% arabinose and 0.5 mM IPTG) and incubated at 37˚C over-day or overnight. 
Later, 100 colonies from this plate were replica plated on two sets of plates (streptomycin; 
kanamycin; 0.2% arabinose and 0.5 mM IPTG), i.e. one plate without ampicillin and another 
plate with ampicillin. The ampicillin sensitive colonies were analyzed by colony PCR 
(Supplementary Table S12) to check for the expansion of CRISPR array (i.e. spacer 
acquisition) 
 
6.8 Spacer acquisition study in the heterologous 
type II-A system of S. pyogenes via phage 
challenge assay 
pCDF-DUETΩcas1cas2csn2 (pEC651) (streptomycin resistant) and 
pEC85ΩtracrRNA-Leader-CRISPR_Cas9 (pEC663) (kanamycin resistant) were stepwise 
transformed into the E. coli BL21-AI. From the transformation, a single colony was inoculated 
into 5 ml of LB medium (10 mM MgSO4; 0.2% maltose; 0.2% glucose; kanamycin; 
streptomycin) and incubated at 37°C overnight with agitation. The overnight pre-culture was 
diluted (1:50) in 10 ml LB medium (10 mM MgSO4; 0.2% maltose; 0.2% glucose; kanamycin; 
streptomycin), and then grown until an OD600 of 0.6-0.8 was achieved. The culture was 
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centrifuged at 4,000 rpm for 10 minutes at 4°C, and the pellet was re-suspended with equal 
amount of fresh LB medium (10 mM MgSO4; 0.2% maltose; kanamycin; streptomycin).  The 
expression of cas genes were induced by adding 0.5 mM IPTG and 0.2% arabinose, and the 
culture was grown for 2 hours at 37°C with agitation. Afterwards, the culture was diluted 10 
times and grown overnight. 100 µl of overnight culture was mixed with 100 µl of phage λvir 
(approximate 106 to 1010 PFU/ml of phage λvir in 100 µl of SM medium (100 mM NaCl; 8 mM 
MgSO4•7H2O; 50 mM Tris-HCl, pH7.5) depending on the MOI), and the mixture was 
incubated at 37°C for 60 minutes without agitation, followed by an incubation at 37°C for 
45 minutes with agitation. 4 ml LB medium (10 mM MgSO4; 0.2% maltose; 0.5 mM IPTG; 
0.2% arabinose) was added to the infected culture and grown overnight. The overnight culture 
was plated on LB agar plate (0.5 mM IPTG; 0.2% arabinose; kanamycin) and incubated at 37°C 
for 3 days. The colonies were screened for spacer acquisition using PCR. 
 
6.9 Plasmid-based spacer acquisition study in the 
endogenous type II-A system of S. pyogenes 
For acquisition study in S. pyogenes WT strain (EC904), pEC85 vector (kanamycin resistant) 
was transformed into WT via electroporation and plated on TSA plate supplemented with 300 
µg/ml kanamycin. Resulting colonies were inoculated in 25 ml of THY medium (kanamycin) 
and grown over-day. The over-day pre-culture was diluted 1:250 in fresh THY medium with 
(kanamycin) and grown overnight. For the initial two steps, the kanamycin was present in the 
medium to ensure a stable environment for the maintenance of the plasmid. Thereafter, the 
culture was diluted (1:250 dilution) twice a day in THY medium without antibiotics for a period 
of at least two weeks. If spacer acquisition occurs, it will lead to interference, i.e. plasmid loss. 
Here, to assure the survival of the cells that have lost the antibiotic resistance due to plasmid 
loss, THY medium without antibiotics was used. The first batch of bacteria that grew in the 
medium without antibiotics is known as cycle 1, the culture of subsequent dilution as cycle 2 
and so on. An aliquot of the culture was sampled for every cycle and spread on the TSA plates 
without antibiotics, and then replica plated on plates with and without kanamycin on the next 
day. Genomic DNA was extracted from the colonies that only grew on plates without 
antibiotics, and then it was used as a DNA template for PCR screening for spacer acquisition. 
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For the acquisition study in S. pyogenes Δcas9 strain (EC1788), pEC85, pEC659 and pEC660 
were transformed into the Δcas9 strain EC1788 via electroporation and plated on the TSA plate 
supplemented with kanamycin. Resulting colonies were inoculated in 25 ml of THY medium 
supplemented with kanamycin and grown overnight. The overnight culture was diluted 1:250 
in fresh THY medium with kanamycin on the next morning, and it was subsequently grown 
overnight. The overnight culture was repeatedly diluted and grown on a daily basis for a 
duration of at least two weeks. An aliquot of the culture from every cycle was sampled for 
genomic DNA extraction and then used as a DNA template for PCR screening for spacer 
acquisition. PCR products were analyzed on 1.5% agarose gel (1x TBE) and visualized by 
staining with ethidium bromide. 
 
6.10 PCR analysis for spacer acquisition  
The template DNA for PCR was either 10 ng plasmid DNA, 50 ng genomic DNA, bacterial 
colony or culture. For colony PCR, a single colony was transferred to 15 µl sterile water and 
boiled at 95°C for 10 minutes. For bacterial culture-based PCR, 1 ml of the bacterial culture 
was centrifuged, the pellet was washed in 1 ml of sterile water, re-suspended with 500 µl of 
sterile water, and boiled at 95°C for 10 minutes. For both colony and bacterial culture-based 
PCR, 5 µl bacterial suspension was used as a template for the PCR reaction. The PCR reaction 
was prepared with a final concentration of 0.10 U/µl of Taq DNA polymerase (Thermo 
Scientific), 1x Taq buffer with (NH4)2SO4, 2 mM MgCl2, 0.2 mM dNTPs, 0.4 µM forward and 
reversed primers. The PCR cycling condition was: initial denaturation at 95˚C for 5 minutes, 
denaturation at 95˚C for 30 seconds, annealing at 54˚C for 30 seconds, extension at 72˚C for 
40 seconds (35 cycles for denaturation to extension) and a final extension at 72˚C for 7 minutes. 
The primers used are indicated in the Supplementary Table S12. The PCR products were 
analyzed by agarose gel electrophoresis. 
 
6.11 Plasmid constructions for the heterologous 
type II-A system of S. thermophilus  
Individual S. thermophilus cas genes were PCR amplified and cloned into vector pCDF-DUET 
using BamHI and NcoI restriction sites (Supplementary Table S11-12).  The CRISPR array 
was cloned into vector pUC85 using BamHI and EcoRI restriction sites.  
Materials and Methods   
 81 
6.12 Plasmid-based spacer acquisition study in the 
heterologous type II-A system of S. thermophilus 
The S. thermophilus heterologous plasmids pCDF-DUETΩcas1-cas2-csn2 (pEC1151) 
(streptomycin resistant) and pEC85ΩLeader-CRISPR1 (pEC1230) (kanamycin resistant) were 
stepwise transformed into the E. coli BL21-AI host. A single colony was inoculated in 20 ml 
LB medium (50 µg/ml streptomycin; 25 µg/ml kanamycin; 0.2% glucose) in the morning and 
grown at 37°C (with agitation) over-day. One ml of the over-day grown culture was sampled 
for PCR screening for spacer acquisition, after washing in 1x PBS buffer twice. The same 
culture was also diluted (1:500) in 20 ml fresh LB medium (25 µg/ml kanamycin; 0.1 mM 
IPTG; 0.2% glucose) and grown overnight at 37°C (with agitation). Starting from this step, the 
bacterial culture was diluted (1:250) twice a day until cycle 24, and the cultures of each cycle 
were sampled for PCR screening. On cycle 16, an aliquot of the culture was diluted and spread 
on a LB agar plate supplemented with kanamycin (25 µg/ml). On the next day, the colonies 
were replica plated on LB agar plate with (1) streptomycin and kanamycin, and with (2) 
kanamycin only. A number of the colonies that grew only on the kanamycin plates (without 
streptomycin) were checked for spacer acquisition by colony PCR. 
 
6.13 Spacer acquisition study in the heterologous 
type II-A system of S. thermophilus via phage 
challenge assay 
 
E. coli BL21-AI harboring plasmids pCDF-DUETΩcas1-cas2-csn2 (pEC1151) (streptomycin 
resistant) and pEC85ΩLeader-CRISPR1 (pEC1230) (kanamycin resistant) was studied here. A 
single colony was inoculated in 50 ml LB medium (50 µg/ml streptomycin and 25 µg/ml 
kanamycin) and grown at 37°C (with agitation) overnight. The pre-culture was diluted (1:100) 
and induced in 200 ml of fresh LB medium (50 µg/ml streptomycin; 25 µg/ml kanamycin; 
0.1 mM IPTG; 0.2% arabinose; 10 mM MgCl2; 5 mM CaCl2; 0.2% maltose) and grown until 
an OD600 of 0.4-0.5 was reached. Equal amounts of the bacterial culture and phage λvir were 
mixed, wherein the concentration of the phage was adjusted according to the MOIs used, 
namely MOIs of 0.1, 1 and 10. The infected cultures with different MOIs were incubated at 
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37°C without agitation, for 5, 10, 15 and 20 minutes, respectively, followed by 15 minutes of 
incubation at 37°C with agitation. The bacteria-phage mixture was subsequently mixed with 
0.7% soft agarose and plated on a LB agar plate (25 µg/ml kanamycin; 0.1 mM IPTG; 0.2% 
arabinose; 10 mM MgCl2; 5 mM CaCl2; 0.2% maltose). The plate was incubated at 37°C for 1-
3 days, and the colonies were screened for spacer acquisition. 
 
6.14 Spacer acquisition study of the endogenous 
type II-A systems of S. thermophilus via phage 
challenge assay  
An overnight culture of S. thermophilus was diluted in 10 ml of LM17 medium and grown until 
an OD600 of approximately 0.5 was reached. CaCl2 (10 mM) was added to the culture. Five 
hundred µl of the culture was mixed with an appropriate amount of phage DT1 to achieve the 
desired MOI. The bacteria-phage mixture was then quickly mixed with 0.7% soft agarose 
supplemented with 0.5% lactose and 10 mM CaCl2, and subsequently transferred to a LM17 
plate, which was incubated at 42°C for 1-3 days. The colonies were screened for spacer 
acquisition. 
 
6.15 Spacer acquisition study of the endogenous 
type II-A systems of S. thermophilus with Cas 
proteins over-expression  
Plasmid pCas1-Cas2-Csn2-Cas9 or pCas1-Cas2-Csn2 (gifts from Michael Terns) was 
transformed into S. thermophilus and plated on LM17 plate (5 µg/ml chloramphenicol). A 
single colony was inoculated in 5 ml of LM17 medium (2 µg/ml chloramphenicol) and grown 
overnight. One ml of the overnight culture was centrifuged, and the resulting pellet was washed 
with sterile water and centrifuged again. Afterward, the pellet was re-suspended with sterile 
water and boiled at 95°C for 10 minutes. Five µl of the bacterial suspension was used as DNA 
template for PCR screening for spacer acquisition. The PCR product was analyzed with 2% 
TAE-agarose gel stained with ethidium bromide. 
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6.16 In vitro pull-down assay 
For cell lysate preparation, an S. thermophilus overnight culture was diluted in LM17 medium 
and grown until an OD600 of approximately 0.70 was reached. The culture was harvested by 
centrifugation at 6,000 rpm for 20 minutes at 4°C, and the pellet was subsequently washed with 
1 ml of 1x PBS buffer twice. The washed pellet was dissolved in thw lysis buffer (50 mM 
Tris-HCl, pH 7.5; 150 mM NaCl; 0.1% Triton X-100) and lysed with FastPrep (MP 
Biomedicals). Next, the cell lysate was centrifuged at 13,000 rpm for 10 minutes at 4°C. The 
concentration of the total protein (in the supernatant) of the cell lysate was determined by 
standard Bradford assay. 
 
For the in vitro pull-down, 150 µg of the purified CPD-His12-tagged Cas1 (the bait) was 
pre-incubated with 300 µg of total cell lysate (containing the prey) at room temperature for 
40 minutes with 100 rpm rotation. Afterward, the bait-prey sample was incubated with TALON 
Co2+ resin (GE Healthcare) at room temperature for 20 minutes with 150 rpm rotation. The 
sample was centrifuged briefly, and the collected solution was the flowthrough sample. The 
mini column was washed the wash buffers (10 mM Tris-HCl, pH8; 300 mM NaCl; 5 mM 
β-Mercaptoetanol; 10% Glycerol) containing 20 mM imidazole for wash 1-3 and 50 mM 
imidazole for wash 4-5. Next, 50 µM phytic acid buffer was incubated with the samples at room 
temperature for 1 hour with 150 rpm rotation.  Phytic acid buffer was used to detach the CPD 
tag from Cas1 protein, which was eluted from the column. The elution was analyzed on 
Coomassie stained-gradient SDS-PAGE gel. The control (cell lysate only) was prepared 
accordingly without the addition of the bait, and same for the preparation of bait only control, 
which was not incubated with the cell lysate. Eventually, all the bait-prey samples, cell lysate 
only control and bait only control were sent for mass-spectrometry analysis to identify the 
interacting partners of Cas1. 
 
6.17 SPOT peptide assay 
The Cas1 SPOT peptide membrane was blocked with blocking buffer (5% skim milk powder 
(Sigma-Aldrich) in 1x TBS-T buffer) at 4°C overnight. Next day, the membrane was washed 3 
times with 1x TBS-T at 4°C for 5 minutes, followed by the washing with protein storage buffer 
(buffer for Cas1: 50 mM Tris-HCl; 500 mM NaCl; 20% glycerol; 5 mM b-mercaptoethanol; 
buffer for Cas9: 20 mM HEPES, pH7.5; 150 mM KCl; 20% glycerol) at 4°C for 10 minutes. 
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Afterwards, the membrane was incubated with 50 nM His6-tagged Cas1 or His6-tagged Cas9 
pre-incubated with tracrRNA, in fresh protein storage buffer at 4°C for 1.5 hours. 
His6-tagged Cas9 was pre-incubated with two molar excess of tracrRNA at 37°C for 
10 minutes. Subsequently, the membrane was washed with protein storage buffer at 4°C for 
5 minutes, followed by 1x TBS-T buffer at 4°C for 5 minutes for 3 times. Next, the membrane 
was incubated with Penta-His antibody (mouse monoclonal IgG1) (Qiagen) in 1x TBS-T buffer 
(1:2,000 dilution) at room temperature for 1.5 hours, followed by multiple washing in 
1x TBS-T buffer. The membrane was subsequently incubated with Mouse IgG HRP 
(horseradish peroxidase-conjugated) Linked Whole Ab (GE Healthcare) (1:10,000 dilution) in 
blocking buffer for 1.5 hour. After the incubation with the secondary antibody, the membrane 
was washed with 1x TBS-T buffer for 5 mins at room temperature for several times. Finally, 
the SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) was 
added to the SPOT peptide membrane and analyzed by ChemiDoc™ Gel Imaging System 
(Bio-Rad). 
 
6.18 Protein purification 
The expression strain E. coli BL21 (DE3) was used for expressing CPD-His12-tagged Cas1 
(C-terminal), His6-tagged Cas1 (C-terminal) and SUMO-His6-tag Cas2 (N-terminal); whereas 
E. coli NiCo21(DE3) was used for expressing His6-tagged Cas9 (C-terminal). The pre-culture 
of an expressing strain harboring a specific expression plasmid was diluted in LB medium 
(ampicillin) and grown until an OD600 of 0.6-0.8 was reached. The expression of Cas proteins 
was induced with 0.5 mM IPTG at either 18˚C (cas1) or 13°C (cas9) overnight, or 37°C (cas2) 
for 4 hours. The culture was harvested at 6,000 rpm, 4˚C for 15 minutes. The resulting pellet 
was re-suspended and lysed in lysis buffer, and harvested again at 18,000 rpm, 4˚C for 
45 minutes. The clarified lysate was bound to TALON Co2+ resin (GE Healthcare) and was 
washed with wash buffer. After extensive washing, the protein was eluted with elution buffer 
and analyzed on Coomassie stained-SDS-PAGE gel.  
 
After IMAC purification with TALON Co2+ resin, His6-tagged Cas1 or CPD-His12-tagged Cas1 
was further purified with SEC. SUMO protease was incubated with SUMO-His6-tag Cas2 at 
4°C for 1 hour to remove the SUMO-tag before SEC. The TALON-purified His6-tagged Cas9 
was further purified with chitin resin (NEB) before SEC. Here, His6-tagged Cas9 was incubated 
with chitin resin at 4°C for 1 hour, and subsequently eluted with buffer A. The SEC column 
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used for protein purification was HiLoad® 16/600 Superdex® 200 pg (GE Healthcare). The 
eluted protein was analyzed again on Coomassie stained-SDS-PAGE gel.  
 
For in vitro pull-down assay (CPD-His12-tagged Cas1 was used) and SPOT peptide assay 
(His6-tagged Cas1 was used), the recombinant Cas1 were purified with Tris-HCl-based 
lysis/wash buffers, whereas His6-tagged Cas9 was purified in HEPES-KOH-based buffers 
(Supplementary Table S9). For SEC and crosslinking assays, HEPES-HCl-based buffers with 
lower pH were used for the purification of His6-tagged Cas1, SUMO-His6-tag Cas2 and 
His6-tagged Cas9, to improve the protein stability 
 
6.19 Protein-protein interaction study via size-
exclusion chromatography 
With regard to the study of Cas9 and Cas1 complex formation, the purified Cas9 and Cas1 (see 
the protocols for protein purification) were pooled together and incubated at 4°C for 45 minutes, 
and their complex formation was subsequently purified with an analytical column 
– Superdex® 200 Increase 10/300 GL by SEC using the buffer described in Supplementary 
Table S9. The elutions were analyzed on Coomassie stained-SDS-PAGE gel. To compare 
elution profile of Cas9-Cas1 with Cas1, Cas1 was also individually purified on Superdex® 200 
Increase 10/300 GL column, and the elutions were analyzed on Coomassie stained-SDS-PAGE 
gel.  
 
As for the study of Cas9-Cas1-Cas2 complex formation, each recombinant protein was 
expressed individually, and then their cell lysates were combined and purified via IMAC and 
SEC as described in the protocol for protein purification. SUMO protease was added to the 
purified proteins mixture to cleave off the SUMO-His6-tag of Cas2 before the subsequent SEC 
purification with Superdex® 200 Increase 10/300 GL. The eluates from the SEC were  
analyzed on Coomassie stained-SDS-PAGE gel, to verify their complex formation. 
 
6.20 Crosslinking 
Different combinations of Cas proteins were pre-incubated together at 4°C for 1 hour in protein 
buffer (20 mM HEPES-HCl, pH 7.0; 250 mM NaCl; 10% glycerol; 0.05% Tween-20). 
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His6-tagged Cas9 was pre-incubated with 2 times molar excess of tracrRNA at 37°C for 
10 minutes, before the incubation with other Cas protein(s). To crosslink the interacting 
proteins, BS3 crosslinker was added to the mixture and incubated at 24°C for 30 minutes. The 
crosslinking reaction was quenched by the addition of Tris-HCl (50 mM), followed by 
15 minutes incubation at 24°C. Then, the reaction was boiled at 95°C for 5 minutes and 
analyzed on Coomassie-stained SDS-PAGE gel (10% or 12%), 4-20% Mini-PROTEAN®TGX 
TM Precast Gel (Biorad) or by Western Blot. 
 
6.21 Western Blot 
Crosslinking reactions were separated by 4-20% Mini-PROTEAN® TGX TM Precast Gel 
(Biorad). The proteins were transferred to a nitrocellulose membrane (GE Healthcare) via Mini 
Trans-Blot® Cell (Biorad). The membrane was subsequently blocked with blocking buffer [5% 
skim milk powder (Sigma-Aldrich) in 1x TBS-T buffer] at room temperature for 1 hour, 
followed by incubation with anti-Cas1, anti-Cas2 or anti-Cas9 antibody (1:1,000 dilution, 
BioGenes) in 1x TBS-T buffer with 2.5% skim milk powder, at 4°C for 2 hours. After extensive 
washing with 1x TBS-T buffer, the membrane was incubated with 1:10,000 dilution of 
anti-rabbit IgG HRP-linked secondary antibody in 1x TBS-T buffer, at room temperature for 
1 hour. The membrane was washed extensively with 1x TBS-T buffer. Finally, SuperSignal™ 
West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) was added to the membrane, 
and the signals were visualized with ChemiDoc™ Gel Imaging System (Bio-Rad). 
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7 Work Contributions 
Unless otherwise mentioned, all works were performed by Shi Pey Wong. 
 
Hagen Richter2,3, Frank Hille 2,3,4,5 and Shi Pey Wong1,2,3,4,5 conducted the endogenous 
S. thermophilus spacer acquisition study via phage challenge. 
 
Shi Pey Wong1,2,3,4,5, Katja Schmidt2,3,4, Hagen Richter2,3 and Ann Kathrin Ahrens3 generated 
the S. thermophilus cas or CRISPR loci knock-out mutants. 
 
Shi Pey Wong1,2,3,4,5 and Katja Schmidt2,3,4 purified the S. thermophilus Cas proteins. 
 
Ines Fonfara1,2,3 coordinated with the samples arrangement with Hybrigenics Services and 
generated the model structure of S. thermophilus LMD-9 Cas1. 
 
Hybrigenics Services6 provided the services of yeast two-hybrid screening. 
 
The laboratory Henning Urlaub7 provided mass-spectrometry services for checking the protein 
samples obtained from S. thermophilus Cas1 in vitro pull-down. 
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Supplementary Figure S1. Sequence similarity of the leader and repeat sequences between the type II-A 
system of S. pyogenes SF370 and the type I-E system of E. coli BL21-AI.  
(A) The pairwise sequence alignments showed that the leader sequences between S. pyogenes SF370 and 
E. coli BL21-AI share only 46.6% of identity. The leader-anchoring sequence (LAS) of S. pyogenes is highlighted 
in grey. (B) The sequence identity of the repeat sequences between S. pyogenes SF370 and E. coli BL21-AI is 



























Supplementary Figure S2. Sequence similarity of the Cas proteins between S. thermophilus LMD-9 and 
DGCC7710 strains.  
The amino acids sequence alignments of (A) Cas9, (B) Cas1, (C) Cas2 and (D) Csn2 between S. thermophilus 








Supplementary Figure S3. Sequence similarity of the leader and repeat sequences between 
S. thermophilus LMD-9 CRISPR1 and CRISPR3 loci.  
(A) The pairwise sequence alignments showed that the leader sequences between CRISPR1 and CRISPR3 share 
only 49.4% of identity. The leader-anchoring sequence (LAS) of the CRISPR3 is highlighted. (B) The sequence 
identity of the repeat sequences between CRISPR1 and CRISPR3 is only 44.7%. Pairwise sequence alignment 
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Supplementary Figure S4. Cas1 SPOT assay reveals the interacting regions.  
The amino acids sequences of Cas1 involved (A) in Cas1 dimerization (region II; residues 73 to 112; b-sheet-8 to 
a-helix-3), and (B) in the interaction with Cas9 (Cas9 was pre-incubated with tracrRNA) (region VII; residues 
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Supplementary Figure S5. The study of Cas9-Cas1-Cas2 complex formation via size-exclusion 
chromatography.  
The cell lysates of the individually expressed recombinant N-terminal His6-tagged Cas9, C-terminal 
His6-tagged Cas1 and N-terminal SUMO-His6-tag of Cas2 were combined and purified via immobilized metal 
affinity chromatography (IMAC) with TALON Co2+ resin. The N-terminal SUMO-His6-tag of Cas2 was cleaved 
off by adding the SUMO protease to the protein mixture before applying the proteins mixture to the size-exclusion 
chromatography (SEC) column Superdex® 200 Increase 10/300 GL (GE Healthcare). The eluates were analyzed 
on Coomassie-stained 12% SDS-PAGE gel, which showed that Cas9 elutes as peak 1, Cas1 eluates as peak 1, 2 
and 3, whereas Cas2 eluates as peak 4. Peak 5 is the elution of imidazole. Cas9, 120.4 kDa; Cas1, 36.2 kDa; Cas2, 
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9 Supplementary Tables 
Supplementary Table S1. The tested conditions and the corresponding results for S. pyogenes type II-A spacer acquisition assay.  
 Heterologous system S. pyogenes endogenous system 
 Two-plasmid system Three-plasmid system Two-plasmid system  
with phage challenge 
Strain E. coli BL21-AI E. coli BL21-AI E. coli BL21-AI S. pyogenes WT  S. pyogenes ∆cas9 








 [1] pEC85 
  [3] pUC19ΩSpy_0700-NTG 
(protospacer_mutated-PAM) 
  [2] pEC85ΩspeM (protospacer) 
     [3] pEC85ΩtracrRNA-cas9-D10A-
speM (a Cas9 RuvC mutant) 
     [4] pEC85ΩtracrRNA-cas9-H840A-
speM (a Cas9 HNH mutant) 
Source of 
new spacers 
Plasmids Plasmids Phage Plasmids Plasmids 
Conditions 2 setups: (1) No antibiotics; (2) With 
Str and Kan during sub-culturing  
Only Str and Kan were used (no 
Amp) during sub-culturing  
WT Cas9 was included to allow 
interference after spacer acquisition 
No antibiotics were used during 
sub-culturing  
Either Cas9 was absent or a Cas9 
RuvC or HNH mutant was 
supplemented.  
   MOIs of 1, 10 and 100  Kanamycin was used during 
sub-culturing  
Results No spacer acquisition was detected in 
S. pyogenes and E. coli CRISPR 
arrays 
No spacer acquisition was detected in 
S. pyogenes and E.  coli CRISPR 
arrays 
No spacer acquisition was detected in 
S. pyogenes and E.  coli CRISPR 
arrays 
No spacer acquisition was detected No spacer acquisition was detected 
 Figure 2B Figure 2C Figure 2D (Figure not shown) Figure 3 
pCDF-DUET, streptomycin resistant (Str); pEC85, kanamycin resistant (Kan); pUC19, ampicillin resistant (Amp). a Multiple vectors were used in the bacteria, unless otherwise indicated. 
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Supplementary Table S2. Sequence similarities of elements of the type II-A CRISPR-Cas systems of 
S.  pyogenes SF370 and S. thermophilus LMD-9. 
Elements Sth_Cr1 vs Sth_Cr3 Sth_Cr1 vs Spy Sth_Cr3 vs Spy 
 Identity Similarity Identity Similarity Identity Similarity 
Cas1 31.6% 48.9% 32.9% 50.0% 79.6% 91.3% 
Cas2 37.1% 54.3% 36.0% 55.3% 86.0% 93.0% 
Csn2 13.3% 23.4% 15.0% 30.4% 56.8% 80.5% 
Cas9 18.9% 32.8% 21.0% 35.0% 57.7% 73.6% 
tracrRNA 48.3% 48.3% 51.4% 51.4% 81.2% 81.2% 
Sth_Cr1, S. thermophilus LMD-9, CRISPR1; Sth_Cr3, S. thermophilus LMD-9, CRISPR3; Spy, S. pyogenes SF370 (M1 GAS). The sequence 
identity and similarity were analyzed by pairwise sequence alignment (EMBOSS Needle). Amino acids sequence identity and similarity were 
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Supplementary Table S3. Sequence similarities of the Cas proteins between S. thermophilus LMD-9 and 
DGCC7710 strains (CRISPR1) 
Protein Identity Similaritya 
Cas1 100.0% 100.0% 
Cas2 99.1% 99.1% 
Csn2 93.4% 95.7% 
Cas9 99.8% 99.9% 
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Supplementary Table S4. Yeast two-hybrid analysis of the interacting partners of Cas1 (Spy_1047) of 
S. pyogenes SF370 and their corresponding S. thermophilus LMD-9 orthologs.   
PBS1 Interacting partners of Cas1  
(S. pyogenes SF370) 
Functions Orthologs for 
S. thermophilus LMD-9 
A Cas1 (Spy_1047) 
 
• CRISPR adaptation  Cas1 (CRISPR3) (STER_1476) 
• Identity: 0.796 
C CMP-binding factor, Cbf (Spy_0267) 
 
• Metal ion binding 
• Nucleic acid binding 
• Phosphoric diester hydrolase 
activity 
CMP-binding protein (STER_1766) 
• Identity: 0.848 
 
C Csn2 (Spy_1049) 
 
• Binds dsDNA Csn2 (CRISPR3) (STER_1474)  
• Identity: 0.573 
C Ribonuclease HII, RnhB (Spy_1162) 
 
• Endonuclease that 
specifically degrades the 
RNA of RNA-DNA hybrids  
• DNA replication 
Ribonuclease HII, RnhB (STER_0920) 
• Identity: 0.676 
1 Predicted Biological Score (PBS) shows the reliability of the interaction, i.e. PBS-A indicates a very high reliability in the interaction, B 
indicates high reliability, C indicates good reliability. The candidates with PBS-D were not analyzed in this study (except for Csn2 analysis), 
as they show moderate reliability in the interaction. This means that PBS-D includes a mix false-positive or hardly detectable interaction, and 
they need to be carefully verified. Due to the low reliability in the interaction for the candidates with PBS-E and F, these candidates were not 
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Supplementary Table S5. Yeast two-hybrid analysis of the interacting partners of Cas2 (Spy_1048) of 
S. pyogenes SF370 and their corresponding S. thermophilus LMD-9 orthologs.  
PBS1 Interacting partners of Cas2  
(S. pyogenes SF370) 
Functions Orthologs for 
S. thermophilus LMD-9 
A Cell-cycle protein (Spy_0013) 
 
• tRNA modification 
 
Cell-cycle protein, MesJ/Ycf62 family 
(STER_0012) 
• Identity: 0.501 





(STER_1847)          
• Identity: 0.837 
A RNA methyltransferase (Spy_1346) 
 
• RNA binding 
• RNA processing 
tRNA methyltransferase, TrmA family 
(STER_0702) 
• Identity: 0.776 
A Exodeoxyribonuclease VII large 
subunit, XseA (Spy_1500)  
• Mismatch repair 
 
 
Exodeoxyribonuclease VII large subunit, XseA 
(STER_1184) 
• Identity: 0.742 
A Excinuclease ABC subunit A, 
UvrA (Spy_1825) 
 
• Nucleotide excision repair 
 
Excinuclease ABC subunit A, UvrA 
(STER_1722) 
• Identity: 0.876 
B Cas1 (Spy_1047) 
 
• CRISPR adaptation Cas1 (CRISPR3) (STER_1476) 
• Identity: 0.796 
B GTP-binding protein TypA 
(Spy_1527) 
• GTPase activity GTP-binding protein TypA/BipA 
(STER_0771) 
identity: 0.941 
C Cell envelope proteinase, PrtS 
(Spy_0416) 
 
• Serine-type endopeptidase 
activity  
Subtilisin-like serine protease (STER_0846) 
• Identity: 0.427 
C 30S ribosomal protein S1, RpsA 
(Spy_0913) 
• DNA binding 
• Structural constituent of 
ribosome 
30S ribosomal protein S1 (STER_0639) 
• Identity: 0.885 
C trigger factor, Tig (Spy_1896) • Promoting folding of newly 
synthesized proteins 
Trigger factor (STER_0191) 
• Identity: 0.775 
1 Predicted Biological Score (PBS) shows the reliability of the interaction, i.e. PBS-A indicates a very high reliability in the interaction, B 
indicates high reliability, C indicates good reliability. The candidates with PBS-D were not analyzed in this study (except for Csn2 analysis), 
as they show moderate reliability in the interaction. This means that PBS-D includes a mix false-positive or hardly detectable interaction, and 
they need to be carefully verified. Due to the low reliability in the interaction for the candidates with PBS-E and F, these candidates were not 
analyzed here.  
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Supplementary Table S6. Yeast two-hybrid analysis of the interacting partners of Csn2 (Spy_1049) of 
S. pyogenes SF370 and their corresponding S. thermophilus LMD-9 orthologs. 
PBS1 Interacting partners of Csn2  
(S. pyogenes SF370) 
Functions Orthologs for 
S. thermophilus LMD-9 
A Queuine tRNA-ribosyltransferase, 
Tgt (SPy_0203) 





• Identity: 0.903 
A NAD-dependent DNA ligase LigA  
(SPy_0751) 
• Nucleotide excision repair 
• Base excision repair 
• Mismatch repair  
• DNA replication 
NAD-dependent DNA ligase LigA 
(STER_1513) 
• Identity: 0.730 
A 30S ribosomal protein S7, RpsG 
(SPy_0272) 
 
• Translation 30S ribosomal protein S7 (STER_1763) 
• Identity: 0.955 
A Serine hydroxymethyltransferase, 
GlyA (Spy_1145)  
 
• Glycine biosynthetic process 
from serine 
• Pyridoxal phosphate binding 
Serine hydroxymethyltransferase 
(STER_0796) 
• Identity: 0.755 
B N-acetylmuramoyl-L-alanine amidase 
(Spy_1764) 
• Amidase activity Peptidoglycan hydrolase (STER_0160)  
Identity: 0.361 
B tRNA/rRNA methyltransferase 
(Spy_1938) 
• RNA binding 
• RNA processing 
tRNA/rRNA methyltransferase 
(STER_0122) 
• Identity: 0.84 
C 16S rRNA methyltransferase GidB 
(Spy_0329) 
• RNA methytransferase 
activity 
16S rRNA methyltransferase GidB 
(STER_0352) 
• Identity: 0.751 
C Aminodeoxychorismate lyase 
(Spy_0348) 
• Lyase activity 
 
Aminodeoxychorismate lyase (STER_0288) 
• Identity: 0.459 
C Branched-chain alpha-keto acid 





Branched-chain alpha-keto acid dehydrogen 
(STER_1034) 
• Identity: 0.764 
C Penicillin-binding protein 2a, Pbp2A 
(Spy_2059) 
• Penicillin binding 
• Transferase activity 
Penicillin-binding protein 2a (STER_0260) 
• Identity: 0.632 
D Cas9 (SPy_1046) • CRISPR interference  
• CRISPR adaptation 
Cas9 (CRISPR3) (STER_1477) 
• Identity: 0.578 
1 Predicted Biological Score (PBS) shows the reliability of the interaction, i.e. PBS-A indicates a very high reliability in the interaction, B 
indicates high reliability, C indicates good reliability. The candidates with PBS-D were not analyzed in this study (except for Csn2 analysis), 
as they show moderate reliability in the interaction. This means that PBS-D includes a mix false-positive or hardly detectable interaction, and 
they need to be carefully verified. Due to the low reliability in the interaction for the candidates with PBS-E and F, these candidates were not 
analyzed here.  
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Supplementary Table S7. Yeast two-hybrid analysis of the interacting partners of Cas9 (Spy_1046) of 
S. pyogenes SF370 and their corresponding S. thermophilus LMD-9 orthologs. 
PBS1 Interacting partners of Cas9 
(S. pyogenes SF370) 
Functions Orthologs for 
S. thermophilus LMD-9 
A Excinuclease ABC subunit A, 
UvrA (Spy_1825) 
 
• Nucleotide excision repair 
 
Excinuclease ABC subunit A, UvrA 
(STER_1722) 
• Identity: 0.876 
B DNA helicase II / ATP-dependent 
DNA helicase PcrA  (SPy_1267) 
• Nucleotide excision repair 
• Mismatch repair 
ATP-dependent DNA helicase PcrA 
(STER_0994) 
• Identity: 0.820 
1 Predicted Biological Score (PBS) shows the reliability of the interaction, i.e. PBS-A indicates a very high reliability in the interaction, B 
indicates high reliability, C indicates good reliability. The candidates with PBS-D were not analyzed in this study (except for Csn2 analysis), 
as they show moderate reliability in the interaction. This means that PBS-D includes a mix false-positive or hardly detectable interaction, and 
they need to be carefully verified. Due to the low reliability in the interaction for the candidates with PBS-E and F, these candidates were not 
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Supplementary Table S8. The interacting partners of Cas1 identified by in vitro pull-down assay in 
combination with mass spectrometry. 
System/ 
Pathway 
Identified Proteins Accession 
Number 
KEGG ID Fold 
Changea 
CRISPR 
CRISPR-associated endonuclease, Cas9 family gi|116101490 STER_0709 8.8 
CRISPR-associated protein, Cas1 family gi|116100820 STER_0710 4.2 
DNA Repair 
DNA mismatch repair protein MutS gi|116100292 STER_0068 3.6 
Excinuclease ABC subunit B, UvrB   gi|116101472 STER_1457 3.5 
DNA helicase/exodeoxyribonuclease V, subunit B, AddB gi|116101679 STER_1682 3.4 
DNA helicase/exodeoxyribonuclease V, subunit A, AddA gi|116101678 STER_1681 3.1 





ATPase component of ABC transporter with duplicated ATPase 
domains 
gi|116101279 STER_1237 3.7 
ABC-type polysaccharide/polyol phosphate transport system, ATPase 
component 
gi|116101450 STER_1434 3.2 
ATPase component of ABC transporter with duplicated ATPase 
domains 
gi|116100599 STER_0462 3.2 
ABC-type polar amino acid transport system, ATPase component gi|116101618 STER_1617 3.0 
DNA 
Replication 
Ribonucleoside-triphosphate reductase class III catalytic subunit / 
ribonucleoside-triphosphate reductase 
gi|116101906 STER_1942 4.0 
DNA polymerase III catalytic subunit, STER_1935 type gi|116100303 STER_0095 3.5 
DNA primase gi|116101465 STER_1449 3.2 
a Only candidates with fold change ³3.0 are shown. 
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Supplementary Table S9. Buffers used for protein purification.  
Experiment1 
in vitro pull-down assay and SPOT 
peptide assay 
in vitro pull-down assay 
Protein-protein interaction study:  
SEC2 and crosslinking assays 
Protein 
CPD-His12-tagged Cas1 and 
His6-tagged Cas1 
His6-tagged Cas9 
His6-tagged Cas1,  
SUMO-His6-tag Cas2 and 
His6-tagged Cas9 
Lysis buffer 
10 mM Tris-HCl, pH8.0; 
300 mM NaCl; 
2.5 mM β-Mercaptoethanol; 10% 
glycerol 
20 mM HEPES-KOH, pH7.5; 
1 M KCl; 0.1% Triton X-100; 
25 mM imidazole 
20 mM HEPES-HCl, pH 6.8; 
500 mM NaCl; 10% glycerol; 10 mM 
imidazole; 2 mM TCEP (Sigma); 
0.1% Triton X-100 (Serva 
Electrophoresis); 0.5 mM PMSF 
(Sigma-Aldrich); Complete 
EDTA-free protease inhibitor (Roche) 
Wash buffer (same as lysis buffer) (same as lysis buffer) 
20 mM HEPES-HCl, pH 6.8; 
1 M NaCl; 10% glycerol; 25 mM 
imidazole; 2 mM TCEP 
Elution 
buffer 
10 mM Tris-HCl, pH8.0; 
300 mM NaCl; 2.5 mM 
β-Mercaptoethanol; 10% glycerol; 
500 mM imidazole 
20 mM HEPES-KOH, pH7.5; 
150 mM KCl; 0.1 mM DTT; 250 mM 
imidazole; 1 mM EDTA 
20 mM HEPES-HCl, pH 6.8; 
250 mM NaCl; 10% glycerol; 0.05% 
Tween-20; 2 mM TCEP; a gradient of 
imidazole, 150, 250 and 500 mM 
Buffer A (N/A) 
20 mM HEPES-KOH, pH7.5; 
100 mM KCl 
(only for Cas9) 20 mM HEPES, 
pH 6.8; 250 mM NaCl; 0.05% 
Tween-20; 10% glycerol; 2 mM 
TCEP 
SEC buffer 
10 mM Tris-HCl, pH8.0; 
300 mM NaCl; 
2.5 mM β-Mercaptoethanol; 10% 
glycerol 
(N/A) 
20 mM HEPES-HCl, pH 6.8; 
250 mM NaCl; 10% glycerol; 0.05% 
Tween-20 
1 The specific assay that involved the purified protein 
2 Size-exclusion chromatography is abbreviated as SEC  
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Supplementary Table S10. List of bacterial and viral strains  
Strain Relevant characteristics Source 
Streptococcus pyogenes 
EC904 SF370 (M1 serotype), WT  ATCC 700294 
EC1788 EC904∆cas9 Deltcheva et al, 2011 
   
Streptococcus thermophilus 
EC2162 LMD-9 (WT) Sylvain Moineau 
EC2724 EC2161∆CR2_∆CR3 This study 
EC2735 EC2724∆cas9_CR1 This study 
   
Escherichia coli 
RDN204 TOP10; Host for cloning Invitrogen 
RDN226 DH5α; Host for cloning Lab collection 
EC1265 BL21 (DE3) Rosetta; Expression expression Novagen 
EC2159 BL21-AI Stan Brouns 
EC2212 NiCo21 (DE3); Expression strain NEB 
   
Phage for Streptococcus thermophilus LMD-9 
Phage DT1  Félix d'Hérelle Reference 
Center for bacterial viruses of 
the Université Laval 
   
Phage for Escherichia coli 
Phage Lamda (virulent)  Stan Brouns 
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Supplementary Table S11. List of plasmids  
Plasmids Relevant characteristics Source 
Vectors for S. pyogenes 
pEC85 repDEG-pAMβ1, pJH1-aphIII, ColE1 Lab collection 
   
Vectors for E. coli 
pEC180 pET21a Lab collection 
pEC225 pET16b Lab collection 
pEC574 pCDFDUET-1 Lab collection 
pEC707 pUC19 Lab collection 
pEC1075 pET20b Lab collection 
pEC1076 pEC-A_Hi_SUMO Lab collection 
pEC1078 pEC21-CPD_Pto Lab collection 
   
Plasmids for S. pyogenes (SF370) adaptation study – Heterologous system in E. coli BL21-AI 
pEC645 pEC85Ω171tracrRNA-Leader-CRISPR (171 nt form) This study 
pEC646 pEC85Ω89tracrRNA-Leader-CRISPR (89 nt form) This study 
pEC663 pEC645ΩPcas9(Spy)-cas9(Spy) Lab collection 
pEC651 pEC574Ωcas1-cas2-csn2 This study 
pEC686 pUC19Ωspy0700-GG(PAM) This study 
pEC687 pUC19Ωspy0700-TG(PAM) This study 
   
Plasmids for endogenous spacer acquisition study in S. pyogenes SF370  
   
pEC488 pEC85ΩspeM (protospacer) Lab collection 
pEC659 pEC85ΩtracrRNA-cas9-D10A-speM (a Cas9 RuvC mutant) Lab collection 
pEC660 pEC85ΩtracrRNA-cas9-H840A-speM (a Cas9 HNH mutant) Lab collection 
   
Plasmids for S. thermophilus (LMD-9) adaptation study – Heterologous system in E. coli BL21-AI 
pEC1151 pEC574Ωcas1-cas2-csn2(Sth_Cr1) This study 
pEC1230 pEC85ΩCR1_5spcs_Sth This study 
   
Plasmids for over-expression of S. thermophilus (LMD-9) Cas proteins 
pEC621 pEC225 inserted with cassette harboring NotI, SacI, SalI site Fonfara et al, 2013 
pEC641 pEC621Ωcas9(Sth_Cr1) Fonfara et al, 2013 
pEC1290 pEC1075Ωcas1(Sth_Cr1) This study 
pEC1295 pEC1076Ωcas2(Sth_Cr1) This study 
pEC1300 pEC1078Ωcas1(Sth_Cr1) This study 
   
Plasmids for endogenous spacer acquisition study in S. thermophilus (LMD-9) – CRISPR1 locus 
pEC2376 pWAR2228Ωcas1-cas2-csn2-cas9_Cr1(Sth_DGCC7710) Wei et al, 2015 
pEC2377 pWAR2228Ωcas1-cas2-csn2_Cr1(Sth_DGCC7710) Wei et al, 2015 
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Supplementary Table S12. List of primers 
Purpose Primer code Sequence 5’-3’a F/Rb Usage 
Plasmids for S. pyogenes (SF370) adaptation study – Heterologous system in E. coli BL21-AI 
pEC645 
 
OLEC2968 GCATCGGGATCCGTTTGCAGTCAGAGTAGAATAGAAGTATC F 
Cloning 171-tracrRNA 
OLEC2969 GCGGAAAATCATATAGTTCACGTGGCCTGCAGGTTAATGACCTCCGAAATTAGTTTAATATGC R 
OLEC2971 GCATATTAAACTAATTTCGGAGGTCATTAACCTGCAGGCCACGTGAACTATATGATTTTCCGC F 
Cloning Leader-CRISPR 
OLEC2967 GGTGGTGAATTCGCTTTAACAGAAAGAATAGGAAGGTATCC R 
OLEC2968 GCATCGGGATCCGTTTGCAGTCAGAGTAGAATAGAAGTATC F LM-PCR; Cloning 171-
tracrRNA-Leader-CRISPR 
OLEC2967 GGTGGTGAATTCGCTTTAACAGAAAGAATAGGAAGGTATCC R 
pEC646 
 
OLEC2968 GCATCGGGATCCGTTTGCAGTCAGAGTAGAATAGAAGTATC F 
Cloning 89-tracrRNA 
OLEC2970 GCGGAAAATCATATAGTTCACGTGGCCTGCAGGGAATTTCTCCTTGATTATTTGTTATAAAAG R 
OLEC2972 CTTTTATAACAAATAATCAAGGAGAAATTCCCTGCAGGCCACGTGAACTATATGATTTTCCGC F 
Cloning Leader-CRISPR 
OLEC2967 GGTGGTGAATTCGCTTTAACAGAAAGAATAGGAAGGTATCC R 
OLEC2968 GCATCGGGATCCGTTTGCAGTCAGAGTAGAATAGAAGTATC F LM-PCR; Cloning 89-tracrRNA 
-Leader-CRISPR  
OLEC2967 GGTGGTGAATTCGCTTTAACAGAAAGAATAGGAAGGTATCC R 
pEC651 
OLEC2973 ATGCAGGGATCCATGGCTGGTTGGCGTACTGTTGTG F 
Cloning cas1cas2csn2 
OLEC1757 CTGCATGAATTCTTATACCATATTTTTAGTTA R 
pEC663 
OLEC3040 ATGACTCTAGAGGAGAAATTCAAAGAAATTTATCAGC F 
Cloning ΩPcas9(Spy)-cas9(Spy) 
OLEC3041 ATGACTCTAGAAACCAGCCATCAGTCACCTC R 
pEC686  
OLEC2106 ATGCAGGGCCGGCCAGTATCAGCGTACTTGGATTTGGG F Cloning spy0700-GG(PAM); 
Source pEC573 
OLEC2107 ATGCAGGGCCGGCCTTGTCTCACTCACTCTATTTTTG R 
pEC687 
OLEC2106 ATGCAGGGCCGGCCAGTATCAGCGTACTTGGATTTGGG F 
Cloning 
OLEC2107 ATGCAGGGCCGGCCTTGTCTCACTCACTCTATTTTTG R 
RT-PCR 
OLEC3048 GTTACCAATATGAGGAAGATTCTGAAC F 
Checking the expression of csn2 




OLEC1749 GGTGGTGGATCCCCACGTGAACTATATGATTTTCCGC F For the type II-A array of 
S. pyogenes (primer set 1) 
OLEC3127 CGCAAGAAGAAATCAACCAGCG R 
OLEC1749 GGTGGTGGATCCCCACGTGAACTATATGATTTTCCGC F For the type II-A array of 
S. pyogenes (primer set 2) 
OLEC2967 GGTGGTGAATTCGCTTTAACAGAAAGAATAGGAAGGTATCC R 
OLEC3066 GACTGAAGTCTAGCTGAGAC F 
For the type II-A array of 
S. pyogenes (primer set 3) 
OLEC1141 CAAATTGAGTTATGTTCATATAAG R 
OLEC3005 GGTGGTGGATCCGCGGTAAAGTTTGGTAGATTTTAGTTTG F For the CRISPR I array of 
E. coli BL21-AI 
OLEC3006 GGTGGTCTGCAGGTTACGTGGATATGTTGCTTATTACAAG R 
OLEC3007 GGTGGTGGATCCCCAGTTATCGTGAGAGTAATTCATCG F For the CRISPR II array of 
E. coli BL21-AI 
OLEC3008 GGTGGTCTGCAGCGTGATGTTATGCGGATAATGCTACC R 
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Purpose Primer code Sequence 5’-3’a F/Rb Usage 
Plasmids for Cas1 over-expression (S. thermophilus LMD-9; CRISPR1) 
pEC1290 
OLEC4721 GGAGAACATATGACTTGGAGAGTTGTACATG F 
Cloning 
OLEC4722 TACCTCCTCGAGTTTTCTCCACTCTAAACTTG R 
pEC1300 
OLEC4721 GGAGAACATATGACTTGGAGAGTTGTACATG F 
Cloning 
OLEC4722 TACCTCCTCGAGTTTTCTCCACTCTAAACTTG R 
Plasmids for Cas2 over-expression (S. thermophilus LMD-9; CRISPR1) 
pEC1295 
OLEC4495 ACCAGGAACAAACCGGCGGCCGCTCGATGAGGTATGAAG F 
Cloning 
OLEC4496 GCAAAGCACCGGCCTCGTTATATGGCCACCAAC R 
Plasmids for S. thermophilus (LMD-9) adaptation study – Heterologous system in E. coli BL21-AI 
pEC1151 
OLEC4518 GGTGGTCCATGGGCACTTGGAGAGTTGTACATGTCAGTC F 
Cloning 








OLEC 4841 CTTTTTATGTTGAATCAACTATTTCACGATATTTTTTCACGAAT R 
OLEC 4842 ATTCGTGAAAAAATATCGTGAAATAGTTGATTCAACATAAAAAGCCGG  F 
OLEC 4838 CACTTTTGTGGGCCTTTTTTGGCCGGCCTGAATTCGAGCCTCCCTATCCTTAATTTG R 
OLEC 4839 GAATTCAGGCCGGCCAAAAAAGG F 
OLEC 4840 GGATCCTCTAGAGTCGACCTGCAG R 
RT-PCR 
OLEC4522 GGTGGTCCATGGGCAAATTTTTTGTACGACATCCTTAC F 
Checking the expression of csn2 




OLEC4778 GATTTTATAATCACTATGTGGG F 
For the CRISPR1 array 
OLEC4779 GATGGTCGGTTATTTTTCAG R 
OLEC4780 GGTGACAGTCACATCTTGTC F 
For the CRISPR3 array 
OLEC4781 GTTTTCGTCTTGGATACCAC R 
 a italic, sequence annealing to the template; underlined, restriction site; No formating, extra nucleotides. 
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